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Summary  
The intestinal epithelium is maintained by intestinal stem cells that replace each 
other stochastically over time. Stem cells that are excluded from the stem cell 
pool will differentiate into the absorptive or secretory cell lineages. However, 
intestinal cell-fate specification is not always restrictive and early secretory 
progenitors can revert back to the stem cell pool. Human colon cancer develops 
by acquisition of oncogenic mutations in the colonic epithelium throughout life. As 
secretory progenitors have unexpectedly been shown to be a significant source 
of colonic stem cells, they could serve a cell of origin for tumorigenesis. 
Furthermore, it has been speculated that tumours could arise in fields that encode 
pro-oncogenic mutations prior to overt tumour development. Mutations in KRAS 
can be found in 10% of healthy human colons in fields of up to 100 crypts that 
may be the cause of a subset of colorectal tumours. The extent to which such 
fields are predisposed to colorectal cancer development is unknown.   
 The aims of this PhD project were to characterise the cell of origin and 
stem cell behaviour of KrasG12D fields and to develop new tools to recapitulate 
sequential mutations in vivo. Cre mediated lineage tracing of Atoh1 expressing 
early secretory progenitors carrying KrasG12D mutations demonstrated that 
KrasG12D expression does not change cell fate choices in homeostasis but 
appears to increase Atoh1+ stem cell contribution in the small intestine after Lgr5 
depletion. In addition, Atoh1 derived KrasG12D stem cells have a competitive bias 
and Atoh1 derived KrasG12D crypts can multiply over time to create fields and 
polyps in the colonic epithelium. In addition, a mouse model that utilises Flp and 
Cre to temporally separate intestinal KrasG12D recombination from lineage-tracing 
was developed to study stem cell behaviour in KrasG12D fields. Lineage tracing in 
this model shows that crypts in KrasG12D epithelium have a markedly higher 
monoclonal conversion rate and accumulate an increased mutation load over 
time compared to WT crypts. Furthermore, the faster monoclonal conversion rate 
is shown to be dependent on Mek signalling downstream of Kras. Thus, KrasG12D 
fields may fix secondary mutations at an accelerated rate and so represent pro-
oncogenic areas. Lastly, in this thesis a Rosa26 DrePr mouse model, that allows 
for recombination independently of other recombinases, is developed and used 
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to initiate lineage tracing in a sequential model of Cre activated intestinal 
tumorigenesis.    
 
Collectively, the data presented in this thesis allows in-dept investigation of the 
cell of origin and stem cell behaviour in pro-oncogenic KrasG12D fields and 
contributes to the understanding of how such fields might lead to colon cancer. 
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1 Introduction 
1.1 The intestinal epithelium  
 
1.1.1 Intestinal tissue organisation 
The intestinal tract is lined by a single layer of epithelial cells and consists of the 
small intestine and the large intestine (Figure 1.1A). The small intestine includes 
the duodenum, jejunum and the ileum. The large intestine includes the caecum, 
colon and the rectum. The intestinal tract has two main functions: to absorb 
nutrients and to protect against insults from the environment. The single layer of 
cells in the intestinal epithelium invaginates into so-called intestinal crypts of 
Lieberkühn. The small intestine also has have finger like protrusions or villi which 
contain cells that mediate nutrient uptake (Gehart and Clevers, 2019). Multiple 
crypts can supply cells to the villus at the base. The large intestine does not 
contain villi and the main function of the colon is water reabsorption and stool 
compaction. 
 
The intestinal epithelium is protected against insults by a thick mucosal barrier, 
immune-epithelial interactions and by a high cell turn-over. To this end, the entire 
intestinal epithelium is renewed every 3-4 days in mice and rats (Leblond and 
Stevens, 1948; Darwich et al., 2014). Tissue renewal is maintained by highly 
proliferative crypt base columnar stem cells (Cheng and Leblond, 1974; Escobar 
et al., 2011) (Figure 1.1C). Daughter cells migrate up the crypt to the transit 
amplifying (TA) zone where they undergo 4-5 rounds of proliferation before they 
leave to terminally differentiate (Figure 1.1C). As differentiated cells reach the 
villus top they undergo apoptosis which provides a balancing mechanism for the 
high levels of proliferation in the crypt base (Cheng and Leblond, 1974; Hall et 
al., 1994) (Figure 1.1C). 
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1.1.2 Crypt propagation                 
During development, as the digestive tube elongates, crypts undergo replication 
and division to line the entire tube; a process called fission (Clarke, 1972). 
Fissioning transpires through bifurcation of a single crypt into two, and this starts 
at the crypt-base and moves up in a zipper-like fashion (Gehart and Clevers, 
2019). Fission occurs at slow rates in the mature intestine meaning that crypt 
multiplication is a dynamic process even in adult intestinal tissue (Snippert et al., 
2014). Recently, a study showed that an opposing mechanism called crypt-
fusion, the process of two crypts fusing back to one, is also occurring in adult 
murine intestines (Bruens et al., 2017). Fission and fusion acting in balance could 
maintain the intestine at a certain length through adult life.               
 
Mature intestinal cell types  
The intestinal epithelium is comprised by six different mature cell types that can 
be separated into two major lineages: absorptive cells and secretory cells. The 
absorptive lineage consists of enterocytes and microfold (M) cells. The secretory 
lineage consists of Paneth, goblet, enteroendocrine and tuft cells (Gehart and 
Clevers, 2019).    
 
1.1.3 Enterocytes and M-cells 
Enterocytes are the most numerous cell type in the epithelium and their primary 
function is to absorb nutrients at their brush-border apical surface and export 
them basally (Cheng and Leblond, 1974; Noah, et al., 2011). The other absorptive 
cell type, the M-cell, overlay lymphoid follicles and is specialized to sample and 
transfer luminal contents to underlying immune cells (Lorenz and Newberry, 
2004).  
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1.1.4 Goblet cells         
The goblet cell is the most abundant secretory cell type and accounts for 
approximately 60% of all secretory cells in the small intestine (Cheng and 
Leblond, 1974b). The relative proportion of goblet cells increase from the 
proximal to the distal small intestine  with the highest levels found in the colon 
(Kemper and Specian, 1991). Goblet cells produce and secrete mucus and thus 
are characterised by their globules of mucin that stain positive for Alcian Blue and 
negative for Pas-haematoxylin (Spicer, 1960).  
 
1.1.5 Paneth cells 
Unlike any other differentiated cells in the crypt-villus axis, Paneth cells, found 
only in small intestine, migrate downward and reside interspaced between crypt-
base stem cells upon differentiation (Cheng, 1974c; Wehkamp and Stange, 
2010). Paneth cells are characterised by their granules with high lysozyme 
activity and their main function is thought to be secretion of antibiotic defensins 
in response to bacterial stimuli (Deckx, et al., 1967; Wehkamp and Stange, 2010). 
However, it has been shown that Paneth cells could be a niche providing cell 
since they express factors required for stem cell maintenance (Sato et al., 2011).  
       
1.1.6 Enteroendocrine cells 
Enteroendocrine cells makes up 0.5% of the intestinal epithelium (Cheng and 
Leblond, 1974a) and their main function is to secrete hormones into the 
bloodstream to regulate responses such as appetite sensation and insulin 
production. Thus, enteroendocrine cells can stimulate production of insulin by 
releasing hormones such as glucagon-like peptide 1 and gastric inhibitory 
polypeptide upon food ingestion (Gribble and Reimann, 2019).       
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1.1.7 Tuft cells 
Tuft cells are rare and only constitute 0.4% of the small intestinal epithelium 
during homeostasis and they are characterised by their apical located microvilli 
(Banerjee et al., 2018). Their function remains unknown, however, recently it was 
reported that tuft cells are important players during intestinal parasitic worm 
infections. In response to parasitic infections tuft cells secrete Interleukin-25 
which leads to tuft cell expansion and mounting of a type 2 immune reaction to 
clear the infection (Gerbe et al., 2016; Howitt et al., 2016; von Moltke et al., 2016).   
 
1.2 Lineage specification  
Stem cell maintenance and lineage specification is regulated by opposing 
signalling cascades and transcription factor programmes along the crypt-villus 
axis. In the crypt base active Wnt and Notch signalling maintains stem cells in an 
undifferentiated state. As daughter cells move out of the stem cell niche, changes 
in Wnt and Notch signalling orchestrate differentiation of cells into either the 
absorptive or secretory cell lineages.   
 
1.2.1 Maintenance of stemness 
Intestinal stem cells expresses the Leucine rich G-protein coupled receptor 5 
(Lgr5) on their cell surface (Barker et al., 2007) and are thought to be kept in their 
undifferentiated state by the transcription factor Achaete Scute-Like 2 (Ascl2) 
(van der Flier et al., 2009). The two main signalling cascades that maintain this 
phenotype are canonical Wnt signalling and active Notch signalling.     
 
During canonical Wnt signalling the Wnt ligands bind to Frizzled-LRP5-LRP6 
receptor complex which in turn inhibits the destruction of ß-catenin. Stabilised ß-
catenin will translocate to the nucleus where it regulates gene expression by 
binding with T cell factors (TCFs) (Gehart and Clevers, 2019). The importance of 
Wnt-signalling on stem cell maintenance was underlined in four studies where 
Wnt-signalling was knocked out or inhibited in the murine intestine. Knock out of 
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the ß-catenin interacting transcription factor TCF-4, either conditionally or in the 
germline, showed that TCF-4 is essential for maintaining crypt structures and 
proliferation in adult and neonatal mice, and the lack thereof lead to premature 
death (Korinek et al., 1998; van Es et al., 2012a). In addition, overexpression of 
the Wnt antagonist Dickkopf-1 (Dkk1), also lead to decreased proliferation and 
loss of crypt and villus structures, however mice survived long-term. This was 
probably due to mosaic Dkk1 expression from constructs and transient Dkk1 
expression vectors (Pinto et al., 2003; Kuhnert et al., 2004).  
 
Stem cells are also dependent on active Notch signalling for maintenance of their 
undifferentiated state (VanDussen et al., 2012). Active Notch signalling requires 
direct interaction between two adjacent cells, one expressing the Notch ligand in 
the form of a family member of the Delta-like ligand (Dll) (non-stem cell) and one 
expressing the Notch receptor (stem cell). Upon interaction, γ-secretase cleaves 
the intracellular Notch receptor domain which translocate to the nucleus and 
activates expression of the basic loop helix transcription factor Hes1. Hes1 in turn 
inhibits expression of the secretory lineage commitment factor Atoh homologue 
transcription factor 1 (Atoh1), also known as Math1 (Philpott and Winton, 2014; 
Gehart and Clevers, 2019). The importance of active Notch signalling in stem 
cells was emphasised in a report showing that intestinal knockout of the Notch 
ligand Delta-like1 (Dll1) resulted in permanent stem cell differentiation and stem 
cell loss in the murine intestine (Pellegrinet et al., 2011).    
 
Wnt and Notch ligands are thought to be supplied by niche providing crypt-base 
cells. Paneth cells have been shown to produce Wnt-ligands in vivo  (Sato et al., 
2011; Farin et al., 2016) thus classifying these as niche cells. However, the 
finding that Paneth cell loss does not affect Lgr5+ stem cell function, suggest that 
Paneth cells are not exclusive in serving this function (Kim et al. 2012). Recently, 
sub-epithelial telocytes have been discovered to be an additional niche providing 
cell-type by secreting Wnt ligands at the bottom of the crypt and Wnt-antagonists 
at the top (Shoshkes-Carmel et al., 2018).   
       
Chapter 1: Introduction 
7 
1.2.2 Secretory and absorptive lineage specification  
As daughter cells move out of the crypt-base niche, they lose active Wnt 
signalling. Wnt signalling is thought to decrease up the crypt-villus axis because 
of the poor solubility of Wnt ligands and secretion of Wnt inhibitory molecules by 
mesenchymal cells (Farin et al., 2016; Gehart and Clevers, 2019). This triggers 
the first binary cell-fate decision: to become a secretory or an absorptive cell.  
 
This decision is dependent on Notch signalling. If cells lack cell-cell contact with 
Dll expressing neighbour cells as they move up the crypt, Notch signalling, and 
thus Hes1 expression, will be lost which leads to Atoh1 expression (Philpott and 
Winton, 2014). In turn, Atoh1 expression will start the secretory lineage 
commitment programme (Figure 1.2). Yang et al. and Shroyer et al. showed that 
germline or intestinal specific Atoh1 ablation lead to loss of secretory goblet, 
Paneth and enteroendocrine cells (Yang et al., 2001; Shroyer et al., 2007). 
Likewise, VanDussen et al. showed that Atoh1 overexpression lead to increased 
levels of secretory cells and loss of absorptive cells (VanDussen and Samuelson, 
2010). These findings confirm that secretory cells arise from a common 
progenitor which is dependent on Atoh1 expression.  
 Atoh1+ secretory progenitors are poised to become Paneth cells if 
they migrate down the crypt and encounter active Wnt signalling (van Es, et al., 
2005b), or goblet cells if they do not (Figure 1.2). Differentiation of 
enteroendocrine cells requires subsequent expression of Neurogenin-3 (Ngn3) 
and NeuroD1 (Jenny et al., 2002; Li et al., 2012) (Figure 1.2). 
 Thus, Atoh1 expression constitutes the initial “on” switch for the 
secretory lineage and Atoh1 expressing cells include the earliest secretory 
progenitors. 
 
On the other hand, daughter cells that leave the stem cell niche but do maintain 
active Notch signalling become absorptive progenitor TA cells due to the lack of 
Atoh1 expression. Thus, upon exit from the TA zone they become enterocytes 
(Gehart and Clevers, 2019) (Figure 1.2). Notch-signalling retardation through γ-
secretase inhibition in mice converts proliferative TA-cells into goblets cells,  
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underlining the crucial effect of Notch-signalling on TA-cell commitment to the 
absorptive lineage (Milano et al., 2004; van Es et al., 2005a).  
 
Thus, early lineage choices are dependent on Notch-signalling and Atoh1 
expression. The relative proportion of secretory versus absorptive cell number 
relies on Notch-ligand availability and strongly favours the absorptive lineage.    
 
1.3 Tracing cells in vivo 
Lineage tracing is the process of identifying all offspring of a single cell 
(Kretzschmar and Watt, 2012). In vivo this is mostly achieved through genetic 
recombination. Here, DNA recombinases are often expressed in a cell-type 
specific manner. Activation of recombinases in cell(s) of interest activates a 
conditional reporter gene to permanently label the cell and its descendants. 
Reporter genes often confer colour labelling to cells for visualisation. The first 
reporter developed was a Cre inducible LacZ allele (Soriano, 1999). However, 
since ß-galactosidase activity is not directly visible, most reporters today employ 
inducible fluorescent proteins (Kretzschmar and Watt, 2012).  
 Lineage tracing in the intestine is thus carried out by marking a single 
cell with a colour and following the multiplication of daughter cells or clones over 
time (Figure 1.3). Therefore, lineage tracing can be used to test stemness in vivo. 
If lineage traced cells have stem cell abilities, they can give rise to daughter cells 
of multiple lineages that move up the crypt and villus (in the small intestine) to 
give rise to long-lived clones (ribbons) (Figure 1.3A). In addition, lineage-traced 
clones can be visualised in the crypt base to study stem cell replacements and 
clonal growth in pulse-chase experiments conducted over several timepoints 
(Figure 1.3B-C) (discussed later).   
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1.4 Plasticity  
The intestinal epithelium is a highly regenerative organ. This is displayed by the 
complete organ renewal every 3-4 days and the impressive capacity of 
regeneration following tissue damage. Intestinal regeneration is fuelled by rapid 
cycling stem cells. Remarkedly, when mice are exposed to full body irradiation 
that results in haematopoietic failure and stem cell depletion, the intestine can 
still regenerate (Beumer and Clevers, 2016). In addition, if Lgr5+ stem cells are 
depleted the gut appears to be unaffected (Tian et al., 2011). Together, these 
results demonstrate the presence of plastic cells that can reacquire stem cell 
function during tissue regeneration.  
 
1.4.1 Plasticity of progenitors  
There are different theories that explains cell plasticity in the intestine, the two 
main models describe the activation of “sleeping” quiescent stem cells or 
dedifferentiation of committed progenitors to re-enter the stem cell pool.  
 
Several early studies identified what was believed to be quiescent stem cells in 
intestinal crypts. Accordingly, by utilizing a Bmi1CreErt mouse two groups 
described the existence of Bmi1+ non-proliferative cells at position +3-4 in the 
crypt (Sangiorgi and Capecchi, 2008; Yan et al., 2012) (Figure 1.1). Bmi1+ cells 
gave rise to stem cell derived clones and upon irradiation the number of Bmi1+ 
cells increased whereas Lgr5+ cells were depleted. Similar results were obtained 
when using the mouse telomerase reverse transcriptase (mTert)-GFP and the 
Homeobox-only protein x (Hopx)CreErt mouse. Here the authors show that mTert 
and Hopx marked slowly proliferating cells that gave rise to stem cell clones 
(Montgomery et al., 2011; Takeda et al., 2011). In addition, mTert+ cells were 
resistant to irradiation and had a high regenerative potential (Montgomery et al., 
2011). Together these publications described the presence of slowly cycling cells 
that can contribute to the stem cell pool upon reactivation.  
 The existence of “sleeping” stem cells that are spared proliferative 
damage have been speculated to be an evolutionary strategy to maintain the 
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integrity of the intestinal stem cell genome. However, this concept implies that 
such cells are destined to only serve a purpose if re-activated. This idea has been 
heavily debated in the community, and therefore, a study was designed to define 
the exact nature of quiescent stem cells. Instead of defining such cells based on 
gene-expression Buczacki and colleagues identified quiescent stem cells based 
on their slowly-cycling properties (Buczacki et al., 2013). In an elegant mouse 
model, they separated the Cre recombinase into two polypeptides (CreA and 
CreB). CreA was expressed constitutively in all cells whilst the CreB was inducibly 
expressed from as a Histone-2B (H2B) fusion construct. Following a pulse of 
H2B-CreB expression, due to cell division, CreB would be diluted out in 
proliferating cells, and therefore, the two complimentary halves of Cre would only 
be present in slowly cycling cells. A dimerizing agent was utilized to activate Cre 
which resulted in linage tracing of slowly cycling cells. This study showed that 
slowly cycling cells are secretory progenitor cells that can re-gain stem cell 
potential during regeneration (Buczacki et al., 2013). Thus, the study exemplified 
that the quiescent stem cell pool consists of committed progenitors that can serve 
as stem cells or as functional differentiated cells.    
 
The discovery that progenitors can contribute to the stem cell pool provides a 
large alternative source of stem cell potential. Several studies have confirmed 
that stem-cell reactivation of progenitors is occurring in vivo. This was 
emphasised in a study that lineage-traced secretory enteroendocrine cells 
expressing Ngn3 and showed that such cells produced rare stem cell clones 
during homeostasis (Schonhoff et al., 2004). An additional study showed that 
Dll1+ secretory progenitors only contributed to the stem cell pool following 
damage (van Es et al., 2012b). Furthermore,  doublecortin like kinase 1+ (Dclk+) 
tuft cells have also been shown to produce rare stem cell clones during 
homeostasis (Westphalen et al., 2014).  
 Cells of other lineages are also plastic. This was demonstrated in a 
study that lineage traced the most abundant intestinal cell type:  Alkaline 
Phosphatase Intestinal+ (Alpi+) absorptive enterocytes and progenitors thereof. 
The results showed that Alpi+ cells only rarely contributed to the stem cell pool 
during tissue homeostasis (Figure 1.2). In contrast, the contribution of this cell 
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type increased when Lgr5 cells were depleted, suggesting a role for them during 
tissue regeneration (Tetteh et al., 2016). Interestingly, Alpi+ stem cell contribution 
decreased the longer the time interval between Alpi tracing and Lgr5 depletion. 
This suggested that the further up the crypt Alpi+ cells migrated the smaller their 
dedifferentiation potential (Tetteh et al., 2016). 
 
Together, these results indicate that committed progenitors contribute to the stem 
cell pool both during homeostasis, and to a larger extent, during damage. 
Furthermore, it seems that the degree to which progenitors regain stem cell 
properties is dictated by where in the lineage hierarchy they reside. The closer to 
their stem cell origin the greater the stem cell potential.  
 This is exemplified by studying the earliest secretory progenitors 
marked by Atoh1 expression. Ishibashi and colleagues related data from Atoh1+, 
Dll1+ and Dclk1+ lineage tracing to compare their relative stem cell contribution 
during homeostasis. By doing so the authors showed that Atoh1+ secretory 
progenitors have a 10-fold higher stem cell contribution potential in homeostasis 
compared to the further differentiated Dll1+ cells and Dclk1+ cells (Ishibashi et 
al., 2018). Later, Tomic et al. constructed a mouse with impaired Atoh1 
phosphorylation potential. Through lineage tracing experiments the authors 
compared the stem cell potential of Atoh1 and phospho-deficient Atoh1 cells and 
it was revealed that stem cell contribution is dependent on Atoh1 phosphorylation 
(Tomic et al., 2018). Furthermore, Atoh1 derived stem cells have an enhanced 
regenerative potential upon colitis induced injury compared to other secretory 
progenitors (Castillo-Azofeifa et al., 2019).  
 Conclusively, these publications demonstrate that Atoh1+ progenitors 
have the highest homeostatic stem cell contribution potential, compared to other 
lineage restricted progenitors. In addition, these studies underline that Atoh1+ 
progenitors contribute significantly to the stem cell pool in homeostasis and 
during injury (Figure 1.2). This greatly enhances the size of the stem cell pool.  
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1.4.2 Regulation of plasticity 
Thus, it is now clear that intestinal cell specification is not always restrictive, and 
that cell fate is defined in a background of context dependent continuum. The 
factors that regulate plasticity are still under investigation. It is clear that tissue 
injury increases the number of cells that fall back into the stem cell pool. Several 
studies have indicated that Wnt and Epidermal growth factor receptor (EGFR) 
signalling are crucial for regeneration following tissue injury and intestinal DNA-
damage (Valentin-Vega et al., 2008; Ashton et al., 2010). In addition, Tomic et al. 
showed that post-translational modifications can regulate the availability of cell 
fate determinants such as Atoh1 (Tomic et al., 2018). In all likelihood, several 
plasticity regulatory pathways will be uncovered in the future.     
  
1.5 Stem cell dynamics  
Plasticity provides a mechanism to protect the integrity of the intestinal 
epithelium. Another layer of protection is applied during stem cell renewal and 
competition in the crypt base. As the size of the intestinal stem cell pool remains 
constant over time, it was believed for many years that stem cells undergo 
asymmetrical division to produce one cell destined for differentiation and one 
stem cell. This theory was mainly fuelled by publications showing that intestinal 
stem cells segregate their DNA asymmetrically during division (Potten et al. 
2002). However, early studies that utilized a random mutagen or chromosome X-
inactivation to study loss of a protein-stain in the murine intestine showed that 
crypts become monoclonal over time, thus disputing the idea that single stem 
cells divide asymmetrically (Griffiths et al., 1988; Winton et al., 1988).  
 
1.5.1 Neutral stem cell drift  
Two studies set out to decipher the fate of single stem cells to determine the exact 
nature of stem cell self-renewal in the murine intestine. One study followed clonal 
growth over time by lineage tracing less than one stem cell per crypt. The results 
showed that the total number of labelled clones declined over time but the relative 
size of surviving clones increased, resulting in 80% of crypts being monoclonal 
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(clonal fixation) after 16 weeks (Lopez-Garcia et al., 2010). The other study 
labelled multiple Lgr5-GFP+ cells in crypts by utilizing a reporter allele that 
randomly allocates one of 4 colours per cell (Confetti-allele). To this end, each 
Lgr5-GFP+ stem cell had a distinct colour at initial labelling which made it possible 
to follow clonal growth over time (Snippert et al., 2010). The results showed the 
same pattern of reduced clone numbers but increased clonal size over time as 
described by Lopez-Garcia and colleagues (Lopez-Garcia et al., 2010). The 
overall conclusion from these ground-breaking studies was that “stem cells follow 
a pattern of neutral drift in which the loss of a stem cell is compensated by the 
multiplication of a neighbour” (Lopez-Garcia et al., 2010).  
 Consequently, during stem cell clonal growth, single cells will divide 
and replace each other in a stochastic manner, thus, clones can grow and 
regress, but with time one clone will win and convert the crypt to monoclonality 
(Figure 1.3B-C). To explain this behaviour in quantitative terms, both papers 
assumed the number of stem cells per crypt to be approximately 15-20 based on 
the number Lgr5+ cells defined by Barker et al. 2007 and used mathematical 
modelling to infer that each stem cell is replaced 0.75-1 times per day (Lopez-
Garcia et al., 2010; Snippert et al., 2010). These findings indicated that the 
majority of intestinal stem cell divisions are actually symmetrical and that the 
decision to exit the stem cell zone and become a TA-cell and committed 
progenitor is based on competition and extinction from the crypt base.    
 
However, since the two above papers were published other reports used single 
molecule in situ hybridisation to document that the Lgr5+ pool also expresses 
markers for committed progenitors (such as mTert, Hopx and Bmi1) that are 
located further up the crypt at location +4 and thus outside the stem cell zone 
(Figure 1.1) (Itzkovitz et al., 2012; Muñoz et al., 2012). This implied that 
evaluating stem cell number based on Lgr5-expression may not always be 
accurate since this population is overlapping with other non-stem cells. Since the 
publications reviewing neutral drift had based their stem cell numbers (and thus 
the inferred stem cell replacement rate) on Lgr5-expression, estimates could be 
inaccurate.  
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In an elegant report, Kozar and colleagues investigated stem cell number and 
stem cell replacement patterns by a Lgr5 free method (Kozar, et al., 2013). Here, 
they utilized a mouse model that encoded a fluorescent reporter that was 
prevented from being expressed by an unstable CA[30] microsatellite. The 
CA[30] microsatellite placed the reporter complimentary DNA (cDNA) out of 
frame and during replication, frameshift mutations in the CA[30] repeat region 
lead to stable marker expression and clonal labelling. Thus, with mouse ageing 
an increasing number of crypts were marked, so-called continuous labelling. The 
results identified a constant level of partially populated crypts (PPCs) over all 
mouse ages (Kozar, et al., 2013). This fitted the assumption that new marked 
clones accumulate over time and that some of these will reach monoclonality to 
become wholly populated crypts (WPCs). As WPCs are derived from PPCs, the 
size of the PPC population was at a steady size over time. Furthermore, an 
expected linear increase in WPCs crypts was also observed (Kozar, et al., 2013). 
Computer simulations estimated that rate of WPC accumulation depended on the 
mutation rate of CA[30] and the stem cell replacement rate and that the frequency 
of PPC depended on the CA[30] mutation rate and the number of stem cells per 
crypt. Thus, by estimating the CA[30] mutation rate and using mathematical 
modelling Kozar et al. concluded that crypts in proximal small intestinal and colon 
are maintained by 5-7 cells, that are replaced 0.1 – 0.3 times per day, respectively 
(Kozar, et al., 2013). These numbers were in striking contrast to the numbers 
reported by Barker et al. 2007, Lopez-Garcia et al. 2010 and Snippert et al. 2010 
and showed that only a small pool of “functional” stem cells, or inferred clonogenic 
fraction, is driving neutral drift in each crypt.  
 
1.5.2 Human stem cell dynamics  
Since these studies much effort has been made to understand how stem cells 
behave in the human colon. For obvious reasons it is not possible to use 
genetically modified reporter genes in humans and thus the community has 
searched for other naturally occurring labels that can mark stem cell clones. 
Taylor and colleagues found that mitochondria DNA (mtDNA) in human colonic 
stem cells is subject to common spontaneous mutations that cause cytochrome 
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c deficiency resulting in a negative staining pattern in the crypts affected (Taylor 
et al., 2003). The group reported that this staining pattern reflected age-
accumulated colonic clones (Taylor et al., 2003). These clones represented the 
first collected continuous-labelling data-set from humans and created an exciting 
way to lineage trace humane intestinal stem cells. Later, the same research group 
showed that these mtDNA clones become fixed in the crypt over time and that 
such mutated crypts spread via fission to create crypt-patches (Greaves et al., 
2006). Baker et al. concluded that colonic cytochrome c deficient clones follow a 
pattern of neutral drift and inferred the number of human colonic stem cells to be 
5 per crypt (Baker et al., 2014).  
 
Later, Nicholson et al. discovered another human clonal mark: detection of loss 
of O-acetylation of sialomucins using a mild reductive periodic acid Schiff (mPAS) 
stain. This mark is thought to arise from somatic mutations in the human genome 
rather than those arising from mtDNA mutations. By screening for mPAS+ clones 
in healthy human colon tissue from patients of different ages the authors showed 
that the number of PPCs remained constant with age, but the number of WPCs 
increased in the same fashion as was described in the murine intestine by Kozar 
et al., 2013. By determining the mutation rate of mPAS staining, and using the 
relationship between PPCs and WPCs the authors used Bayesian inference to 
define that stem cell renewal arises from the activity of around 7 stem cells per 
human colon crypt which replace each other approximately 1.3 times/year/crypt 
(Nicholson et al., 2018).  
 
Thus, it appears that the number of stem cells per crypt is very similar in humans 
and mice, however, the rate by which clones drift toward fixation is approximately 
100-fold faster in mice compared to humans. This discrepancy could stem from 
a much slower stem cell proliferation rate in humans or could be because human 
stem cells divide mostly asymmetrical, creating very few cells for clonal drift 
(Stamp et al., 2018). However, it seems more likely that the timing of stem cell 
dynamics in human colonic crypts reflects a resolved behaviour that has not yet 
been fully explained in the literature.                     
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1.6 Intestinal cancer  
Colon and rectal (colorectal) cancer is the third most common cancer worldwide 
and accounts for approximately 10% of cancer related mortality (Kuipers et al., 
2015). There are two major subgroups of colorectal cancer; the hereditary and 
the non-hereditary forms. Lynch Syndrome, a form of hereditary colorectal 
cancer, results from germline mutations in DNA mismatch repair genes such as 
MutL Homolog 1 (MLH1), MutS protein Homolog 2 (MSH2), PMS2 and Epithelial 
Cell Adhesion Molecule (EPCAM). Impaired DNA mismatch repair during 
replication causes accumulation of DNA mutations in microsatellite regions 
(microsatellite instability, MSI) and increased risk of developing cancer at an early 
age. Familial adenomatous polyposis (FAP), another form of hereditary colorectal 
cancer, is caused by germline mutations in the Adenomatous Polyposis Coli 
(APC) gene that controls the activity of the Wnt signalling pathway (Kuipers et al., 
2015). Most patients with this disease develop multiple colorectal adenomas and 
colorectal cancer at an early age. In the following, the non-hereditary sporadic 
form of colorectal cancer will be discussed.  
       
1.6.1 Non hereditary colorectal cancer  
The common risk factors for sporadic colorectal cancer development are lifestyle 
and inflammatory diseases such as inflammatory bowel disease, ulcerative colitis 
or Crohn’s Ileocolitis. Sporadic colorectal cancer is initiated with aberrant crypts 
which can progress into polyps that can develop into early and late adenomas 
which, with time, can become carcinomas. This process takes 10-15 years and 
is driven by sequentially acquired somatic mutations and epigenetic alterations 
that activate oncogenes or silences tumour suppressor genes (Kuipers et al., 
2015). In 1990 Fearon and Vogelstein stated that the majority of adenomas that 
develop into carcinomas follow a sequence of events initiated by mutations and 
loss of function of APC. Next, step-wise acquisition of hypomethylated tumour 
suppressor genes, oncogenic mutations in Kirsten Rat Sarcoma (KRAS), loss of 
chromosome 18q and Tumour Protein 53 (TP53) mutations drives the process 
(Fearon and Vogelstein, 1990).  
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 However, since the publication of this paradigm setting paper, it has 
become evident that sporadic colorectal cancer is a heterogenous disease. For 
improved clinical intervention it is important to be able allocate clinical sub-types 
to the disease, thus, many efforts have been made to define such. Most studies 
divide sporadic colorectal cancer into 3 main subgroups: 1) a subgroup that 
displays a high degree of chromosome instability (CIN) 2) a subgroup that 
displays an aberrant CpG island methylation phenotype (CIMP) which results in 
silencing of tumour suppressor genes and 3) a subgroup that is initiated by 
somatic mutations in mismatch repair genes causing MSI and hypermutated 
tumours (Fearon, 2011; Nojadeh et al., 2018). Additionally, a newly recognised 
subgroup which evolves through sessile serrated polyps and comprises 5-10% 
of cases has been identified (De Sousa E Melo et al., 2013). The initiating event 
for such are thought to be oncogenic mutations in BRAF and KRAS (Kuipers et 
al., 2015). Furthermore, next generation sequencing of hundreds of human 
colorectal tumours allocated two major subtypes to sporadic colorectal cancer: 
the hypermutated tumours wherein the highest mutated genes are Activin A 
Receptor Type 2A (ACVR2A) (63%), APC (51%), and Transforming Growth 
Factor, Beta Receptor II (TGFBR2) (51%) and non-hypermutated tumours 
wherein the highest mutated genes are APC (80%), TP53 (60%) and KRAS 
(43%) (The Cancer Genome Atlas Network, 2012). Additionally, several research 
groups have tried to classify the disease based on clinical outcome (Sadanandam 
et al., 2013; Phipps et al., 2015).  
  
Recently, a study decided to assign molecular subtypes to classify the disease 
based on transcriptional behaviour instead of mutation profile. This report 
combined gene expression data from 18 different studies to define four 
consensus molecular subtypes: the microsatellite instability immune subtype 
(CMS1), the hypermutated microsatellite unstable and strong immune activation 
(CMS2), the epithelial, marked Wnt and Myc signalling activation (CMS3) and 
epithelial and evident metabolic dysregulation subtype (CMS4) (Guinney et al., 
2015). Some subtypes showed a clear enrichment for certain mutations such as 
KRAS mutations in CMS3, however none of them were defined by an individual 
event and no genetic mutation was limited to a subtype (Guinney et al., 2015). 
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However, mutations in APC were common to all subtypes, which supports the 
crucial role for this gene in tumorigenesis. Several mouse studies have confirmed 
this by showing that Apc loss can initiate multiple intestinal tumours in vivo (Su et 
al., 1992; Cheung et al., 2009; Robanus-Maandag et al., 2010).        
 
Therefore, it appears that colorectal cancer development cannot be summed up 
by any specific sequence of events and it seems much is still to be discovered 
about the initiation of the disease.  
 
1.7 Tumour initiation 
 
1.7.1 Cell of origin 
Since the intestine displays a high degree of plasticity it has been heavily debated 
what cell type constitutes the cell of origin in intestinal tumorigenesis. As the 
intestinal epithelium is renewed every 3-4 days it is clear that accumulation of 
cancerous mutations must be present in stem cells, or change the migration 
abilities of the cell of origin, to be maintained in the tissue over time.  
 
Therefore, it has generally been believed that transformative mutations originate 
in stem cells. This was disputed by a study showing that early neoplastic lesions 
contain dysplastic cells and APC mutations in the upper crypt only (a non-stem 
cell zone), with the base of the crypt looking histologically normal (Shih et al., 
2001). The authors debated a “Top-Down” origin of intestinal tumours, where 
cells in intercryptal zones encode the transformative mutational event. These 
cells could divide and migrate down to occupy the whole crypt and thus could be 
the cell of origin. This was later refuted in a report studying colonic tissue from 
patients with FAP to catch the earliest lesions possible (Preston et al., 2003). This 
study showed that the earliest adenomas consist of discrete monoclonal crypts 
that stop sharply at the junction of the surface epithelial, and thus do not involve 
the intercryptal zones (Preston et al., 2003). In addition, adenoma development 
Chapter 1: Introduction 
21 
was shown to be a result of crypt fission, supporting a “Bottom-Up” origin of 
colorectal tumours. In this model, the transformative event takes place in stem 
cells which create clones that expand stochastically making the crypt monoclonal 
over time. The monoclonal crypt can then spread by fission (so-called lateral 
spread) to progress tumour development (Preston et al., 2003).            
 
To confirm that stem cells can initiate tumours Barker and colleagues showed 
that Apc deletion in Lgr5+ cells resulted in a high tumour penetrance with rapidly 
growing adenomas being macroscopic after 3-5 weeks (Barker et al., 2009). This 
confirmed that intestinal stem cells can in fact initiate tumours if they harbour 
cancerous mutations. Several other studies have confirmed this by deleting Apc 
or stabilising ß-catenin in stem cells by activating stem cell restricted Cre 
recombinases: (Sangiorgi and Capecchi, 2008; Zhu et al., 2009; Powell et al., 
2014).      
 In contrast, when researchers have tried to employ non-stem cells as 
tumour initiating cells in vivo it has been obvious that they have much lower 
tumour initiation capabilities than stem cells. This was emphasised by Barker et 
al. (2009). By using low level intestinal epithelium specific Cre recombinase 
activity (Ireland et al., 2004), Barker et al. deleted Apc in TA cells. By doing so, 
they saw a low penetrance of tumours, although some ß-catenin foci and 
microadenomas were retained in the upper crypt over time (Barker et al., 2009). 
In addition, deletion of Apc combined with oncogenic activation of Kras in Alpi+ 
enterocytes did not give rise to tumours in vivo (Tetteh et al., 2016). Similarly, 
deletion of Apc in tuft did not provoke any tumour formation. However, dextran 
sodium sulfate (DSS) exposure (an inflammation inducing agent) lead to multiple 
colonic tumours arising from tuft cells with Apc deletions (Westphalen et al., 
2014). In addition, Schwitalla and colleagues constructed a mouse model where 
Cre is only active in non Lgr5 cells (X-Box Binding Protein 1, Xbp1CreErt) 
(Schwitalla et al., 2013). By using this model they showed that stabilised ß-
catenin alone was not sufficient to drive tumour initiation in non-stem cells, 
however, combining stabilisation of ß-catenin with loss of IκBα (inhibitor of the 
NF-κB pathway) lead to de-differentiation and tumour initiation of Lgr5 negative 
cells (Schwitalla et al., 2013). 
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Together these results suggest that intestinal stem cells have a greater tumour 
formation capability than non-stem cells. However, differentiated progenitor cells 
are able to form tumours if they are exposed to intestinal injury/inflammation. This 
leads to the hypothesis that progenitors will mostly initiate tumours if they fall back 
into the stem cell pool, thus underlining that stem cells almost certainly are the 
cell of origin in colorectal cancer. Nevertheless, it is not clear whether cancer 
drivers promote stem cell contribution from different progenitors or not.      
 
1.7.2 Biased stem cell competition could fuel tumour initiation  
As described earlier stem cell drift is determined by a small number of cells and 
thus it is interesting to speculate that perturbations can have big effects on stem 
cell homeostasis. An exciting paper set up to explore how different oncogenic 
alterations affect stem cell behaviour. Vermeulen et al. 2013, used low Cre 
recombinase activity (Kemp et al., 2004) to express oncogenic Kras, p53 or 
delete of Apc in less than one stem cell per crypt. By examining the size of 
oncogenic stem cell clones over time it was possible, via mathematic modelling, 
to determine if such clones had any competitive advantage over their WT 
neighbours. These results showed that heterozygous and homozygous Apc 
deleted stem cells had a 69% and 79% chance of replacing their neighbours, 
respectively, during clonal drift (Vermeulen et al., 2013). In addition, oncogenic 
p53 had little effect on clonal growth unless mice were exposed to DSS where 
after p53 clones had a 58% chance of replacing their neighbours (Vermeulen et 
al., 2013). Lastly, stem cells expressing oncogenic Kras had a 78% chance of 
outcompeting their WT neighbours over time (Vermeulen et al., 2013). Together, 
these observations demonstrated that oncogenic alterations can alter stem cell 
behaviour and confer competitive bias to such stem cells during clonal drift. This 
means that stem cells harbouring such oncogenic mutations are more likely to fix 
in the crypt and thus be present in the intestinal epithelium long-term.  
 
Such biased stem cell behaviour was later confirmed in the human colon. The 
same paper that studied the neutral mPAS clonal mark in the human colon also 
studied other biased clonal marks (Nicholson et al., 2018). By screening for loss 
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of X-chromosome linked proteins the paper identified loss of Stromal Antigen 2 
(STAG2) as a clonal mark. Quantification of clones in human colonic tissue 
allowed them to identify PPCs and WPCs in patients of different ages. If STAG2 
clones had a competitive bias it would be expected that the transition from PPC 
to WPC would be accelerated, compared to that of neutral mPAS clones. Thus, 
comparison of WPC/PPC ratios showed that STAG2 clones had a strong 
competitive advantage during monoclonal conversion (Nicholson et al., 2018). 
This underlines that biased competition also occurs in the human colon and thus 
this could be the first event in colorectal cancer development.        
              
1.7.3 Tumour origin 
In 1987 Fearon and colleagues examined the level of X-inactivation in colorectal 
tumours from females to determine tumour clonality. This study concluded that 
all tumours analysed (N=50) were of monoclonal origin (Fearon et al., 1987). This 
was later confirmed in vivo, by studying the staining pattern of Glucose-6-
phosphate dehydrogenase (G6PD) in tumours from heterozygotes G6PD 
deficient mice induced with mutagens or by using Lgr5 driven multicolour lineage 
tracing system in tumour-prone animals (Griffiths et al., 1989; Schepers et al., 
2012). However, several studies have established that colorectal tumours can 
also be of poly-clonal origin. In 1997, a study used Y-chromosome in situ 
hybridisation in a XO/XY male with FAP to show that 76% of microadenomas in 
this patient were polyclonal (Novelli et al., 1997). Later, Merritt et al. used Apcmin 
mice chimeric for a lineage tracing allele to show that 22/260 tumour analysed 
were polyclonal (Merritt et al., 1997).  
 Thus, it seems that most tumours arise from a single crypt, or a single 
patch of crypts. However, that does not mean that tumours do not encode 
different mutational clones. Such clones could be acquired through successive 
mutational clonal sweeps to populate tumours entirely during progression. If so, 
little to none intra-tumour heterogeneity would be present in tumours. However, 
intra-tumour heterogeneity in human colorectal tumours has been confirmed by 
sampling single tumour glands from two sides of the same tumour. The first report 
to study intra-tumour heterogeneity submitted such samples to genomic 
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sequencing and methylation pattern analysis to show that there was a high 
degree of clonal heterogeneity between different tumour glands from the same 
tumour (Sottoriva et al., 2013). This concept was further explored by the same 
first author in 2015. By using the same tumour sampling technique and advanced 
computational modelling the authors could conclude that intra-tumour 
heterogeneity occurred early in tumour growth and that selective clonal sweeps 
were rare after the transition to an advanced tumour because of spatial 
constraints (Sottoriva et al., 2015). From these results a new model of tumour 
initiation arose: the “Big Bang” model which dictates that colorectal tumours grow 
as a single expansion of numerous intermixed sub-clones when a critical 
molecular threshold has been reached (Sottoriva et al., 2015).  
 
Thus, it appears that colorectal tumours originate from tissue that is “primed” with 
oncogenic clones before overt tumour formation, so-called field characterisation, 
field cancerisation or field effect.  
 
1.7.4 Field effect primes cancer initiation 
Somatic mutations accumulate in normal cells with age and this is thought to be 
an unavoidable trait of self-renewing tissues. Age accumulated somatic 
mutations have been debated to mainly arise from intrinsic replication errors thus 
making ageing the biggest risk factor of cancer development (Tomasetti, et al., 
2017). This is highlighted in a study showing that the lifetime risk of developing 
cancer is highly correlated with the total number of stem cell divisions the tissue 
has undergone (Tomasetti and Vogelstein, 2015). A field effect can be described 
in many ways but for the purposes of this thesis they will be defined as: “the 
expansion of cells with acquired pro-tumorigenic mutations that does not produce 
morphological alterations but predisposes to cancer formation” (Patel et al., 
2015).  
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1.7.5 Field effect in different tissues 
A study that examined the total number of mutations in different types of tumours 
inferred that half or more of all tumour mutations are present in the tissue before 
apparent tumour formation (Tomasetti, et al., 2013). Thus, the presence of pro-
oncogenic fields seems to be a general trait in many different tissues.  
 That is exemplified in a variety of papers. For instance, ultra-deep 
sequencing of eye-lid skin, has shown that physiological and histological normal 
skin carry as many as 0.29 known cancer driver mutations per cell (Martincorena 
et al., 2015). Analysis of clone sizes showed that some mutant clones were 
significantly larger than synonymous clones, suggesting increased selection and 
clonal expansion of some mutations (Martincorena et al., 2015). However, a 
follow up study later used mathematical modelling to predict that out of 1338 
mutant clones identified by Martincorena et al., only 6 had clonal sizes that would 
imply a non-neutral expansion (Simons, 2016). Thus, it appears that most clones, 
both mutant and synonymous, behave neutrally in the skin epidermis. Together, 
these studies elegantly showed that fields, in the form oncogenic clones, are 
present before the onset of tumour formation. Within such fields the pro-
oncogenic population is expanded.    
 Martincorena et al. later applied their technology to oesophageal 
samples from healthy organ donors of different ages. Here they showed that 
somatic mutations accumulate with age and that some oncogenic mutations are 
under strong selection in the aging oesophageal tissue (Martincorena et al., 
2018). An interesting finding from this study was that a mutation that is only rarely 
found in oesophageal cancer was found in enormous amounts in the normal 
tissue (Martincorena et al., 2018). This proves that some non-cancerous 
mutations can also be subject to positive selection and could be of protective 
nature.  
 However, field effects have not only been observed in epithelial 
tissues. An important study that sequenced normal control blood samples from a 
variety of cancer patients showed that somatic mutations also accumulate in the 
haematopoietic system with age (Xie et al., 2014). A subset of these samples 
also contained oncogenic mutations that are known to cause clonal expansion 
and blood cancer (Xie et al., 2014).  
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Together, these studies underline that some oncogenic fields are present before 
tumorigenic transformation thus priming different tissues to reach the critical 
threshold for cancer initiation (Hanahan and Weinberg, 2011).   
 
1.7.6 Intestinal field effect 
Importantly, field effect is also a known concept in human colonic tissue. Colonic 
mutational fields are thought to arise through the process of acquiring a mutation 
in an intestinal stem cell followed by mutated clone fixation and crypt fission 
(Figure 1.4) (Patel et al., 2015). Many publications have shown that oncogenic 
mutational fields are present in colonic tissue prior to tumour formation: (Chen et 
al., 2005; Galandiuk et al., 2012; Nicholson et al., 2018).  
 One of the most reported field effect causing alterations is the 
oncogenic KRAS mutation (discussed later). It has been shown that Kras 
mutations confer advantaged behaviour to stem cells and that mutated Kras 
crypts have an increased fission rate in the murine intestine (Vermeulen et al., 
2013; Snippert et al., 2014). Together, this gives KrasG12D mutations the potential 
for creating pre-neoplastic fields in vivo.  
1.8 Ras  
The RAS genes were first discovered as being involved in the oncogenic Harvey 
murine sarcoma virus and the Kirsten murine sarcoma virus (Cox and Der, 2010) 
and they constitute the most frequently mutated oncogenes in human cancer 
(Cox et al., 2014).  
 The RAS family constitutes: Neuroblastoma RAS (NRAS), Harvey 
RAS (HRAS) and KRAS. RAS proteins are membrane bound GTPases and with 
the help of guanine nucleotide exchange factors (Gefs) and GTPase activating 
proteins (Gap) they switch between their inactive GDP bound form to the active 
GTP bound form (Hobbs et al., 2016) (Figure 1.5). Active Ras binds to and 
activates multiple different targets to induce cellular responses such as 
proliferation, protein synthesis and survival (Pylayeva-Gupta, et al., 2011). The 
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 two main signalling cascades that Ras proteins activates are: the 
Phosphoinositide 3-kinae (PI3K) / Akt / mammalian target of rapamycin (mTor) 
pathway and the Raf / mitogen activated kinase (Map/Mek) / extracellular 
regulated kinase (Erk) pathway (Pylayeva-Gupta et al., 2011) (Figure 1.5).  
 
1.8.1 Oncogenic Ras and tumour initiation 
KRAS is the predominant oncogenic RAS family member involved in colorectal 
cancer. There are three main oncogenic hot spots in the KRAS: glycine-12 (G12), 
glycine-13 (G13) and glutamine-61 (Q61). Oncogenic mutations in these hotspots 
render KRAS constitutively active (Figure 1.5).  
 The transformative capabilities of RAS proteins have been debated. 
Early in vitro studies showed that RAS alone is not enough to transform fibroblast 
and kidney cells in culture (Land et al., 1983; Ruley, 1983). However, combining 
RAS with other oncogenes or loss of tumour suppressor genes lead to 
transformation of the cell lines (Land et al., 1983; Ruley, 1983). In contrast, the 
first in vivo reports to study Ras function overexpressed Hras during mouse 
development or in adult transgenic mice. These investigations showed that Hras 
alone could lead to tumour formation in the foetal exocrine pancreas and in the 
adult mammary and salivary glands and lymphoid tissue, suggesting that Ras 
expression alone can initiate tumours in vivo (Quaife et al., 1987; Sinn et al., 
1987).  
 
KRAS is mutated in up to 50% of all colorectal tumours and thus many efforts 
have been made to understand its tumour initiating potential in the intestine 
(Pylayeva-Gupta, et al., 2011). In an interesting report, Janssen and colleagues 
over-expressed oncogenic KrasG12V in the entire intestinal epithelium and saw 
tumours occurring with high penetrance (Janssen et al., 2002). These tumours 
were negative for nuclear ß-catenin suggesting that tumours arising from Kras 
activation do not follow the classical Apc route. However, with the development 
of inducible KraslslG12D/V animals, which encode the G12D or the G12V mutation 
at the murine Kras locus, it was possible to explore what effect endogenous 
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KrasG12D/V expression has on intestinal tumour development (Jackson et al., 
2001; Guerra et al., 2003). This was an important development since KRAS is 
normally mutated but not overexpressed in human colorectal tumours. Two 
separate studies showed that long term expression of KrasG12D from the 
endogenous allele leads to hyperproliferating intestinal crypts but not tumour 
formation (Haigis et al., 2008; Feng et al., 2011). However, intestinal KrasG12V 
expression appeared to have no immediate morphological effect, although, after 
long-term exposure (>500 days) mice did develop intestinal tumours (Sansom et 
al., 2006). Interestingly, expression of oncogenic Kras in combination with loss of 
tumour suppressor genes greatly increases tumour burden and tumour 
aggressiveness in the murine intestine (Jackstadt and Sansom, 2016).  
 
Based on these observations, oncogenic Kras appears to be a poor initiator of 
intestinal cancer in vivo.  
 
1.8.2 Colonic Kras field effect 
Oncogenic KRAS mutations in codons 12 and 13 have been discovered in normal 
human colon mucosa by highly sensitive PCR methods (Dieterle et al., 2004; 
Kraus et al., 2006; Parsons et al., 2010). Parsons et al. predicted the KRAS 
mutant fraction (i.e how many cells had the mutation per sample) in normal 
mucosa and tumour tissue (Parsons et al., 2010). By doing so they showed that 
normal mucosa contains a significantly lower KRAS mutant fraction than tumours, 
suggesting that some tumours could arise from KRAS fields (Parsons et al., 
2010). However, because of the nature of the PCR based experiments is was 
hard to extrapolate field growth from these results.  
 The nature of mutant KRAS field growth has mostly been studied in 
patients with Ulcerative Colitis or Chron’s Illeocolitis. Such patients are subject to 
chronic colonic inflammation that causes regeneration and thus increased 
replication and/or direct DNA damage (Baker et al., 2018). In such conditions 
clonal expansion is greatly enhanced. In addition, such patients are often subject 
to colonic resections making it possible to examine mutation burden in a spatial 
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manner. To this end, one publication showed that a Ulcerative Colitis patient 
carried oncogenic KRAS mutations in 3 independent tumours and normal crypts 
which were located up to 14 cm apart (Leedham et al., 2009). These results 
indicate that KRAS fields can cover big colonic areas and shows that mutations 
in KRAS could be an early oncogenic event. In addition, an important study that 
followed the same Chron’s Illeocolitis patients over several years could map the 
spread of mutational fields over time. In one patient a KRAS mutation was present 
in normal and dysplastic crypts 4 years prior to tumour formation (that also carried 
the KRAS mutation), suggesting this mutation was the initial oncogenic event 
(Galandiuk et al., 2012).  
 Recently, Nicholson et al. showed that mutated KRAS fields also 
increase in size with age in normal non-inflammatory colonic tissue. Here, the 
authors used samples with a known number of crypts to sequence the oncogenic 
region of KRAS. Based on the mutant allele frequency it was possible to 
extrapolate the number of mutant crypts per sample. The results showed that 
mutated KRAS fields are present in 10% of healthy human colons and increase 
in size with age with the largest field recorded as consisting of approximately 100 
crypts (Nicholson et al., 2018).      
  
From these studies it appears that colonic KRAS mutations are present as fields 
in some individuals prior to overt tumour formation. Such areas might predispose 
to cancer development. However, the cell of origin for such fields and the pro-
oncogenic mechanism of them is still unknown.   
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Aim 
 
The Aim(s) of this thesis is to determine the origin and properties of KrasG12D pro-
oncogenic fields in the intestinal epithelium. Specifically, the project aims to:   
1. Determine whether KrasG12D expression affects Atoh1+ secretory 
progenitor stem cell contribution both during tissue homeostasis and after 
Lgr5+ cell depletion. This will aid the understanding of how oncogenic 
KRAS fields arise.  
2. Determine the stem cell dynamics, defined by number of clonogenic stem 
cells per crypt and stem cell replacement rate, in KrasG12D mutant crypts 
of KrasG12D fields. This will help the to interpret the pro-oncogenic 
properties of mutated KRAS fields.  
3. Create a transgenic mouse encoding an inducible Dre recombinase to be 
used for lineage tracing in sequential mutation models of colorectal cancer 
in vivo.    
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2 Materials and methods 
2.1 Molecular biology and in vitro techniques 
2.1.1 Genomic DNA (gDNA) and RNA isolation 
gDNA was isolated from mouse ear-biopsies or form fractionated intestinal 
epithelium using the Promega ReliaPrepTM gDNA Tissue Miniprep System (cat. 
A2052) according to manufacturer’s protocol.  
2.1.2 Polymerase chain reaction (PCR) 
PCR was carried out using the NEB Q5 High-Fidelity DNA Polymerase using 
manufacturer’s instructions. Briefly, 5 µl 5X Q5 Reaction Buffer was mixed with 
0.5 µl 10 mM dNTPs, 5 µl primer-mix (forward primer + reverse primer 20 µM final 
concentration), 13.25 µl H2O, 0.25 µl Q5 High-Fidelity DNA Polymerase and 1 µl 
gDNA. For PCR primers see Appendix 1.  
2.1.3 Real time Quantitative RT-qPCR  
Gene copies were analysed using TaqMan gene expression probes (Thermo 
Fisher). Briefly, reactions consisted of: 5.4 µL TaqMan Fast Universal PCR 
Master Mix (Applied Biosystems cat. 4352042), 0.6 µL TaqMan probe and 6 µL 
gDNA of 5 ng/µL stock. Total reaction volume was 12 µL. Amplification was 
carried out in a 384 well-plate using a QuantStudio 6 instrument (Thermo Fisher).  
2.1.4 Restriction digest, agarose gel purification and ligation 
Plasmids and PCR amplified inserts were digested with restriction enzymes 
following manufacturer’s instructions (New England Biolabs). Volume for 
diagnostic digests were 10 µl and 100 ng of DNA was used. For experimental 
digests 1 µg of plasmid DNA was used in a reaction volume of 50 µl. All fragments 
were separated by agarose gel electrophoresis. If fragments were used for 
subcloning they were cleaned using Zymeclean Gel DNA Recovery kit (Zymo 
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Research) according to manufacturer’s instructions. Ligation reactions were 
carried out using the T4 DNA ligase with a 1:3 vector to insert molar ratio.   
2.1.5 Transformation and E. coli expansion 
For E. coli transformation and expansion XL2-Blue Ultracompetent cells 
(Stratagene) were used. Briefly, 1 µl of plasmid DNA was added to 30 µL of XL2-
Blue cells and kept on ice for 30 minutes. The E. coli/DNA suspension was then 
heat-shocked for 30 seconds at 42°C and 0.9 mL Lysogeny Broth (LB) medium 
was added. 100 µl of the cell-plasmid suspension was plated on LB agar plates 
containing appropriate antibiotics and incubated overnight at 37°C. Single 
colonies were picked and expanded in 5-100 mL of LB medium containing 100 
µg/mL Ampicillin at 37°C 2000 RPM overnight. Plasmid DNA isolation was carried 
out with QIAprep Spin Miniprep kit or QIAGEN Plasmid Maxi Kit according to 
manufacturer’s instructions (Qiagen).    
2.1.6 Plasmids and oligonucleotides  
Dre coding sequence (Anastassiadis et al., 2009) was synthesized by Invitrogen 
(construct ID 15ACQONP). The human progesterone receptor (Pr) sequence 
was amplified from the CrePR2 vector kindly given to us from Günther Schütz 
laboratory (Kellendonk et al., 1996). The Pr fusion site on Dre has previously 
been described by Anastassiadis et al., 2009.  
2.1.7 Cloning of R_Dre and R_DrePr plasmids  
The Rosa26 (R26) targeting vector used in this study was kindly given to our lab 
from Anton Berns and has previously been described in: (Vooijs et al., 2001). The 
vector contains a total of ~13 kilobases (KB) of the endogenous murine R26 
sequence located at chromosome 6 and is designed for homologous 
recombination in mouse embryonic stem cells (mESCs). The vector is built so 
that a 5’ ~3 KB homology R26 sequence precedes a NheI cloning site. This 
cloning site is followed by a Phosphoglycerate Kinase (PGK) promoter driven 
Puromycin selection cassette which in turn is followed by ~10 KB 3’ R26 
homology sequence. The splice acceptor, Dre and/or Pr coding sequence and a 
Bovine Growth Hormone (BGH) poly-adenylation signal was merged together by 
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In-fusion cloning (Takara cat. 121416) in pUC19 (Addgene #5005). The In-fusion 
reaction contained two or three inserts: the Dre coding sequence (insert 1), the 
Pr coding sequence (insert 2) and the BGH coding sequence (insert 2 or 3). The 
consensus splice acceptor sequence was added to the forward primer sequence 
of insert 1. All inserts were PCR amplified from plasmids and treated with DpnI 
for 30 minutes at 37°C to remove any residual vector. After cleaning the 
PCR+DpnI reaction (Zymogene clean and concentrate, cat. D4004) the inserts 
and the restriction digested vector were mixed in 4 µl (200 ng total) and 1 µl of 
In-Fusion enzyme and was added. The reaction was incubated for 30 minutes at 
50°C and used for E. coli transformation. After assembly in pUC19, the constructs 
were isolated from the vector backbone by restriction digest and agarose gel 
purification and ligated into a R26 targeting vector at the NheI cloning site. For in-
fusion primer sequences see Appendix 1 and for vector map see Appendix 2.   
2.1.8 mESC targeting and colony picking 
This procedure was carried out by the Xiangang Zou in the CRUK CI Genome 
Editing Core. Briefly, C57BL/J mouse embryonic stem cells (mESCs) were 
electroporated with linearized plasmids. After electroporation the mESCs were 
plated on feeder cells under puromycin selection (1 ng/µl). Single mESC colonies 
were picked and transferred to 96-well plates individually. Each plate was grown 
up and split into two identical plates. One plate was stored at -80°C to be use for 
later 8-cell stage embryo injections. The duplicate plate was used for gDNA 
extraction and PCR amplification to identify correctly targeted clones.  
2.1.9 mESC gDNA extraction and clone verification 
60 µl of DNA extraction buffer (5M NaCl, 1M Tris-HCl ph 7.5, 0.5M EDTA, 20% 
SDS, 0.2 mg/mL proteinase K) was added to each well of mESCs on 96-well 
plates and the plates were then incubated at 37°C overnight. After lysis, all wells 
were transferred into 8-strip PCR tubes. 130 µl 100% cold ethanol was added to 
each well to precipitate DNA. After precipitation the buffer was removed, and DNA 
pellets were air-dried. 50 µl of water was added to each pellet to dissolve DNA. 
To verify 5’ and 3’ arm insertions PCR amplification was carried out using 
SequalPrep Long PCR kit (Applied Biosystems, cat. A10498) according to 
The origin and properties of pro-oncogenic fields in the intestinal epithelium 
36 
manufacturer’s instructions with F1 and R1 primers (5’ arm) or F2 and R2 primers 
(3’ arm) (Appendix 1 for primers).  
2.1.10 R_Dre and R_DrePr mouse model creation 
Figure 2.1 shows the workflow of creating mouse models from targeted mESCs. 
Briefly, positive C57BL/J mESC clones were injected into fertilized Balb/c 
oocytes. The oocytes were then placed in pseudo-pregnant Balb/c females. As 
C57BL/J mESC contributed to the embryo the resulting litters were chimeric for 
both C57BL/J and Balb/c origin. This manifested as mosaic black/agouti/white 
coats in resulting litters (Figure 2.1). Pups of which the C57BL/J mESCs 
contributed to >70% of the coat colour were chosen for further breeding and 
crossed to C57BL/Js (Figure 2.1). The C57BL/J black coat colour is dominant, 
therefore pups with white coats resulting from this breeding were considered as 
negative for C57BL/J mESC origin. ~50% of black coated pups carried either Dre 
or DrePr upon genotyping. These mice are considered to be the origin of the Dre 
and DrePr lines and were used for further sub-breedings (Figure 2.1).  
2.1.11 Organoid establishment and maintenance   
Organoids were prepared from the colon as previously described (Sato et al., 
2009). Briefly, the colon was flushed with Phosphate-buffered saline (PBS) and 
mesentery fat was carefully removed. The tissue was then opened up 
longitudinally and cut into 0.5 cm pieces. Tissue was washed in 10 mL cold PBS 
10 times where after they were resuspended in 25 mL of PBS/25 mM EDTA and 
incubated on ice for 30 minutes. PBS/EDTA was removed and 10 mL PBS was 
added to tissue and samples were hand shaken thoroughly for 10 seconds. This 
was repeated 4 times to collect crypt different crypt fractions. Crypt enriched 
fractions (fraction 2-4) were combined and pelleted by centrifugation (1200 RPM, 
5 minutes, 4°C). Crypts were then passed through a 70 µM filter and collected by 
centrifugation (600 RPM, 3 minutes, 4°C) and seeded in a 20 µL drop of ice-cold 
growth factor reduced Matrigel (Corning, cat. 356231) on pre-warmed 24-well 
plates. Crypts were maintained in the following medium: Advanced DMEM/F12 
(ADF) containing: 0.1% Bovine serum albumin (BSA); 1X L-Glutamine (Gibco, 
cat. 25030-024); 10 mM HEPES; 1X PenStrep (Gibco, cat. 15070-063);   
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1X N-2 Supplement (Invitrogen cat. 17502-048), 1X B-27 Supplement (Invitrogen 
cat. 12587-010); 50 ng/mL human EGF (Prepotech, cat. AF-100-15); 100 ng/mL 
murine NOGGIN (Prepotech, cat. 250-38); 50% Wnt-conditioned medium (made 
in-house) and 10% R-spondin-1 conditioned medium (made in house) and kept 
at 37°C with 5% CO2.     
2.1.12 Library preparation  
Organoids were released from Matrigel after 5 days of culture by gently 
dissociation in ice cold PBS. Single organoids were picked under a light 
microscope using an EZ-Grip pipettor (RI Life Sciences, ref. 8-72-2802) with 200 
µm EZ-TIP (RI Life Sciences, cat. 7-72-2200/1). Single organoids were then 
transferred directly into 96-well plates containing 20 µL Picopure extraction buffer 
(cat. KIT0103) and were incubated at 65°C for 3 hours. After lysis, 100 µL 1XTE 
buffer and 80 µL Ampure XP beads (Beckman Coulter, cat. A63882) were added 
to each reaction. After 5 minutes of binding at room temperature a magnetic 96-
well rack was used for magnetic bead separation. Supernatant was removed and 
gDNA was washed twice in 75% ethanol and eluted in 20 µl nuclease-free water. 
Libraries were prepped using the NEBNext Ultra II FS DNA Library Prep Kit for 
Illumina according to manufacturer’s instructions (NEB, cat. E6177). Briefly, the 
low DNA input protocol was used, fragmentation was carried out for 30 minutes 
and 11 cycles of PCR was performed using Agilent SureSelect indexing primers. 
2 µl of each library was quantified on a 4200 TapeStation System (Agilent) and 
via QubitTM dsDNA HS Assay kit (Invitrogen, cat. Q322854). Libraries with similar 
DNA content from the Tapestation and Qubit analysis were used for exome 
capture (6 libraries per mouse).          
2.1.13 Exome capture and sequencing  
1000 ng library DNA was concentrated using a vacuum Concentrator plus 
(Eppendorf) and exomes were hybridized, captured and amplified using the 
SureSelectXT Low Input Target Enrichment System for Illumina Paired End 
Multiplexed Sequencing Library (Agilent Technologies) according to 
manufacturer’s instructions. After exome capture, the libraries were quantified on 
the 4200 TapeStation System (Agilent Technologies) and by KAPA Library 
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Quantification Kit according to manufacturer’s instructions (KAPA Biosystems 
Roche, ref. 07960338001). Libraries were pooled (20 nM each) and sequenced 
on the Illumina HiSeq 4000 (1 lane, paired-end 150 base-pair (bp)).    
2.2 In vivo and mouse tissue techniques 
2.2.1 Mouse models 
Rosa26 rox STOP rox tdTomato (R_tdTomrsr): the R_tdTomrsr were generated in 
house by germline deletion of the LoxP STOP LoxP (lsl) cassette from 
R_tdTomrsrlsl mouse (Jackson Laboratories, stock no. 021876). This was carried 
out by Xiangang Zou and Guocheng Lan in the CRUK CI Genome Editing Core. 
R_tdTomrsrlsl early embryos were cultured with the cell permeable TAT-Cre in vitro 
and embryo transfer was performed as described by (Ryder et al., 2014). PCR 
screening was used to ensure lsl cassette deletion.  
Rosa26 lsl tdTomato (R_tdTomlsl): R_tdTomlsl was bought from the Jackson 
Laboratory (stock no. 007908) and described here: (Madisen et al., 2010). 
Rosa26_Dre (R_Dre) and Rosa26_DrePr (R_DrePr): were generated in house at 
the CRUK CI Genome Editing Core in the Biological Resource Unit by mESC 
electroporation and homologous recombination of R26 targeting vectors and 
subsequent pro-nuclear injections.  
KrasfsfG12D and KraslslG12D: was obtained from The Jackson Laboratory (stock no. 
008653 and 019104).  
VilllinFlp: was kindly provided to us from Dierte Saur Laboratory, Germany.   
Atoh1CreERT2: was described and generated by Tomic et al., 2018.  
Ctnnb1flox(ex3): was described by (Harada et al., 1999) and was kindly given to us 
by Richard Gilbertson at CRUK CI.  
AhCreErt: was described and generated by: (Kemp et al., 2004). 
Cyp1A1FlpO: was generated in the Winton lab at CRUK CI. In this mouse the FlpO 
expression cassette is under transcriptional control of the ß-naphthoflavone 
inducible Cyp1A1 promoter. This model has not been yet been published.   
VillinCreErt: was described by (El Marjou et al., 2004).   
The origin and properties of pro-oncogenic fields in the intestinal epithelium 
40 
2.2.2 Genotyping 
Genotyping of animals was performed on ear-biopsies from 3-week old mice. 
Most genotyping was carried out by Transnetyx. For primers and probes see 
Appendix 3. Determination of allelic zygosity of AhCreErt2 and VillinFlp was carried 
out by performing RT-qPCR copy-number assay of ear biopsy gDNA. 
Determination of allele zygosity of Atoh1CreErt2 was carried out by PCR 
amplification of ear biopsy gDNA as previously described (Tomic, et al., 2018).        
2.2.3 Crypt isolation of small intestine and colon 
After dissection the small intestine and colon were flushed with cold PBS to 
remove faeces and a 10 cm piece of the small intestine and the entire colon was 
fed on to a glass pastor pipette and inverted. The inverted intestinal tube was 
then fed on to a glass spiral and washed in PBS. The spiral was then covered in 
50 mL Hank’s Balanced Salt Solution (HBSS) with 1 mM Na2-EDTA and 2 mM 
NaOH and subjected to 6 cycles of 10 minutes 37°C incubation followed by 10 
times 5 seconds pulses of mechanical vibration using a Chemap transformer 
/vibrator (110/240 Volt). After mechanical vibration the HBSS buffer was collected 
as crypt-fraction 1-6. Fractions were pelleted at 1200 RPM and the highly crypt 
enriched fractions (normally 2-6) were combined and subjected to PCR and/or 
RT-qPCR analysis or dissociated into single cells for flow cytometric analysis or 
sorting (see below).            
2.2.4 Flow cytometry for EpCam and tdTomato 
Isolated crypts were dissociated into single cells by resuspending crypt-pellets in 
20 mL of 0.05% Trypsin-EDTA (Gibco cat. 25300054). Crypt-Trypsin suspension 
was incubated at 37°C for 7 minutes and after each minute the suspension was 
subjected to 10 seconds of vigorous shaking. After 7 minutes, 30 mL of PBS with 
2% foetal bovine serum (FBS, Thermo Fisher A38401) was added and the cell 
suspension was filtered through a 70 µM filter. Single cells were pelleted by 
centrifugation (1200 RPM, 5 min, 4°C) and washed twice in PBS 2% FBS before 
being subjected to antibody staining with EpCam Alexa Fluor 647 (BioLegend 
clone G8.8 0.5 mg/mL, 1:2000) and DAPI (1 mg/mL stock, 1:1000). All flow 
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cytometry was performed on a BD FACSAria or a BD LSRFortessa Instrument 
(BD Biosciences). 
2.2.5 Paraffin embedding, block sectioning and histochemical staining  
All tissue samples were fixed for 24 hours in 4% natural buffered formalin (NBF) 
or 4% paraformaldehyde (PFA) and transferred into 70% ethanol. All paraffin 
embedding and block sectioning as well as histochemical staining for 
Haematoxylin and Eosin (H&E) and Pas/Alcian Blue was carried out at the CRUK 
CI histology core facility. For H&E staining sections were dewaxed and hydrated, 
incubated in Haematoxylin for 2 minutes, washed in water, incubated in 2% Acid 
Alcohol for 20 seconds, washed and incubated in 1% Eosin for 7 minutes, all in 
a ST5020 Multi-stainer (Leica). For Pas/Alcian Blue staining sections were 
dewaxed and hydrated in a ST5020 Multi-stainer (Leica), incubated in Alcian Blue 
for 10 minutes, washed in water, incubated in 0.5% periodic acid for 5 minutes, 
washed 3 times, incubated in Schiffs reagent for 30 minutes, washed 3 times and 
counterstained in Mayers Haematoxylin for 30 seconds.     
2.2.6 Immunohistochemistry (IHC) 
IHC for BrdU, tdTom, GFP, Ki-67, Lysozyme and ß-catenin were carried out by 
the CRUK CI histology core facility unit, for antibodies and antigen retrieval see 
Appendix 4. 
 Staining for phosphorylated Mek (pMek) and Dusp6 was carried out 
by manual IHC. Antigen retrieval was performed with 10 mM citrate buffer (ph=6) 
in a pressure cooker. Tissue sections were then incubated in 3% H2O2 (in 
Methanol) for 15 minutes and washed 3 times for 5 minutes in PBS/0.05% Tween 
20 (PBS-T). Tissue sections were then blocked in 10% donkey serum (Sigma, 
D9663) (in PBS-T) for 30 minutes and primary antibodies for pMek or Dusp6 (Cell 
Signalling, cat. 2338 or Abcam, ab76310, dilution 1:50) were added and 
incubated on sections over night at 4°C. Sections were then washed 3 times in 
PBS-T and incubated with biotinylated donkey anti-rabbit secondary antibody 
(Jackson ImmunoResearch cat. 711-065-152, dilution 1:500) for 40 minutes at 
room temperature. Sections were washed and incubated with ABC HRP Kit 
(Vectastain, cat. PK-6100) for 40 minutes at room temperature. Next, sections 
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were washed and DAB Chromogen substrate (Dako, cat. K3468) was added for 
dye development for 5 minutes. Counterstain and dehydration were performed 
on the ST5020 Multi-stainer (Leica).             
2.2.7 Crypt-counting: BrdU, lysozyme and Pas/Alcian Blue 
All histology sections were counted manually under a light microscope at either 
20X or 40X magnification. BrdU+ cells were scored in 25 fully sectioned half 
crypts. A score of 1 or 0 was given to a positive or negative nucleus, respectively, 
at all positions up the crypt until the crypt-villus border (small intestine) or the 
crypt top (colon) was reached. Lysozyme+ cells were scored in 25 fully sectioned 
crypts. Pas/Alcian Blue+ cells were scored in 15 fully sectioned half-villi. The 
number of nuclei from the villus bottom to the top and number of Pas/Alcian Blue+ 
cells clearly associated with a nucleus was quantified.  
2.2.8 Subcutaneous insertion of Ru486 slow release pellet(s) in mice 
This procedure was carried out by Matthew Clayton at the Biological Resource 
Unit Core at CRUK CI. Mice receiving pellet insertion surgery were all 8-10 weeks 
of age. Mice were placed under general anaesthesia and a 1 cm subcutaneous 
incision was made on the back flank of each mouse in which 1-3 Ru486 pellets 
(Innovative Research of America, 10 mg/pellet, 90 days release, cat. NX-999) 
were placed. The wound was closed with surgical glue.  
2.2.9 Intra-peritoneal (I.P) and oral gavage administered drugs 
Ru486 (Sigma, cat. M8046) was dissolved in 100% ethyl alcohol (Honeywell, cat. 
E7023) to make a 50 mg/mL solution and further diluted into a working solution 
of 10 mg/mL in 40% cyclodextrin/H2O. ß-naphthoflavone (Sigma, cat. N3633) 
was dissolved to a working solution of 8 mg/mL or 2 mg/mL in corn oil (Sigma, 
C8267). All 40 mg/kg and 8 mg/kg I.Ps were made from 8 mg/mL or 2 mg/mL 
stocks, respectively. Tamoxifen (Sigma, cat. T5648) was dissolved in 100% ethyl 
alcohol (Honeywell, cat. E7023) to make a 200 mg/mL solution and further diluted 
to a working solution of 20 mg/mL, 5 mg/mL or 1 mg/mL in sunflower oil (Sigma 
S5007). All 2-4 mg, 0.5 mg and 0.15 mg I.Ps were made with 20 mg/mL, 5 mg/mL 
or 1 mg/mL stocks respectively. Diphtheria toxin: was dissolved in saline at 50 
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µg/ml working solution and administered at 50 µg/kg. AZD6244: was dissolved in 
0.5% HPMC + 0.1% Tween-80 to a working solution of 6.25 mg/mL and 
administered at 25 mg/kg.     
2.2.10 Whole mounting of mouse small intestine and colon   
The small intestine and colon were dissected from mice and flushed with cold 
PBS. The gut was opened longitudinally, pinned out and fixed for 3 hours at room 
temperature in 4% PFA. After fixation, whole mounts were washed in PBS and 
incubated with de-mucifying solution (3 mg/mL DTT, 20% ethanol, 10% glycerol, 
0.6% NaCl, 10 mM Tris, pH 8.2) for 20 minutes at room temperature. Mucus was 
removed by pipetting and wholemounts were stored in PBS at 4°C.  
2.2.11 Dapi and EpCam staining of whole-mounted tissue  
1-2 cm of intestinal tissue was permeabilised in 0.1% PBS-Tween20 for 24 hours 
at 4°C. EpCam Alexa Fluor 647 (BioLegend clone G8.8 0.5 mg/mL, 1:100) or 
DAPI (1 mg/mL stock, 1:100) was then added and the tissue was incubated for 3 
days at 4°C. After antibody/DAPI incubation tissue was washed in 0.1% PBS-
Tween20 for 24h where after it was subjected to imaging on a TCS SP5 confocal 
microscope (Leica).  
2.2.12 Tumour clearing  
Whole-mounted tissue was fixed in 4% PFA overnight at 4°C. Hereafter, tissue 
was washed in PBS for 8-hours at room temperature. Tissue was then incubated 
in CUBIC-1A solution (10% Triton, 5% NNNN-tetrakis (2-HP) ethylenediamine 
(Sigma, 122262), 10% Urea, 25mM NaCl) with DAPI 1:100 (10 mg/mL stock) at 
37°C 60 RPM for a total of 5 days. On day 2 and 4 CUBIC-1A + DAPI was 
refreshed. After CUBIC-1A incubation, tissue was washed in PBS for 2 hours and 
then placed in Rapi Clear (SunJin Lab., cat. RC152002) and incubated at room 
temperature until tissue was see-through. Hereafter, tissue was mounted on 1 
mm inserts (iSpacer, SinJun Lab.) on glass-slides in Rapi Clear and subjected to 
imaging on a TCS SP5 confocal microscope (Leica).    
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2.2.13 Lineage tracing and scoring  
For lineage tracing mice were induced with a pulse of ß-naphthoflavone and 
tamoxifen (40 mg/kg and 0.15 mg, respectively) or Ru486 (50 mg/kg) and tissue 
was whole mounted at day 4, 7, 10, 14 and 21 after pulse administration. Clone 
sizes were scored manually under a fluorescent microscope using the 550 nm 
filter. 2 cm of tissue was mounted muscle side up, on a glass-slide and clone 
sizes were scored as fractions of 8. All tissue was scored blinded.  
 
2.3 Computational methods  
2.3.1 Exome mutation calling  
Mutations were called by Lee Hazelwood using a composite sample background 
of the same type and age as the organoid under detection. The programme 
Varscan 2.4.3 with quality filter 10 and allele frequency 0.35-0.65 was used to 
detect somatic mutations.     
2.3.2 Clonal collision prediction  
Prediction of clonal localisation was carried out by Richard Kemp. A pearl loop-
script randomly allocates clones (by a given clonal frequency) on a 400X400 crypt 
grid. This script assumes that each crypt has 6 neighbouring crypts. Clonal 
collision and clone patches were quantified manually on print-outs of predicted 
datasets. For pearl script see Appendix 5.  
2.3.3 Determining l and PR of Atoh1 derived stem cells    
This modelling was produced by Edward Morrissey. It relies on the neutral drift 
model (Lopez-Garcia et al. 2010; Vermeulen et al. 2013). Previous lineage tracing 
data-sets were used and by fixing N=7, or λ to 0.25 it was possible to predict how 
λ or PR, respectively, would affect the WPC/PPC ratio 30 days post lineage trace 
initiation. In this analysis all 1/8 clone sizes were removed. For R-script see 
Appendix 6.   
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3 Determining the effect of KrasG12D expression on the 
stem cell contribution potential of early secretory 
progenitors  
3.1 Introduction 
As discussed in Chapter 1 the intestinal epithelium is maintained by crypt base 
intestinal stem cells which regenerates the tissue by constantly giving rise to cells 
of the absorptive and secretory lineages. These different lineages are specified 
based on differential transcriptional programmes in cells that exit the crypt base. 
Expression of the transcription factor Atoh1 constitutes the initial “on” switch for 
the secretory lineage and Atoh1 expressing cells include the earliest secretory 
progenitors. However, it is now clear that intestinal cell specification is not always 
restrictive, and that cell fate is a context dependent continuum. In addition, recent 
studies have shown that Atoh1+ early secretory progenitors contribute to the 
stem cell pool during injury and homeostasis (Castillo-Azofeifa et al., 2019; 
Ishibashi et al., 2018; Tomic et al., 2018), but the effect conferred by pro-
oncogenic mutations, such as KrasG12D, has not yet been investigated. 
Additionally, it is known that oncogenic mutations in KRAS are present in healthy 
human colonic tissue (Dieterle et al., 2004; Kraus et al., 2006; Parsons et al., 
2010; Nicholson et al., 2018). These mutations exist in fields of up to 
approximately 100 crypts and such areas could pre-dispose to colorectal cancer 
in some patients.  
 
Thus, the aim of this chapter is to study the cell of origin of KRAS fields by 
investigating how KrasG12D expression affects cell fate choices of early secretory 
progenitors.  
 
In this chapter cell fate choices are studied in KrasG12D expressing progenitor cells 
primed for the secretory path by quantifying their stem cell contribution potential 
in the small intestine and colon. To develop a suitable in vivo model for such 
studies the Atoh1CreErt (Tomic, et al., 2018), KraslslG12D (Jackson et al., 2001) and 
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R26lsltdTom (Madisen et al., 2010) mouse lines were inter-crossed to generate mice 
in which both KrasG12D and tdTom expression could be activated in Atoh1+ 
secretory progenitors. In this model it is possible to trace cell fate choices in early 
secretory progenitors by activating Cre recombinase in cells that express the 
Atoh1 transcription factor. Here, stem cell contribution was examined by 
quantification of stem cell derived clones after saturated pulse-labelling. Such 
stem cell contribution requires the achievement of two processes acting in series: 
firstly Atoh1 expressing cells must contribute to the stem cell pool instead of 
maturing into goblet or Paneth cells (Figure 3.1A) and secondly upon stem cell 
contribution Atoh1+ stem cells must replace their neighbours to persist as clones 
in the intestinal crypts over time (Figure 3.1B).  
 In addition to investigating stem cell contribution this study also aims 
to investigate the behaviour of Atoh1+ and Atoh1+KrasG12D stem cells by 
quantifying their monoclonal conversion time (Figure 3.1B). Finally, the Atoh1 
derived KrasG12D inter-crypt multiplication pattern is also investigated (Figure 
3.1C) as well as examination of the tumorigenic potential of long-term KrasG12D 
activation in Atoh1+ cells.  
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3.2 Results 
The Atoh1CreErt allele was crossed to the KraslslG12D allele and the R26lsltdTom 
reporter allele to generate Atoh1CreErt;KraslslG12D; R26lsltdTom mice referred to as 
Atoh1;KrasG12D;RT. Control animals did not carry the KraslslG12D allele and will be 
referred to as Atoh1;RT. All animals in this chapter were homozygote for the 
Atoh1CreErt allele and heterozygote for the KraslslG12D and R26lsltdTom alleles. 
Because of differences in clonal frequencies the small intestine and colon will be 
analysed separately throughout this chapter.     
3.2.1 Partial KrasG12D and tdTom co-recombination is observed in Atoh1+ 
cells after CreErt activation 
In the Atoh1CreErt mouse the CreErt cassette is targeted to the Atoh1 locus thus 
restricting CreErt expression to Atoh1 expressing cells (Atoh1+) (Tomic, et al., 
2018). To be able to analyse the effect of KrasG12D expression in Atoh1+ cells 
based on reporter expression (tdTom) it is important that the KraslslG12D and 
R26lsltdTom allele co-recombine after CreErt activation (Figure 3.2). To examine the 
level of co-recombination in Atoh1+ cells, Atoh1;RT and Atoh1;KrasG12D;RT 
animals received 3 mg Tamoxifen and 4 days later the small intestine and colon 
was subjected to flow cytometric cell sorting (Figure 3.3A). To investigate the 
amount of co-recombination epithelial EpCam+/tdTom- and EpCam+/tdTom+ 
cells were sorted (Figure 3.3C) and subjected to PCR analysis for KraslslG12D 
recombination. As seen in Figure 3.3D, KraslslG12D recombination (G12D band) 
was only present in tdTom+ cells. However, not all tdTom+ cells were recombined 
at the KraslslG12D allele as un-recombined (LSL) band remained evident in these 
samples even after Tamoxifen exposure (Figure 3.3D). Thus, partial co-
recombination of KrasG12D and tdTom was observed in Atoh1+ cells after 
maximum Tamoxifen exposure. This means that a number of tdTom+ cells in 
Atoh1;KrasG12D;RT animals will be KrasWT which will negatively skew the data 
during quantification. Thus, effects observed in Atoh1;KrasG12D;RT animals will 
be underestimated. However, the saturation labelling strategy of these 
experiments did not allow for further optimisation of KraslslG12D recombination 
without risking a departure from the steady state due to Tamoxifen toxicity and 
therefore this was accepted as the working KrasG12D resolution.  
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3.2.2 KrasG12D expression does not alter Atoh1+ cell contribution to the 
stem cell pool 
To investigate stem cell contribution of Atoh1+ and Atoh1+KrasG12D cells during 
tissue homeostasis, Atoh1;KrasG12D;RT and Atoh1;RT animals were 
administered 3 mg Tamoxifen and analysed 30 days later (Figure 3.4A, Figure 
3.5A). Labelled stem cells give rise to differentiated daughter cells that will inherit 
the label. As such cells proliferate and move up the crypt and villus lineage traced 
ribbons or clones will appear (Figure 3.4B). Clones that persists with time are 
stem cell derived. In the small intestine the number of Atoh1+ derived stem cells 
was relatively low and thus quantification required low magnification microscopy. 
Therefore, stem cell contribution was quantified by manually counting the total 
number of tdTom+ crypt/villus ribbons in whole-mounted strips of small intestinal 
tissue (Figure 3.4B). The total number of tdTom+ ribbons per small intestinal 
tissue strip was normalised to the length of tissue-strip quantified. Ribbon 
quantification showed that the amount of Atoh1+ stem cell contribution increased 
from proximal to distal small intestine but did not change with KrasG12D expression 
(Figure 3.4C-D).  
 
Epithelial clones expressing tdTom were more common in the colon than the 
small intestine. Therefore, in the colon stem cell contribution was assessed by 
quantifying the frequency of tdTom+ crypt clones in approximately 1500 
crypts/animal by manual crypt quantification on confocal microscopy images 
(Figure 3.5B-C). On each tiled image the total number of crypts, the number of 
crypts wholly populated by tdTom+ cells (WPC), and the number of crypts 
partially populated by tdTom+ cells (PPC) was quantified (Figure 3.5B, magnified 
boxes). Single cells were excluded from this analysis as these were considered 
non-proliferating goblet cells. From this data, the frequency of clones in all crypts 
was calculated. Quantification of colonic stem cell clone frequency showed no 
significant difference between Atoh1;KrasG12D;RT and Atoh1;RT animals (Figure 
3.5C).  
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Next, examination of stem cell behaviour in the crypt base was carried out. Over 
time, due to neutral drift, stem cell clones will become fixed or lost. This will be 
observed as an increase in WPCs and a decrease in PPCs following pulse 
labelling. If stem cells have a positive bias, they exhibit an increased likelihood 
generating WPCs. This will present as an accelerated increase in WPCs and 
decrease in PPCs over time. Such behaviour can be expressed as a ratio of 
WPC/PPC where an increased ratio suggests accelerated fixation potential of the 
stem cells analysed.  Thus, to examine the stem cell fixation potential of Atoh1+ 
and Atoh1+KrasG12D derived stem cells WPC/PPC ratios were analysed from the 
same dataset as was used to obtain clonal frequencies in Figure 3.5B-C. To this 
end, it was possible to determine stem cell contribution and stem cell behaviour 
from the same experiment, 30 days post pulse labelling.  Interestingly, the 
WPC/PPC ratio was significantly higher in Atoh1;KrasG12D;RT animals compared 
to Atoh1;RT, suggesting a biased behaviour of Atoh1 derived KrasG12D derived 
stem cells (Figure 3.5D).  
 
As seen from the representative images in Figure 3.5B (magnified boxes) some 
clones were adjacent (colliding) when analysed. Clonal collisions could arise by 
chance or by fissioning of one crypt into two. Fissioning events could lead to 
overestimation of clonal frequencies, as one original clone would be counted as 
2 or more. Importantly, KrasG12D crypts have a higher fissioning rate than WT 
crypts which could skew clonal quantification (Snippert et al., 2014).  
 The data presented in Figure 3.5 counts all clones as individuals and 
assumes that collisions are due to chance. To check this assumption, it was 
investigated whether collisions observed in the datasets were due to chance or 
due to fission. To this end, a mathematical tool that randomly marks clones on a 
grid of 400 X 400 crypts was created by Richard Kemp (a subset shown in Figure 
3.6A). Marking 10% of these crypts randomly (approximately the clonal frequency 
found in Atoh1;KrasG12D;RT and Atoh1;RT at day 30) followed by manual 
quantification of clonal collisions and patch sizes showed that 26.8(+/- 6.5)% of all 
clones would be colliding due to random chance (Figure 3.6A). Next, 
quantification of clonal collisions in the images used to obtain the data presented 
in Figure 3.5 was carried out (Figure 3.6B). In this analysis, adjacent partial 
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clones were also quantified as collisions/patches. This analysis showed that 
25.8(+/- 3.2)% and 29.0(+/- 6.9)% of clones were colliding in Atoh1;RT and 
Atoh1;KrasG12D;RT animals, respectively at day 30 (Figure 3.6C). This was not 
significantly different from that found in the predicted datasets (Figure 3.6C). In 
addition, analysis of clonal patch sizes showed no significant difference in patch 
size distribution in the predicted model and experimental mice (Figure 3.6D). This 
suggest that the clonal collisions recorded 30 days post induction in experimental 
animals are due to the random nature of crypt marking and not fission, and thus 
validated the original assumption. In addition, the fission rate does not seem to 
be increased in Atoh1;KrasG12D;RT animals after 30 days. 
 
Taken together these results indicate that Atoh1+ progenitors contribute to the 
stem cell pool independent of KrasG12D expression but possess a biased 
behaviour once they have entered the stem cell pool when KrasG12D is present.  
 
3.2.3 Lgr5 depletion increases Atoh1+KrasG12D stem cell contribution in the 
proximal small intestine but not in the colon  
After examining Atoh1+ stem cell contribution during tissue homeostasis it was 
next investigated in a non-homeostatic setting. Lgr5 has been reported as a 
marker of rapidly cycling stem cells in the small intestine and colon (Barker et al., 
2007). In addition, ablation of Lgr5+ stem cells has been shown to increase the 
stem cell contribution of both enterocyte and secretory progenitors (Tetteh et al., 
2016; Castillo-Azofeifa et al., 2019). Thus, to examine the maximum potential for 
stem cell contribution of Atoh1+ and Atoh1+KrasG12D cells, Lgr5 stem cell specific 
deletion in Atoh1;KrasG12D;RT and Atoh1;RT animals was desired. To create a 
model that allowed for this, the Atoh1;KrasG12D;RT line was crossed to Lgr5Dtr-GFP 
animals (Tian et al., 2011) to generate Atoh1;KrasG12D;Lgr5GFP-Dtr;RT and 
Atoh1;Lgr5GFP-Dtr;RT, referred to as Atoh1;KrasG12D;Dtr;RT and Atoh1;Dtr;RT. In 
this line, Lgr5+ stem cells express the human Diphtheria toxin (DT) receptor (Dtr) 
and GFP from the Lgr5 locus (Figure 3.7A). When DT binds to Lgr5+ cells these 
are ablated (Figure 3.7A). All animals shown in this chapter were heterozygotes 
for the Lgr5GFP-Dtr allele.  
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Confirmation of Lgr5+ depletion was carried out by administering Lgr5GFP-Dtr 
animals with 50 mg/kg DT and assessing GFP expression in the small intestine 
and colon after 24- and 72 hours by immunohistochemistry (IHC) (Figure 3.7B). 
Here, GFP served as a marker of Lgr5 expression. As seen from Figure 3.7B, 
one single dose of DT ablated nearly all Lgr5+ cells after 24 hours in the small 
intestine and the colon. Lgr5+ cells re-populated the base of the crypts after 72 
hours to the same level as the saline control (Figure 3.7B). Importantly, these 
results were in line with previous reports (Castillo-Azofeifa et al., 2019; Tian et 
al., 2011; Tomic et al., 2018). 
 
To investigate the effect of KrasG12D expression on Atoh1+ driven contribution 
after Lgr5+ cell depletion Atoh1;KrasG12D;Dtr;RT and Atoh1;Dtr;RT animals were 
administered 3 mg Tamoxifen and 50 mg/kg DT. Since Tamoxifen is believed to 
have a slower bioavailability than DT, a 6-hours break between the first 
Tamoxifen and the subsequent DT injection was given to ensure that Atoh1+ cells 
were marked at the time of DT ablation. 30 days post induction the small intestine 
and colon was collected for analysis (Figure 3.8A and 3.10A).  
 
There appeared to be a higher number of tdTom+ cell ribbons present in the 
proximal small intestine of Atoh1;KrasG12D;Dtr;RT animals compared to Atoh1;RT 
animals when examining the tissue macroscopically (Figure 3.8B). However, the 
number of ribbons was too great for low magnification quantification. Therefore, 
clonal frequencies in the proximal small intestine was quantified as described for 
the colonic data presented in Figure 3.5. The frequency of clones was 
significantly increased in Atoh1;KrasG12D;Dtr;RT animals compared to 
Atoh1;Dtr;RT animals, with the frequency being approximately 10% and 5%, 
respectively  (Figure 3.8C-D). In addition, examination of the WPC/PPC ratio 
revealed a significant increase in Atoh1;KrasG12D;Dtr;RT animals compared to 
Atoh1;Dtr;RT (Figure 3.8E). However, clonal collisions also appeared to increase 
(Figure 3.8C). 
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To ensure that an increased fission rate in Atoh1;KrasG12D;Dtr;RT animals did not 
falsely increase the clonal frequency and the WPC/PPC ratio, comparison of the 
expected and experimental clonal-collisions was carried out. The computational 
tool described in Figure 3.6 was used to predict the amount of random clonal 
collision and to quantify patch sizes by marking 5% (approximate clonal 
frequency in Atoh1;Dtr;RT) and 10% (approximate clonal frequency in 
Atoh1;KrasG12D;Dtr;RT) of clones on a 1600 crypt grid (Figure 3.9A+D). This 
analysis showed that the percentage of clonal collisions and patch sizes observed 
experimentally was not significantly different to what would be predicted by 
random clonal marking (Figure 3.9B-C and 3.9E-F). This suggested that the 
increased clonal frequency found in Atoh1;KrasG12D;Dtr;RT was in fact due to 
increased stem cell contribution of Atoh1+KrasG12D cells in the small intestine 
after Lgr5 depletion.  
 
Examination of the effect of Lgr5 depletion on Atoh1+ and Atoh1+KrasG12D 
progenitor behaviour was also carried out in the colon of the same animals 
(Figure 3.10A). Quantification of clonal frequencies in the colon showed no 
significant difference between Atoh1;KrasG12D;Dtr;RT and Atoh1;Dtr;RT animals, 
however, as before the WPC/PPC ratio was significantly increased in 
Atoh;KrasG12D;Dtr;RT (Figure 3.10B-D). Interestingly, comparison of the previous 
homeostatic results (Figure 3.5C) to the results gained after Lgr5 depletion 
showed no significant difference in clonal frequencies between the two 
experimental conditions (Figure 3.10E). The same was true for WPC/PPC ratios, 
Atoh1;KrasG12D;Dtr;RT ratios remained significantly higher compared to 
Atoh1;Dtr;RT, but there was no significant difference in ratios from homeostatic 
experiments to Lgr5-depletion experiments (Figure 3.10F).   
 
These results suggest that small intestinal Atoh1+KrasG12D cells have an 
increased contribution potential after Lgr5 depletion, and that colonic Atoh1+ 
contribution is independent of both KrasG12D expression and Lgr5 ablation. 
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3.2.4 Atoh1+ derived stem cells have a neutral behaviour whereas Atoh1+ 
derived KrasG12D stem cells have an increased probability of replacement 
Stem cells derived from progenitors may have been through partial lineage 
restriction and it is not known whether such stem cells still carry intrinsic factors 
that alter their behaviour or tumorigenic abilities. Therefore, to understand 
whether Atoh1+ derived stem cells act neutrally or if they have an intrinsic bias, 
mathematical modelling was used to predict stem cell behaviour based on the 
colonic data from homeostatic experiments (Figure 3.5). Small intestinal data was 
not included in this analysis as the WPC and PPC populations were not quantified 
in homeostatic experiments. The modelling presented here was produced by 
Edward Morrissey and relies on the principle of the neutral drift model previously 
described by Lopez-Garcia et al. 2010 and Vermeulen et al. 2013. The neutral 
drift model is based on in vivo pulse-chase experiments where data is collected 
over several timepoints and clone sizes are quantified in this case as fractions of 
8, where 8/8 is a WPC. It utilizes three major factors to predict stem cell 
behaviour; number of stem cells per crypt (N), stem cell replacement rate/stem 
cell/day (λ) and probability of replacement (PR). By using data-sets from previous 
in vivo pulse-chase experiments and fixing N=7 (the number of stem cells in the 
colon estimated by Kozar et al. 2013) it was possible to predict how λ and PR 
would affect the WPC/PPC ratio at day 30 (Figure 3.11A-B).   
 
Firstly, the control data for Atoh1;RT animals was compared to historical control 
data taking the same assumptions. These were that the number of stem cells per 
crypt is fixed at N=7 and assuming neutrality in stem cell replacement (by fixing 
PR to 0.5). Under these conditions this model was used to predict the WPC/PPC 
ratios after 30 days of pulse-labelling when varying λ (Figure 3.11A). Interestingly, 
the WPC/PPC found in Atoh1;RT animals predicted that each Atoh1+ derived 
stem cell had a λ of 0.25 (Figure 3.11A). This is in line or slightly higher with λ’s 
found in previous colonic control pulse chase experiments produced in the Winton 
lab where λ= 0.22 approximately (data not shown).  
 The observation that the WPC/PPC ratios was significantly increased 
in Atoh1;KrasG12D;RT suggests that Atoh1 derived KrasG12D stem cells have a 
positive bias. To estimate the bias of Atoh1 derived KrasG12D cells the  
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model in Figure 3.11A was changed to predict WPC/PPC ratios at day 30 by 
fixing N=7 and λ=0.25 (as found in 11A) and varying the PR (Figure 3.11B). This 
analysis showed that the WPC/PPC ratio observed in Atoh1;KrasG12D;RT animals 
predicted Atoh1derived KrasG12D stem cells to have a PR of 0.65 (Figure 3.9B).  
 
In summary, these result show that Atoh1+ derived stem cells behave neutrally 
whereas KrasG12D stem cells derived from Atoh1+ cells have a competitive 
advantage. 
    
3.2.5 Atoh1 derived KrasG12D crypts have increased fission rate in the 
proximal small intestine and colon 
Next, the nature of inter-crypt colonization over time was examination. The 
previous experiments have shown that random clonal collisions do create crypt-
patches following saturation pulse labelling in the Atoh1CreErt model (Figure 3.6). 
However the size-distribution of these were not different in Atoh1;RT and 
Atoh1;KrasG12D;RT after 30 days (Figure 3.6). Thus, the only route of patch-size 
growth over time in animals with the same initial clonal induction and patch size 
distribution is by crypt multiplication. Crypt multiplication happens through the 
process of crypt-fission. Snippert et al. 2014 reported that KrasG12D crypts have 
an increased fission rate compared to WT crypts in the small intestine (Snippert 
et al., 2014). Thus, to investigate if this behaviour was retained in Atoh1 derived 
KrasG12D crypts, Atoh1;KrasG12D;RT and Atoh1;RT animals received 3 mg 
Tamoxifen on D0 and the small intestine and colon was collected 12- and 24 
weeks later for analysis (Figure 3.12A and 3.13A).  
 
Figure 3.12B-E shows patch size analysis in the proximal and distal small 
intestine (SI-1 and SI-4, respectively) after 12 and 24 weeks. Here, crypt patch 
sizes were manually quantified under a fluorescent microscope. The 12-week 
analysis included ~200-350 events and the 24-week analysis included 400-700 
events in N=2-3 mice per condition, with more events found in the distal part of 
the small intestine. Over time, clonal patches grew significantly larger in 
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Atoh1;KrasG12D;RT proximal small intestine (SI-1) compared to Atoh1;RT, with 
~75% vs >90% single crypts at 24 weeks, respectively (Figure 3.12C). In addition, 
Atoh1;KrasG12D;RT animals had patch sizes of up to 6 crypts whereas the biggest 
patch size recorded in Atoh1;RT animals consisted of 3 crypts (Figure 3.12C). 
Interestingly, no significant difference was observed between Atoh1;KrasG12D;RT 
and Atoh1;RT in the distal small intestine and only few fission events were 
recorded here (2.5-5% of all events) (Figure 3.12D-E).  
 
Figure 3.13B-C shows patch size distributions in Atoh1;KrasG12D;RT and 
Atoh1;RT colons after 12 and 24 weeks of pulse-labelling. The 12-week analysis 
included ~550-700 events and the 24-week analysis included 600-1000 events 
in N=2-3 mice per condition. Quantification of patch sizes showed that Atoh1 
derived KrasG12D crypts had a significantly increased fission rate compared to 
Atoh1+ crypts over time (Figure 3.13C).  
 After 12 weeks, Atoh1;RT animals had 90% single crypts and 10% 
double crypt patches, whereas Atoh;KrasG12D;RT animals contained 85% single 
crypts and patch sizes of up to 4 crypts (Figure 3.13C). At the 24-week timepoint, 
Atoh1;RT animals had 85% single crypts and patch sizes of up to 3 crypts. In 
contrast, Atoh1;KrasG12D;RT animals had only 70% single crypt patches at this 
timepoint, and patches of up to >7 crypts present (Figure 3.13C). 
 As a note, there were fewer single crypts (patch size = 1) in the 30-
day data-sets than in the 12- and 24-week datasets (Figure 3.6 vs. Figure 3.13). 
This is due to the fact that the 30-day analysis of patch sizes included partial 
clones as patches (as the mathematical tool did not distinguish full and partial 
clones during clonal collision prediction). Thus, two colliding partial clones were 
quantified as a patch of two. At 12- and 24-week post induction, clonal drift was 
mostly completed hence many partial clones were lost leading to the difference 
observed.       
 
Together, these results show that Atoh1 derived KrasG12D crypts spread via an 
increased fission rate in the proximal small intestine and colon.  
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3.2.6 Atoh1;KrasG12D;RT animals develop colonic lesions over time  
Long-term widespread intestinal activation of KrasG12D has shown to cause 
hyperproliferative crypts but to not lead to tumour formation (Haigis et al., 2008; 
Feng et al., 2011). However, surprisingly, when examining the colons of 
Atoh1;KrasG12D;RT at 12 and 24 months post induction, tdTom+ multicrypt-
patches that resembled early adenomas when subjected to confocal microscopy 
were found (Figure 3.14A), something that was never observed in the small 
intestine or in Atoh1;RT animals (Data not shown). Examination of the total 
number of tdTom+ lesions 12- and 24 weeks post induction in Atoh1;KrasG12D;RT 
showed the same number of lesions over time (Figure 3.14B). This suggested 
that the lesions arise early and only progress in size and not number over time.   
 
To further explore the nature of these lesions the colons were subjected to 
histological examinations. Different types of lesions where observed upon 
sectioning from 3 different levels in the colonic paraffin blocks (Figure 3.15). 
Firstly, enlarged crypts with high Ki-67+ hyperproliferation and increased Dusp6 
expression were found, here referred to as hyperproliferative crypts (Figure 3.15). 
Dusp6 is an Erk specific phosphatase that has been reported to be a marker of 
high MAPK signalling (Buffet et al., 2017) – here it was used as a surrogate 
marker for KrasG12D origin. These crypts seemed to be confined to the basement 
membrane and did not protrude into the colonic lumen (Figure 3.15). However, 
crypts that had “umbrella-shaped” protrusions into the lumen were also found 
(Figure 3.15). These were also recorded as Ki-67high and Dusp6 positive. A few 
of these lesions seemed to involve several crypts and have a serrated phenotype, 
these were referred to as “serrated polyp lesion” (Figure 3.15). In all lesions, Ki-
67 activity were found in the base of the crypt and never in the distal part (Figure 
3.15). None of these lesions found were positive for stabilised nuclear ß-catenin 
(Figure 3.15). In addition, most of these were found in the upper colon.  
 
In conclusion, these results show that KrasG12D expression in Atoh1+ cells can 
induce hyperproliferative crypts and serrated colonic polyps over time.                                  
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3.3 Discussion 
 
Taken together the results in this chapter show that KrasG12D expression does not 
change cell fate choices of Atoh1+ cells during tissue homeostasis but might 
increase the small intestinal Atoh1+ stem cell potential after Lgr5 depletion. In 
addition, KrasG12D mutations that arise in Atoh1+ progenitors can produce 
KrasG12D stem cells with a competitive bias and KrasG12D crypts that spread via 
fission in the proximal small intestine and colon and develop colonic polyps over 
time.  
 
It has previously been reported that KrasG12D expression and MAPK signalling 
affects lineage choices in the intestine towards the secretory goblet cell lineage 
(Haigis et al., 2008; Heuberger et al., 2014; Gagné-Sansfaçon et al., 2016). This 
could lead to the hypothesis that KrasG12D expression in secretory progenitors 
could induce a terminal goblet cell differentiation pattern. In theory, this would 
decrease the stem cell contribution potential of these cells. In contrast, a study 
that examined gene expression patterns in KRAS mutated tumours showed an 
increased embryonic stem cell like expression pattern in such tumours (Le Rolle 
et al., 2016). This suggests that KRAS mutations infer de-differentiation of 
intestinal cells which leads to the hypothesis that KrasG12D mutations would give 
progenitor cells an increased stem cell potential.  
 However, results in this chapter suggest that early Atoh1 expressing 
progenitors contribute to the stem cell pool independent of KrasG12D expression 
during homeostasis. Importantly, even though the potential contribution has not 
changed with KrasG12D expression, stem cell clones originating from 
Atoh1+KrasG12D cells are observed. This underlines that KrasG12D mutations are 
not excluded from the stem cell pool if they arise in Atoh1 progenitors. This greatly 
expands the pool of cells that can give rise to mutated KRAS colonic fields.   
 In addition, these findings propose that KrasG12D expression might be 
important for cell fate decisions in the stem cell pool but is dispensable in cells 
that have started to express secretory commitment transcription factors such as 
Atoh1. In the future, to further investigate the effect of KrasG12D signalling on 
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Atoh1+ stem contribution it will be interesting to administer Mek inhibitor to the 
Atoh1;RT animals. In addition, it would be interesting to explore Atoh1+ stem cell 
contribution in KrasG12D activated tissue to determine if secretory progenitors 
have an increased/decreased role in monitoring the epithelium in KrasG12D pro-
oncogenic fields.  
 
Interestingly, the results in this chapter suggest that Lgr5 deletion in the small 
intestine gives Atoh1+KrasG12D cells a higher chance of becoming stem cells 
compared to Atoh1+ cells. Thus, KrasG12D expression could expand the de-
differentiation potential of Atoh1+ cells in response to injury. This could be crucial 
for patients undergoing chemotherapy or radiotherapy. Such treatments are 
known to kill rapidly-cycling intestinal stem cells (Potten, 1977; Keefe et al., 
2000). Thus, because KrasG12D secretory progenitors appear to have an 
increased regenerative potential during such responses patients could have a 
higher chance of gaining KRAS mutations in intestinal stem cells in response to 
treatment. This would potentially increase their chance of developing secondary 
cancer over time.      
 
In contrast, no significant increase in clone frequencies after colonic Lgr5 deletion 
was observed. This suggest that Atoh1+ stem cell contribution is independent of 
Lgr5 depletion and KrasG12D expression in the colon. Interestingly, this is in 
contrast to a report by Castillo-Azofeifa et al. 2019. Here, the authors show a 15-
fold increase in Atoh1+ traced colonic clones after Lgr5 ablation. In the paper the 
authors use a Lgr5 depletion strategy in which DT is administered on two 
consecutive days prior to Atoh1 tracing in addition to 1 day after tracing starts. 
Taken together, this could mean that the Lgr5 regenerative response is slower in 
the colon than in the small intestine and that our Atoh1+ tracing do not catch the 
window of Lgr5 induced regeneration with our same-day DT administration 
strategy. On the other hand, it is also a possibility that the DT strategy employed 
by Catillo-Azofeifa et al. induces an increase in Atoh1+ cell numbers. This would 
mean that they in fact sample more Atoh1+ cells which implies that the stem cell 
contribution potential of each Atoh1+ cell is not changed in response to Lgr5 
ablation. Thus, in the future it will be important to test the Lgr5 depletion strategy 
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applied by Catillo-Azofeifa et al. in our Atoh1;KrasG12D;Dtr;RT model. This will 
emphasise whether stem cell contribution is independent on KrasG12D during Lgr5 
depletion in the colon. Further, it would be interesting to test other injury strategies 
to fully determine the regenerative response of Atoh1+KrasG12D cells.      
 
After assessing the stem cell contribution potential of Atoh1+ and Atoh1+KrasG12D 
cells it was next examined whether stem cells derived from secretory progenitors 
are impaired in their stem cell function. Here, we are the first to show that Atoh1+ 
derived colonic stem cells have a neutral behaviour with an λ that is similar to that 
found in other neutral Cre models. In addition, the results show that Atoh1+ 
derived KrasG12D stem cells have a competitive advantage over WT stem cells 
with a PR of 0.65 vs 0.5 respectively. Vermeulen et al. 2013 has previously 
reported that small intestinal KrasG12D stem cells have a PR of 0.78. The 
difference between the PR recorded in the two experiments could be due to small 
intestine and colon discrepancies or lacking co-recombination in the model 
presented here.  
 However, taken together this suggest that stem cells derived from 
Atoh1+ progenitors behave like any other stem cell in the crypt base and do not 
carry any intrinsic factors that alter their behaviour.    
 
Next, the nature of long term Atoh1+ and Atoh1+KrasG12D lineage tracing was 
investigated, to expose the inter-crypt spread and the tumorigenic potential of 
such crypts. The results show that Atoh1 derived KrasG12D crypts have an 
increased fission rate in the proximal small intestine and colon compared to Atoh1 
derived crypts. This is in line with data from Snippert et al. 2014 also showing 
increased fission in the small intestine following KrasG12D lineage tracing. This 
indicates that KrasG12D expression accelerates fission independent of cell origin. 
However, Snippert et al. reports 60% single crypts after 16 weeks of lineage 
tracing in the small intestine of KrasG12D animals in contrast to 75% after 24 weeks 
reported here (proximal small intestine). The higher fission frequency reported by 
Snippert et al. could be due to increased clonal collision in their 
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Lgr5CreErt;KraslslG12D;Confetti model or it could be due to differential co-
recombination of KrasG12D and reporter alleles in the two models.  
 Interestingly, here the results show a differential fission effect of 
KrasG12D crypts in the proximal and distal small intestine, with no difference in 
fission events between WT and KrasG12D crypts in the distal small intestine. This 
could be due to a differential co-recombination rate in the proximal and distal 
small intestine.  
 Importantly, the results report that KrasG12D crypts also spread via 
increased fission in the colon in vivo. This appears to occur at the same rate as 
in the proximal small intestine. This verifies that KrasG12D crypt spread also occurs 
in the colon which supports the modelling of increased mutated KRAS crypt 
fission rate found in human colons (Nicholson et al., 2018).    
 
Lastly, long term exposure of Atoh1 derived KrasG12D lead to production of early 
lesions in the colonic epithelium. The microscopic features of these lesions leads 
to the hypothesis that they are different stages of the more severe serrated-
lesions. These could start as hyperproliferative crypts that develops into umbrella 
shaped polyp-crypts and serrated lesions over time. The hyper-plasticity resulting 
from KrasG12D colonic expression has previously been reported and is also 
observed in other models with more widespread KrasG12D activation (Haigis et al., 
2008; Feng et al., 2011) (and the Winton lab). However, polyp lesions have not 
been reported upon colonic KrasG12D activation alone. The lesions reported here 
could arise due to the secretory Atoh1+ origin, indicating that Atoh1+ derived 
KrasG12D stem cells are in fact different to KrasG12D stem cells of other origins. 
These differences do not alter their stem cell behaviour, but it is possible that 
Atoh1 derived KrasG12D crypts and patches select for clones with other amplifying 
genetic mutations that could cause the lesions observed. However, the sporadic 
nature of the KrasG12D activation in this model could also be the source of 
initiation. If so, that indicates that KrasG12D lesions might require extrinsic factors 
from surrounding WT crypts to progress into serrated lesions and polyps. A good 
control for this would be sporadic colonic KrasG12D activation by a stem cell driven 
Cre.   
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 The serrated neoplasia pathway is a new classification of colon cancer 
that is thought to comprise 20% of sporadic cases (Rashtak et al., 2017). The 
precursor lesion for this type of colon cancer is sessile serrated polyps. However, 
it has been proposed that hyperplastic polyps might in fact be an even earlier 
stage of the disease (Jass, 2004). It is believed that the initiating event for such 
lesions are BRAFV600E mutations though a recent study found that 20% of 
serrated polyps contained KRAS mutations (Juárez et al., 2017). If the lesions 
found in Atoh1+KrasG12D animals are in fact hyperplastic and serrated, they could 
be initial stages of serrated colon-cancer. It is, however, clear that these lesions 
are not part of the classical colorectal cancer progression pathway as they lack 
nuclear ß-catenin staining. In the future, it will be interesting to age and 
characterise these lesions further.                   
 
In conclusion, early secretory progenitors could in fact be the origin of KrasG12D 
mutations in stem cells and may be one of contributors generating colorectal 
KRAS fields. This finding means that the pool of cells that can give rise to KRAS 
fields is larger than previously expected.  
 
In the future, it will be interesting to investigate how KrasG12D activation affects 
precursors of different cell lineages such as Alpi+ enterocytes and Ngn3+ 
enteroendocrine progenitors. This would map the relative influence of progenitor 
stem cell contribution on KrasG12D field origin 
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4 Defining stem cell dynamics in intestinal KrasG12D 
fields  
4.1 Introduction 
Cancer development is believed to be a step-wise process of mutational 
acquisition, selection and clonal expansion (Baker et al., 2018). Thus, pre-
neoplastic cells clonally expand and acquire the molecular identities essential for 
tumour development over time. In this interpretation, some pre-neoplastic cells 
carry oncogenic mutations but are not yet morphological distinct (Baker et al., 
2018). Consequently, pre-neoplastic clones can be in a “pre-disposed cancerous” 
state, which is referred to as field characterisation or field effect. The notion that 
oncogenic mutations can be discovered in cells before overt tumour formation 
and that mutational burden increases with age supports the idea that field effect 
is an unavoidable trait of self-renewing tissues (Tomasetti et al., 2013; 
Alexandrov et al., 2015). Additionally, field effects have been discovered in many 
different tissue types, such as the skin (Martincorena et al., 2015), the 
oesophagus (Martincorena et al., 2018), haematopoietic stem cells (Xie et al., 
2014) and the colonic epithelium (Galandiuk et al., 2012; Nicholson et al., 2018).    
 
In 1990 the Vogelstein model predicted that colorectal cancer develops through 
sequential mutational acquisition in the colonic epithelium with the initiating event 
being loss of APC (Fearon and Vogelstein, 1990). In this model, oncogenic KRAS 
and TP53 mutations occur after early adenomas have formed (Fearon and 
Vogelstein, 1990). However, recent studies have shown that oncogenic 
mutations in KRAS can be found in 10% of morphological healthy human colon 
tissue and can exist in fields of up to 100 crypts (Dieterle et al., 2004; Kraus et 
al., 2006; Parsons et al., 2010; Nicholson et al., 2018). This leads to the 
hypothesis that KRAS mutated fields arise early in colorectal tissue and might 
pre-dispose to cancer development.  
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As intestinal stem cells are self-renewing, they are the only cells that live long 
enough to maintain tumorigenic mutations in the epithelium. Therefore, a field 
effect might begin with the process of acquiring mutation(s) in a single stem cell 
which through neutral or biased drift will create monoclonally converted mutated 
crypts, so-called clonal fixation (Lopez-Garcia et al., 2010; Snippert et al., 2010). 
Such mutated crypts can spread by fission to create mutated fields within the 
intestinal epithelial. In the previous chapter and by Vermeulen et al. 2013, it was 
shown that intestinal stem cells harbouring KrasG12D mutations have a 
competitive bias over WT stem cells. This gives KrasG12D stem cells an increased 
chance of outcompeting WT cells and creating monoclonal KrasG12D crypts during 
clonal drift and thus fixing in the tissue. Furthermore, data from the previous 
chapter and Snippert et al. 2014 has shown that KrasG12D crypts have an 
increased fission rate. Together, this gives KrasG12D mutations the potential for 
creating pre-neoplastic fields.  
 
Studies exploring the long-term effects of Kras mutations in the murine intestinal 
epithelium have found that oncogenic Kras alone does not initiate cancer (Haigis 
et al., 2008; Feng et al., 2011). Thus, it is not clear if mutated KRAS fields are 
directly oncogenic or whether they indeed pre-dispose to cancer development. 
Therefore, it is important to characterise the cellular behaviour and clonal 
dynamics of such fields to understand their tumorigenic potential. Such results 
will aid the general understanding of early colorectal cancer development and 
might help identify new ways to treat or prevent the disease.  
 
To define clonal dynamics in KrasG12D fields, the Cyp1A1FlpO;KrasfsfG12D;AhCreErt; 
R26lsltdTom (referred to as Flp;KrasG12D;CreErt;RT) mouse model, that allows 
temporal separation of the creation of a KrasG12D field from pulse-chase lineage 
tracing, was created.  
 The cytochrome P450 family member 1, subfamily a, polypeptide 1 
(Cyp1A1) Cyp1A1FlpO allele was developed in the Winton lab and has not been 
published yet. Here, the FlpO expression cassette was targeted to the Cyp1A1 
mouse promoter and enhancer element located on chromosome 9. Cyp1A1 is a 
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xenobiotic metabolising enzyme that is active in the intestinal epithelium, liver 
and in the immune system (Ireland et al., 2004; Gutié Rrez-Vá Zquez and 
Quintana, 2018). The Cyp1A1 promoter is silent until exposed to lipophilic 
xenobiotics (such as ß-naphthoflavone) which can bind to the cytoplasmic aryl 
hydrocarbon receptor (Ah). The Ah receptor will in turn translocate to the nucleus 
and bind to the xenobiotic response element in the Cyp1A1 promoter to initiate 
transcription (Matsushitasq et al., 1993). The AhCreErt allele was developed by 
placing the CreErt expression cassette under the transcriptional control of the rat 
Cyp1A1 promoter and delivering this transgene by oocyte pro-nuclear injection 
(Kemp et al., 2004). To this end, the AhCreErt allele is created by random genetic 
insertion and the Cyp1A1FlpO by targeted insertion, but otherwise FlpO and CreErt 
are transcriptionally regulated by the same inducing agent.   
 A single dose of ß-naphthoflavone will initiate a pulse of Flp and CreErt 
expression from the Cyp1A1 and Ah promoter, respectively, in the in intestinal 
epithelium of Flp;KrasG12D;CreErt;RT animals. Since CreErt encodes the inducible 
oestrogen receptor (Ert) this recombinase is not active until Tamoxifen is 
administered. However, Flp recombinase is directly functional upon expression. 
Thus, ß-naphthoflavone administration alone will lead to widespread intestinal 
KrasG12D expression by Flp mediated removal of the frt flanked STOP cassette 
from the KrasfsfG12D allele (Figure 4.1A). Subsequently, a dose of ß-
naphthoflavone and Tamoxifen will activate CreErt to remove the loxP flanked 
STOP cassette on the R26lsltdTom allele to initiate tdTom lineage tracing in 
KrasG12D fields (Figure 4.1B). Therefore, combining Cyp1A1FlpO and AhCreErt in the 
same model theoretically makes it possible to separate two recombination events 
temporally and thus facilitates lineaging tracing in KrasG12D intestinal fields. All 
animals presented in this chapter were heterozygotes for all alleles.    
   
The aim of this chapter is to characterise the nature of stem cell replacement and 
clonal drift within murine KrasG12D mutant crypts in KrasG12D fields, to expose any 
pro-oncogenic features of stem cell behaviour. The second aim is to explore the 
pathways that govern clonal growth in KrasG12D fields.    
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4.2 Results  
4.2.1 Optimisation of the Flp;KrasG12D;CreErt;RT mouse  
To be able to utilize Cyp1A1FlpO and AhCreErt alleles temporally it was important 
that the initial induction of FlpO did not activate the second recombinase in the 
sequence: AhCreErt. Cyp1A1FlpO is activated by ß-naphthoflavone and AhCreErt, in 
theory, requires both ß-naphthoflavone and Tamoxifen to be activated. However, 
if in fact the induction of Cyp1A1FlpO creates background AhCreErt activity it could 
skew lineage tracing as some tdTom+ clones would originate early from 
background activity and not from the intended pulse chase.  
 Therefore, it was firstly tested whether ß-naphthoflavone 
administration alone would lead to background activity of Cre recombinase. This 
was examined by quantifying the number of tdTom+ small intestinal villus ribbons 
and colonic crypts present 30 days post one dose of either 40, 20, 8 or 4 mg/kg 
ß-naphthoflavone in AhCreErt;R26lsltdTom (referred to as, AhCreErt;RT) animals 
(Figure 4.2A). In this experiment, tdTom+ expression served as a surrogate 
marker for AhCreErt activity. A positive control animal was administered 40 mg/kg 
ß-naphthoflavone as well as 4 mg Tamoxifen to induce high levels of AhCreErt 
activity (Figure 4.2B). A negative control animal did not receive any drugs (Figure 
4.2B). The number of tdTom+ ribbons and crypts were counted manually in 
whole-mounted small intestine and colon under a fluorescent microscope and 
normalised to the length of the tissue strip scored (figure 4.2C). Importantly, the 
positive control contained a vast amount of tdTom+ crypts in the proximal small 
intestine, demonstrating Cre activity in these animals, whereas no tdTom+ crypts 
were observed in negative controls (Figure 4.2B). Quantification of AhCreErt 
background activity showed greater tdTom+ levels in the proximal small intestine 
(SI-1 and SI-2) than the distal small intestine (SI-3 and SI-4) and colon (Figure 
4.2C). In addition, background activity behaved in a dose-responsive manner, 
with the greatest number of ribbons (>60 ribbons / cm in SI-1) found in animals 
administered 40 mg/kg ß-naphthoflavone (Figure 4.2B-C). Importantly, the 
background activity was negligible in animals treated with 8 and 4 mg/kg ß-
naphthoflavone with only 0-2 ribbons / cm found in the proximal small intestine 
and none in the colon (Figure 4.2B-C).  
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Therefore, 8 mg/kg ß-naphthoflavone was chosen as the Cyp1A1FlpO induction 
dose for any future experiments. Clonal quantification in AhCreErt;RT lineage 
tracing experiments normally requires approximately 2 cm of small intestinal 
tissue to quantify 100-300 clones. Thus, the approximate number of background 
clones scored during lineage tracing in Flp;KrasG12D;CreErt;RT would be a 
maximum of 4/100 clones (4%) which was viewed as an acceptable error margin.  
 
It was important that the initial KrasfsfG12D recombination was highly efficient in 
creating tissue wide fields. Therefore, to investigate this Flp;KrasG12D;Cre;RT 
animals were administered 8 mg/kg ß-naphthoflavone and 21 days post induction 
the intestinal epithelium was isolated from the proximal small intestine and colon. 
gDNA from these samples was subjected to PCR amplification to examine the 
level of KrasfsfG12D recombination (Figure 4.3A). Here, uninduced 
Flp;KrasG12D;CreErt;RT animals served as a negative control for background 
KrasfsfG12D recombination (Figure 4.3A). In addition, wild-type (WT) gDNA (from 
ear-biopsy) served as a negative control for PCR specificity (Figure 4.3A). 
Examination of PCR amplified DNA by gel-electrophoresis showed high levels of 
KrasfsfG12D recombination in both small intestine and colon as the unrecombined 
band (FSF) was extremely diminished in samples exposed to ß-naphthoflavone 
(Figure 4.3A). In addition, it appeared that recombination efficiency was higher in 
the colon than in the small intestine (Figure 4.3A). Importantly, recombination was 
absent in un-induced samples underlining that recombination was dependent on 
Cyp1A1FlpO induction (Figure 4.3A).  
 Conclusively, this result showed that 8 mg/kg ß-naphthoflavone was 
sufficient to induce high levels of KrasfsfG12D recombination, whilst inducing 
negligible levels of tdTom+ cell marking. 
      
The standard dose for AhCreErt mediated tdTom+ pulse lineage chasing is 40 
mg/kg ß-naphthoflavone + 0.15 mg Tamoxifen. This dose marks <1 cell per crypt 
on average which is desired in lineage trace experiments. To test whether this 
dose was still applicable for lineage tracing in the Flp;KrasG12D;CreErt;RT model, 
animals were administered 8 mg/kg ß-naphthoflavone to induce Cyp1A1FlpO 
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activity and 21 days later a dose of 40 mg/kg ß-naphthoflavone + 0.15 or 0.3 mg 
Tamoxifen to initiate AhCreErt mediated lineage tracing (Figure 4.3B). Confocal 
microscopy of the proximal small intestine (highest AhCreErt activity) 4 days post 
lineage trace initiation showed that 40 mg/kg ß-naphthoflavone + 0.15 mg 
Tamoxifen lead to <1 tdTom+ cells / crypt whereas 0.3 mg Tamoxifen lead to >1 
tdTom+ cells / crypt (Figure 4.3B). Thus, 40 mg/kg ß-naphthoflavone + 0.15 mg 
Tamoxifen was the chosen dose for lineage tracing in the Flp;KrasG12D;CreErt;RT 
model.       
 
However, induced Flp;KrasG12D;CreErt;RT animals developed oral papillomas 
over time (Figure 4.3C). This was never observed in WT animals and thus was 
KrasG12D specific. Because of mouth obstruction this allowed 
Flp;KrasG12D;CreErt;RT animals to be kept alive for approximately 50 days post 
KrasG12D induction (Figure 4.3C). Lineage tracing is a 21-day experiment and 
therefore it was concluded that initial KrasG12D recombination should last for 21 
days (Figure 4.3D).   
 
In conclusion, the result show that Cyp1A1FlpO and AhCreErt can be utilized in the 
same model to temporally separate KrasfsfG12D recombination from lineage 
tracing. In addition, it appeared that 8 mg/kg ß-naphthoflavone was the optimal 
dose to use for initial Cyp1A1FlpO activation as this dose created negligible levels 
of AhCreErt background activity and high levels of KrasfsfG12D recombination.    
 
4.2.2 Clonal dynamics are significantly accelerated in KrasG12D fields 
After thorough optimisation and characterisation of the Flp;KrasG12D;CreErt;RT 
model lineage tracing was carried out in KrasG12D fields to define clonal dynamics.  
 Flp;KrasG12D;CreErt;RT (KrasG12D) or Flp;WT;CreErt;RT (WT) animals 
received 8 mg/kg ß-naphthoflavone to induce KrasG12D expression or not and 21 
days later they received 40 mg/kg ß-naphthoflavone + 0.15 mg Tamoxifen to 
initiate lineage tracing of tdTom+ clones (Figure 4.4A). Animals were sacrificed 
4, 7, 10, 14 and 21 days post pulse-chase initiation (Figure 4.4A). The proximal 
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small intestine and colon were then subjected to manual clone quantification by 
fluorescent microscopy to score the relative sizes of tdTom+ clones in intestinal 
crypts recorded as fractions of 8 (Figure 4.4B). Each timepoint contained 3-4 
animals. In WT animals a total of 450-750 clones were quantified per timepoint in 
the small intestine and colon. In KrasG12D animals 450-900 and 150-650 clones 
were quantified in the small intestine and colon respectively, with fewest clones 
quantified at later timepoints. As a note, the clonal frequency was lower in 
KrasG12D colons leading to the relative low clone count here. 
 Analysis of average clone size showed that clones in KrasG12D small 
intestine and colon were significantly larger than clones in WT animals at all 
timepoints (Figure 4.4C). This implies that the rate by which stem cells replace 
each other during clonal expansion (replacement rate) is increased in KrasG12D 
fields. To investigate clonal fixation time in these animals, the percentage of 
wholly populated clones (WPC) (scored as 1, Figure 4.4B) over time was plotted 
(Figure 4.4D). From this analysis, it was clear that clones in KrasG12D epithelium 
have a significantly decreased monoclonal conversion time, with nearly 60% of 
all clones being scored as WPC at day 21 in both the small intestine and colon, 
compared to <20% in WT animals (Figure 4.4D). In addition, there appeared to 
be a lag in the time it took clones to become WPC in KrasG12D colons compared 
to the small intestine (Figure 4.4D). Heatmap analysis of clone size distribution 
further confirmed that overall, clones grew larger at an accelerated rate in 
KrasG12D small intestine and colon compared to WT (Figure 4.4E).   
 
In conclusion, the lineage tracing data here showed that dynamics of clonal 
growth appear to be accelerated in KrasG12D fields with significantly larger 
average clone sizes and percentage of WPCs over time compared to that of WT 
crypts.            
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4.2.3 Determining stem cell number and stem replacement rate in KrasG12D 
fields  
To be able to quantitively compare stem cell dynamics in the KrasG12D and WT 
fields mathematical modelling was used to predict stem cell number per crypt (N) 
and stem cell replacement rate per stem cell per day (l). The mathematical model 
was designed by Edward Morrissey and has previously been applied to describe 
stem cell behaviour in the mouse intestine (Kozar et al., 2013; Vermeulen et al., 
2013). The model assumes neutral behaviour between stem cells in intestinal 
crypts and it relies on Bayesian inference to explain stochastic stem cell 
behaviour to predict average clone sizes over 100 days in KrasG12D and WT small 
intestinal and colonic fields (Figure 4.5A).  
 From the model it is also clear that stem cell dynamics are accelerated 
in KrasG12D fields. Thus, the model predicts that all crypts in KrasG12D fields are 
monoclonal after approximately 60 days of neutral drift whereas 100 days of drift 
is insufficient for all crypts to become monoclonal in WT fields (Figure 4.5A).      
 From the average clone sizes the model inferred N to be 6 and 7 and 
l to be 0.17 and 0.21 in the WT small intestine and colon respectively (Figure 
4.5B). In contrast, N was inferred to be 5 in both the small intestine and colon of 
KrasG12D animals and l was estimated to 0.31 and 0.26 in the KrasG12D small 
intestine and colon respectively (Figure 4.5B). As a note, the model suggested to 
a low probability that N=4 and l=0.18 in the KrasG12D colon. This was probably 
due to the higher variability in the colonic dataset (Figure 4.5B).  
 
Thus, this analysis shows that KrasG12D crypts mediate accelerated clonal growth 
by employing fewer stem cells with a relative increased replacement rate for 
clonal drift.  
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4.2.4 Crypts in KrasG12D fields have an increased mutational burden 
Theoretically, an accelerated monoclonal conversion rate will lead to faster 
fixation of neutral and oncogenic mutations. Thus, if the rate of mutations per cell 
division is the same in WT and KrasG12D crypts, KrasG12D crypts should fix an 
increased amount of mutations compared to WT crypts during aging. To test this 
experimentally, exome sequencing was employed to examine mutational burden 
in WT and KrasG12D crypts.    
 Previous exome sequencing data has shown that the single nucleotide 
variant (SNV) mutation rate is 0.37 X 10-10 per cell division per base pair in normal 
crypts (Lugli et al., 2017).  Therefore, it was expected that the relative acquisition 
of SNVs over time would be low. Thus, to make it statistically possible to test if 
there was a difference between KrasG12D and WT crypts it was concluded that 
aged crypts that had time to acquire some mutational burden would be 
appropriate for this analysis. As Flp;KrasG12D;CreErt;RT animals could not be 
maintained long term VillinCreErt;KraslslG12D and VillinCreErt;WT animals were used 
for these experiments. In this model VillinCreErt allows for conditional intestinal 
specific expression of KrasG12D by administration of Tamoxifen. Additionally, this 
analysis focused on colonic crypts to be as close to the human colorectal 
pathology as possible. 
 For widespread intestinal KrasG12D expression (or not) 61 and 126 
days old VillinCreErt;KraslslG12D (KrasG12D) and VillinCreErt;WT (WT) animals received 
3 mg Tamoxifen (Figure 4.6A). Single crypts were isolated from the colon 186 
days post induction (Figure 4.6A). To expand the genetic material for sequencing, 
crypts were cultured as organoids for 5 days (Figure 4.6A). Thereafter, genomic 
DNA was isolated from 6 single organoids per animal and these were subjected 
to exome capture and next generation sequencing (Figure 4.6A).  
 Mutation calling was performed by Lee Hazelwood. To filter out 
germline single nucleotide polymorphisms (SNPs) and call somatic SNVs each 
sample was compared against a sample background. Background samples 
consisted of a composite sample in which sequencing data from organoid groups 
of same genotype and age was collated. Organoid SNVs were called by 
comparing them back to the background sample minus the organoid under 
investigation. Only monoclonal somatic SNVs were called in this analysis. Such  
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were expected to be largely heterozygous with an allele frequency of 0.5 
therefore the allele frequency window used to call SNVs were set to 0.35-0.65 at 
a read-depth of 30 reads per base.    
 
This analysis showed that colonic KrasG12D crypts acquired significantly more 
somatic mutations over time compared to WT crypts (Figure 4.6D). 
 
4.2.5 KrasG12D fields accelerate ß-catenin mediated tumorigenesis  
As described above the clonal dynamics found in KrasG12D fields imply that such 
areas could speed up cancer initiation time by decreasing monoclonal conversion 
time of additional oncogenic mutations. The increased fission rate observed in 
KrasG12D crypts (explained in chapter 3) could give new mutated crypts in a 
KrasG12D field the potential to spread and thereby create a new field within the 
field. Over time these could develop into intestinal adenomas and carcinomas in 
some instances by acquiring additional oncogenic mutations. In addition, it is 
clear that increased Wnt signalling is an initiating factor of colorectal cancer, 
underlined by the fact that 80% of human colon tumours contain mutations in 
APC (The Cancer Genome Atlas Network, 2012).  Furthermore, it has been 
shown that conditional deletion of exon 15 and 3 in Apc and Ctnnb1, respectively, 
can cause nuclear ß-catenin stabilisation and adenoma development in the 
mouse intestine (Harada et al., 1999; Robanus-Maandag et al., 2010).   
 To functionally examine whether KrasG12D fields accelerate cancer 
initiation caused by stabilised nuclear ß-catenin the VillinFlp;KrasfsfG12D; 
AhCreErt;Ctnnb1floxex3 (denoted as KrasG12D;ß-cat) mouse was created. The Villin 
promoter is gut specific and is active during development and in adult mice 
(Maunoury et al., 1992). Thus, in this model, animals were born with intestinal 
KrasG12D fields and sporadic stabilisation of nuclear ß-catenin was created by 
deleting exon 3 in Ctnnb1 by Cre activation. The control for these mice were 
VillinFlp;WT;AhCreErt;Ctnnb1floxex3 (denoted as WT;ß-cat). Due to time constraints 
and the difficulty of this breeding only two KrasG12D;ß-cat animals were included 
in the analysis described below.  
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 To induce clonal levels of stabilised nuclear ß-catenin, 8-weeks old 
KrasG12D;ß-cat and WT;ß-cat animals received 40 mg/kg ß-naphthoflavone and 
0.5 mg Tamoxifen and were culled when moribund (Figure 4.7A). The clonal 
induction of nuclear ß-catenin was chosen so that the experiment would be as 
close to the human equivalent as possible and to allow the animals to survive 
long enough for the experiment to reveal true differences between KrasG12D;ß-cat 
and WT;ß-cat.  
 The results revealed a noticeable difference in survival of the two 
groups of animals (Figure 4.7B). KrasG12D;ß-cat animals survived 49 and 73 days 
whereas WT;ß-cat animals survived to a median of 161 days (N=3 animals) 
(Figure 4.7B). To investigate tumour progression side by side, matched controls 
samples were collected upon harvest of KrasG12D;ß-cat animals. Upon tissue 
inspection in such matched samples it was clear that KrasG12D;ß-cat had a more 
severe phenotype than WT;ß-cat animals (Figure 4.7C). This manifested as 49 
and >100 tumours in the proximal small intestine (SI-1) of KrasG12D;ß-cat animals 
compared to just 9 and 4 found in WT;ß-cat animals (Figure 4.7C-D).  
 
Together these preliminary results suggest that KrasG12D fields in fact do speed 
up cancer initiated by stabilisation of nuclear ß-catenin. This further supports the 
hypothesis that KrasG12D fields are pro-oncogenic areas.  
 
4.2.6 Mek1/2 inhibition can rescue accelerated clonal dynamics in KrasG12D 
fields 
The Ras family proteins are GTPases that are involved in many different cell-
signalling cascades. One of the main substrates of the activated GTP bound Ras 
proteins are the Raf family of protein kinases (Pylayeva-Gupta et al., 2011). Upon 
Ras-Raf interaction Raf proteins will be left in an active phosphorylated state. The 
main substrates of Raf mediated phosphorylation are the protein kinases Mek1/2 
(Pylayeva-Gupta et al., 2011). Phosphorylated Mek1/2 will in turn phosphorylate 
Erk1/2 which can phosphorylate a variety of target proteins to induce cellular 
responses such as: proliferation, protein synthesis and survival (Pylayeva-Gupta 
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et al., 2011; Cox et al., 2014). RAS genes constitute the most frequently mutated 
oncogenes in human cancer and thus many efforts have been made to create 
inhibitors for the Ras proteins and their downstream signalling (Cox et al., 2014). 
The compounds that have had success in the clinic are inhibitors of the 
downstream effectors Mek1/2 and Erk1/2 (Cox et al., 2014). AZD6244 is a 
selective Mek1/2 inhibitor that has been shown to be well tolerated by patients in 
phase I clinical trials (Adjei et al., 2008).  
 Based on the foregoing, it was next investigated if the accelerated pro-
oncogenic clonal dynamics observed in KrasG12D fields could be inhibited by the 
administration of the clinically available Mek1/2 inhibitor AZD6244 (Meki). To test 
the effect on clonal growth, Meki was administered during lineage tracing in 
KrasG12D fields. Experimentally, the Flp;KrasG12D;CreErt;RT (KrasG12D) and 
Flp;WT;CreErt;RT (WT) were administered 8 mg/kg ß-naphthoflavone to induce 
KrasG12D expression (or not) and 21 days later lineage tracing was begun (Figure 
4.8A).  To obtain Mek1/2 inhibited KrasG12D fields at the beginning of lineage 
tracing, administration of Meki (25 mg/kg) or vehicle treatment was begun one 
day prior to lineage trace initiation (Figure 4.8A). Meki or vehicle was then 
administered twice daily by oral gavage and animals were culled 14 days post 
lineage trace initiation (Figure 4.8A).  
 Initially it was clear that Meki treatment regressed oral papilloma 
growth in KrasG12D animals, which confirmed that the drug appeared to target 
KrasG12D affected cells (Figure 4.8A). To ensure that the treatment had reached 
the small intestine and colon the levels of phosphorylated Mek1/2 was assessed 
by IHC in animals treated with vehicle or Meki. This confirmed a clear reduction 
in active Mek1/2 protein levels post treatment in both WT and KrasG12D animals 
(Figure 8B). Next, the size of lineage traced clones and percentages of WPCs 
were quantified as described for Figure 4.4. The data obtained from this 
experiment was then compared back to data obtained at day 14 post lineage 
tracing in Figure 4.4 (Figure 4.8C-D). This analysis revealed that Meki treatment 
significantly reduced the average clone size and percentage of WPCs in small 
intestinal and colonic KrasG12D fields (Figure 4.8C-D). However, the average 
clone size and percentage of fixed clones was still significantly greater in Meki 
treated KrasG12D fields compared to WT fields (Figure 4.8C-D). In addition, this  
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effect was Meki specific as there was no significant difference in KrasG12D 
samples with or without vehicle treatment (Figure 4.8D). Importantly, Meki 
treatment did not appear to have any influence on clonal dynamics in WT animals 
(Figure 4.8C-D).  
 
These results show that accelerated clonal dynamics in KrasG12D fields were 
dependent on active Mek1/2 signalling and could be rescued by Mek1/2 
inhibition.  
 
Previous reports have shown that KrasG12D expression in the murine intestine 
mediates hyperproliferation, increased levels of goblet cells and decreased levels 
of Paneth cells (Feng et al., 2011). Interestingly, it was also shown that Mek 
inhibitor treatment lead to a reversion of this phenotype in KrasG12D animals (Feng 
et al., 2011). Therefore, to investigate if the same could be observed in the 
experimental samples here and to understand the cellular effect of Meki treatment 
on KrasG12D fields in more detail, controls and samples illustrated in Figure 4.8 
were subjected to histology analysis for proliferation, Paneth and goblet cells.  
 Meki treated animals from Figure 4.8, and Meki untreated controls 
consisting of Flp;KrasG12D;CreErt;RT (KrasG12D, N=3) and Flp;WT;CreErt;RT (WT, 
N=4) induced with 8 mg/kg ß-naphthoflavone and culled 21 post induction were 
administered a pulse of BrdU for 45 minutes before termination. The proportion 
of BrdU+ cells was quantified in the proximal small intestine and the colon by IHC 
analysis and manual scoring. 25 half-crypts were measured per animal and each 
cell position from base to top of crypts was scored either BrdU+ or BrdU- (Figure 
4.9A+E). This analysis showed that cells in KrasG12D crypts had an increased 
proportion of BrdU+ cells at most cell positions compared to WT crypts in both 
the small intestine and colon (Figure 4.9B+F). In addition, Meki treatment 
appeared to reduce proliferation in KrasG12D but not in WT crypts (Figure 4.9B+F).  
 Neutral drift is a result of stem cell division and replacement and thus 
is impacted by cellular proliferation. During lineage tracing stem cell clonal growth 
is measured at the crypt base and therefore the proportion of BrdU+ cells at the 
crypt base could be indicative of stem cell division. To understand whether  
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reduced stem cell proliferation could be the cause of the repressed stem cell 
dynamics observed in Meki treated KrasG12D fields the proportion of BrdU+ cells 
at cell position 1-5 (defined as the stem cell zone) was examined. This showed a 
significantly increased proportion of BrdU+ cells in KrasG12D samples compared 
to WT (Figure 4.9C+G). Additionally, Meki treatment significantly decreased stem 
cell zone proliferation in KrasG12D samples (Figure 4.9C+G). Interestingly, the 
proliferation in the stem cell zone of Meki treated KrasG12D samples was still 
increased compared to WT samples in the small intestine but not in the colon 
(Figure 4.9C+G).  
 
Additionally, KrasG12D activation lead to significantly elongated crypts compared 
to WT (Figure 4.9D+H). This appeared inhibited in KrasG12D Meki treated samples 
as small intestinal and colonic crypts were significantly smaller than untreated 
KrasG12D crypts, however, still significantly longer than WT crypts (Figure 
4.9D+H).  
 
To further characterise the KrasG12D mediated tissue re-organisation after Meki 
treatment the number of Paneth and goblet cells was examined in the small 
intestine of the animals described in Figure 4.9.  
 Paneth cells were identified by their lysozyme containing granules 
(Deckx, et. al, 1967). The number of lysozyme+ Paneth cells was quantified in 25 
crypts per animal (Figure 4.10A). This analysis showed KrasG12D animals had 
significantly fewer Paneth cells per crypt compared to WT animals (Figure 4.10A-
B). However, Meki inhibition partially reversed this phenotype as significantly 
increased numbers of Paneth cells were found per KrasG12D crypt after treatment, 
though this level was still significantly decreased compared to WT animals 
(Figure 4.10A-B).   
 Goblet cells were identified by Alcian blue / Pas positive mucin staining 
(Figure 4.10A). The number of goblet cells was quantified in 15 half villi per animal 
from villus bottom to villus tip (Figure 4.10A). The number of goblet cells per villus 
was normalised against the length (in cell number) of the villus quantified. This 
analysis showed an increased number of villus associated goblet cells and villus 
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length in KrasG12D animals (Figure 4.10A+C). These were significantly decreased 
after Meki treatment in KrasG12D animals, however, the villus length in Meki 
treated KrasG12D samples was still significantly longer compared to WT (Figure 
4.10A+C). Importantly, Meki treatment did not seem to have any major effect on 
WT crypts (Figure 4.9 + 4.10).  
 
In conclusion, the results presented here suggest that Meki treatment partially 
reveres the KrasG12D field phenotype.   
 
4.2.7 The long-term effect of Mek1/2 inhibition 
Meki treatment inhibited the accelerated pro-oncogenic clonal dynamics 
observed in KrasG12D fields and reverted the KrasG12D phenotype. Therefore, it is 
possible that Meki could repress the pro-oncogenic effect of KrasG12D fields. In 
theory, at least, Meki treatment could be used as a chemo-preventative in the 
clinic. A successful chemo-preventative treatment would have little side-effects 
and theoretically be given in cycles (and not continuously) during patient lifespan. 
Meki treatment should therefore ideally have a long-term effect to achieve activity 
even during the pauses of treatment cycles.  
 Thus, to test whether Meki treatment had long-term effects on clonal 
dynamics, KrasG12D animals were treated with Meki in a cycle of Meki on and Meki 
off (Meki on/off) and clonal dynamics were examined. Experimentally, 
Flp;KrasG12D;CreErt;RT (KrasG12D) or Flp;WT;CreErt;RT (WT) animals were 
administered 8 mg/kg ß-naphthoflavone to induce KrasG12D expression (or not) 
on day -51 (Figure 4.11A). 21 days later Meki treatment was administered for 15 
days as described in Figure 4.8 (Meki on) (Figure 4.11A). On day -15 Meki 
treatment was stopped (Meki off) and lineage tracing was initiated on day 0 for a 
total of 14 days of pulse-chasing labelling (Figure 4.11A). 
 
Examination of pMek by IHC showed similar levels in untreated animals and Meki 
on/off animals both in the small intestine and colon suggesting a return of normal 
Mek1/2 levels after termination of Meki treatment (Figure 4.11B). The average 
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clone size and percentage of WPCs found in this experiment was compared back 
to data from Figure 4.8. The average clone size and percentage of WPCs were 
significantly increased in KrasG12D Meki on/off animals compared to KrasG12D Meki 
samples (Figure 4.11C-D), suggesting a reversion of clonal dynamics after Meki 
treatment ended. If KrasG12D clonal dynamics were completely reverted after 
termination of Meki treatment no significant difference would be expected 
between untreated KrasG12D and Meki on/off samples. Interestingly, there 
appeared to be a trend that the clonal dynamics in KrasG12D fields were not fully 
reverted to KrasG12D levels after Meki treatment termination (Figure 4.11C-D). 
This was underlined by the fact that the average clone size and the percentage 
of WPCs in the KrasG12D Meki on/off small intestinal and colon were significantly 
decreased compared to KrasG12D untreated samples, respectively (Figure 4.11C-
D). However, the difference in average clone size and percentage of WPCs 
between KrasG12D Meki on/off and KrasG12D failed to reach significance in the 
colon and small intestine, respectively (Figure 4.11C-D).  
 
Conclusively, these results show that clonal dynamics in KrasG12D Meki treated 
fields partially revert back to normal KrasG12D levels after treatment suggesting a 
limited sustained long-term effect of Meki.  
 
To further examine whether KrasG12D mediated tissue changes were also 
reverted after cessation of Meki treatment, BrdU positivity and number of Paneth 
and goblet cells were examined in Meki on/off animals from Figure 4.11. Next, 
this data was compared to the data presented in Figure 4.9+10. As no difference 
was observed in WT samples this analysis only included KrasG12D samples.   
  Analysis of proportion of BrdU+ cells at all cell positions in the small 
intestinal and colonic crypts showed that cells in KrasG12D Meki on/off crypts had 
reached (and in some cases exceeded) levels in KrasG12D crypts (Figure 4.12A-
B+E-F). This suggested a proliferative burst in Meki KrasG12D fields after 
treatment ended. Examination of proportion of BrdU+ cells in the stem cell zone 
showed a significant increase in S-phase cells in KrasG12D Meki on/off samples 
compared to KrasG12D Meki in both the small intestine and colon (Figure 
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4.12C+G). In addition, the proportion of BrdU+ cells in the stem cell zone in 
KrasG12D Meki on/off was not different to levels in KrasG12D untreated samples 
(Figure 4.12C+G). This suggested that proliferation was restored back to 
KrasG12D levels after Meki treatment ended. However, small intestinal Meki on/off 
crypts were slightly longer than KrasG12D crypts whereas Meki on/off colonic 
crypts were shorter than KrasG12D (Figure 4.12D+H). 
 Lastly, quantification of number of crypt-base Paneth cells and villus 
associated goblet cells showed decreased Paneth cell numbers and increased 
goblet cell numbers and villus length in Meki on/off samples compared to Meki 
samples (Figure 4.13A-C). Interestingly, Paneth cell numbers and villus length in 
the Meki on/off samples was not different to levels observed in KrasG12D untreated 
samples (Figure 4.13A-D). However, the number of goblet cells in KrasG12D Meki 
on/off samples was significantly increased compared to untreated KrasG12D 
samples suggesting a spike in goblet cell fate choice after Meki termination 
(Figure 4.13A+D). 
 
Together, BrdU, Paneth and goblet cell counts confirm that Meki treated KrasG12D 
fields revert back to full KrasG12D phenotypic status after treatment ended. From 
these counts, it appeared that this transition was mostly complete.  
 
 
 
 
 
 
 
 
 
 
  
Chapter 4: Defining stem cell dynamics in intestinal KrasG12D fields 
105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The origin and properties of pro-oncogenic fields in the intestinal epithelium 
106 
 
  
Chapter 4: Defining stem cell dynamics in intestinal KrasG12D fields 
107 
4.3 Discussion 
 
Conclusively, the results presented here show that clonal dynamics are 
accelerated in KrasG12D fields of the mouse small intestine and colon. In addition, 
the results demonstrate that KrasG12D fields accelerate the process of fixing new 
mutations as well as accelerating tumour initiation. These features make KrasG12D 
fields more likely to be pro-oncogenic. 
 The accelerated clonal dynamics can be partially repressed, short and 
long term, by inhibiting Mek1/2 signalling downstream of activated Kras. Thus, 
Mek1/2 inhibition could serve as a chemo preventative for cancer associated with 
oncogenic KRAS mutations.      
 
Stem cell dynamics have not previously been calculated in the new steady state 
that is achieved in crypts entirely populated by KrasG12D mutant cells or in any 
pro-oncogenic field. Vermeulen et al. 2013 showed that 30% of crypts were 
monoclonal after 21 days when a single KrasG12D stem cell competes with WT 
stem cells for the niche during clonal drift. Thus, the finding that 60% of crypts 
were monoclonal in KrasG12D mutant crypts after 21 days show that stem cell 
dynamics are additionally accelerated during neutral competition in fields 
compared to when KrasG12D cells are competing with WT cells during biased 
competition. 
 In addition, mathematical modelling revealed that clonal dynamics in 
KrasG12D fields are accelerated by employing relatively fewer stem cells with an 
increased stem cell replacement rate per crypt for neutral drift. Even though the 
difference between inferred N and l in KrasG12D and WT appear modest, these 
changes in combination have a dramatic effect on monoclonal conversion times. 
This is exemplified by the fact that it takes KrasG12D crypts and WT crypts 15 and 
45 days, respectively, to reach an average clone size of 0.75.    
 Analysis of clonal dynamics in human colons has revealed that crypts 
contain 7 stem cells and have a neutral monoclonal conversion rate of 
approximately 6.3 years (Nicholson et al., 2018). This is approximately 100-fold 
slower than in mice. The results in this chapter show that monoclonal conversion 
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rate is at least 2-fold accelerated in KrasG12D fields. If the same effect is true in 
humans, this means that fixation of new mutations (some of which could be pro-
oncogenic) would only take approximately 3 years in a human colonic KRAS field. 
Thus, the relative difference in clonal dynamics characterised here in mice 
confers a paramount difference in the human equivalent case and could have a 
major impact on tumour progression time in patients with mutant KRAS fields. 
Thus, to verify these findings, it would be interesting to determine the human 
clonal fixation time within a mutated KRAS field.  
 
Neutral drift is a process of cell division and clonal replacement (Lopez-Garcia et 
al., 2010; Snippert et al., 2010). Inherently this links stem cell division to the rate 
by which single clones convert a crypt to monoclonality. However, the link 
between the two is not yet clear as there are many more stem cell divisions than 
inferred replacement events during neutral drift.  
 Here, the results show a link between neutral drift behaviour and crypt-
base BrdU positivity. This is underlined by the fact that KrasG12D crypts have both 
increased BrdU+ cells at the crypt base and accelerated clonal dynamics. 
Additionally, Meki1/2 inhibition decreases both KrasG12D clonal drift and BrdU 
incorporation. This could suggest that a reduced stem cell cycle time is the 
general trait that drives the accelerated clonal dynamics in KrasG12D fields. 
However, BrdU incorporation only indicates which and how many cells are in S-
phase over a given period of time and does not specify an actual cell-
cycle/division time per cell. Therefore, in the future, it will be important to 
determine whether the stem cell division time in KrasG12D fields is in fact reduced. 
This could be done by employing the Fucci system or triple nucleotide labelling 
in KrasG12D crypts to visualise and quantify the length of the different phases of 
the cell cycle (Sakaue-Sawano et al., 2008; Podgorny et al., 2018). Another 
approach could be to measure the time it takes a single cell ‘clone’ to divide 
immediately post clone-labelling as done by Andersen et al. 2019. Here the 
authors show that KrasG12D expression in skin sebaceous-gland progenitors has 
only a small effect on cellular division time although gland expansion is increased 
in a KrasG12D dependent manner (Andersen et al., 2019). This could imply that 
accelerated KrasG12D clonal behaviour is not only a result of cellular proliferation. 
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Thus, other factors could also play a role for the accelerated clonal growth in 
KrasG12D fields. It is speculated that cell-cell interactions and cell morphology 
could be important mechanisms of epithelial clonal expansion (Vincent, et al., 
2013; Levayer and Moreno, 2016). Consequently, an altered morphology and 
physical interaction of stem cells in KrasG12D mutant crypts could be a driver of 
the accelerated clonal dynamics observed. This could be fuelled by the loss of 
Paneth cells located between stem cells in KrasG12D small intestinal mutant crypts 
(Sato et al., 2011) which could create enhanced cell-cell interaction and stem cell 
replacement patterns.  
 
To functionally investigate the pro-oncogenic potential of the accelerated clonal 
dynamics in KrasG12D fields, crypt mutational accumulation was tested.  
 In a recent study it was shown that Apcmin pre-cancer crypts acquire 
11-fold more somatic mutations in their genome compared to normal crypts 
during ageing (Lugli, et al., 2017). Here, a 1.3-fold increased mutational burden 
was reported in KrasG12D crypts compared to WT crypts. The increased 
mutational burden could be a direct result of the accelerated clonal dynamics 
observed in KrasG12D mutant crypts or it could be the effect of an additional 
increased mutation rate. An increased mutation rate would imply that KrasG12D 
cells inherently acquire more mutations per cell division than WT cells. This would 
make KrasG12D mutant cells hyper-mutagenic and thus could be an additive 
mechanism for enhanced oncogenesis in KrasG12D fields. However, the fold 
difference in mutational burden reported in Apcmin crypts by Lugli and colleagues 
compared to what is observed in KrasG12D crypts could explain why spontaneous 
tumours are only rarely formed in KrasG12D activated murine intestines compared 
to frequently in Apcmin mice (Moser, et. al, 1990). In the future, additional analysis 
of the exome sequencing data presented here, and mathematical modelling will 
be utilized to determine the exact mutation rate and mutational signature(s) of 
KrasG12D mutant crypts.  
 
To be able to assess whether tumour initiation time was in fact decreased in 
KrasG12D fields sporadic stabilised nuclear ß-catenin clones were left to progress 
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into tumours over time in WT or KrasG12D fields. The results presented here show 
that the time it takes for stabilised ß-catenin clones to develop into tumours is 
greatly decreased in KrasG12D fields.  
 It has been described that Kras signalling interacts with the Wnt-
signalling pathway thus supporting a synergistic effect of KrasG12D and stabilised 
nuclear ß-catenin (Janssen et al., 2006; Moon et al., 2013; Lemieux et al., 2015). 
Therefore, it is not clear whether KrasG12D fields simply accelerate tumour 
initiation time and/or additionally increases the rate of growth of nuclear ß-catenin 
driven tumours. This could be investigated by examining how many nuclear ß-
catenin crypts are converted into adenomas in KrasG12D and WT fields over time. 
In addition, it will be important to understand whether the potential added effect 
could stem from an additional competitive bias of stabilised ß-catenin+/KrasG12D+ 
stem cells during clonal drift. Accordingly, lineage tracing of stabilised nuclear ß-
catenin stem cells in KrasG12D fields could determine the probability of 
replacement of ß-catenin+/KrasG12D vs KrasG12D cells in detail.  
 
Results in this chapter strongly suggest that the clonal behaviour in KrasG12D 
fields makes them pro-oncogenic. Thus, it is exciting to theorise about the 
possibility of inhibiting this behaviour to prevent cancer initiation, so-called 
chemo-prevention (Issa and Noureddine, 2017). In this chapter, a clinically 
available Mek1/2 inhibitor is employed to do so.  
 The data presented here show that Mek1/2 inhibition of KrasG12D fields 
could repress the accelerated clonal dynamics. Importantly, Meki1/2 inhibition did 
not seem to have any influence on clonal growth in WT tissue, suggesting that 
neutral drift in WT tissue is independent on Mek1/2. Thus, Meki could be used as 
a chemo-preventative agent in patients diagnosed with oncogenic KRAS 
mutations prior to cancer diagnosis without significantly affecting WT crypts. In 
theory this treatment could prolong such individuals’ tumour free period and/or 
prevent the disease all together.  
 Interestingly, Meki1/2 inhibition only partially rescued clonal dynamics 
and cellular changes in KrasG12D fields. This could be because of the length of 
the treatment (15 days), suggesting that a longer treatment period or single 
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treatments given periodically, could regress the KrasG12D phenotype further. 
However, this could also be because activated Kras does not only signal via 
Mek1/2 (Cox et al., 2014). This is supported by the findings that Mek1/2 inhibition 
only has a limited effect on tumour regression in advanced colorectal cancer 
(Hochster et al., 2015). However, studies have shown that combination of Mek1/2 
inhibitors and inhibitors of the Wnt-pathway can supress tumour progression in 
vivo and in clinical phase-IB trials (Krishnamurthy et al., 2018; Moon et al., 2019). 
Thus, a combination of Mek1/2 inhibition and other targeted therapies could 
potentially completely rescue clonal dynamics in KrasG12D fields. However, it is 
not clear what the toxic effect of long-term inhibitor therapy would be in “healthy” 
individuals.  
 After termination of Mek1/2 inhibition clonal dynamics revert partially 
back to KrasG12D untreated levels. This partial reversion indicates that Mek1/2 
inhibition might have a lingering long-term effect. However, proliferation, Paneth 
cell loss and villus length fully returned to normal KrasG12D levels after termination 
of Meki treatment. This implies that stem cell dynamics respond slower to 
termination of Mek1/2 inhibition than cellular changes do. This seems intuitive, 
proliferation and cell death (Paneth cell loss) are immediate cellular responses 
whereas clonal growth is a dynamic change.  
 
Together, the results in this chapter explain how oncogenic colonic KRAS fields 
could pre-dispose to cancer development. However, the notion that pro-
oncogenic KRAS fields are present in patients before mutations in genes such as 
APC challenges the sequence of events predicted by Fearon and Vogelstein in 
1990. Thus, it will be important to convince the scientific community that a subset 
of tumours in fact arise in mutated KRAS fields. This could be done by 
investigating mutated KRAS allelic frequencies in human tumours. If tumours 
have arisen in oncogenic KRAS fields they would be expected to have a near 
clonal KRAS allele frequency.     
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5 Inducible Dre recombinase: a tool for temporal 
sequential colorectal cancer modelling in vivo 
5.1 Introduction 
Colorectal cancer is the third most common cancer worldwide (Kuipers et al., 
2015). The disease develops by acquisition of mutations in the colonic epithelium 
during patient lifespan which can lead to development of early polyp and 
adenoma lesions that can further progress into late adenocarcinomas (Fearon 
and Vogelstein, 1990). Even though, Fearon and Vogelstein determined a 
mutational sequence of colorectal cancer development in 1990, recent studies 
have shown that the disease is heterogenous and can be driven many diverse 
events that can classify different colorectal cancer sub-types (The Cancer 
Genome Atlas Network, 2012; De Sousa E Melo et al., 2013; Sadanandam et al., 
2013; Phipps et al., 2015; Nojadeh et al., 2018). Although tumours of different 
subtypes are driven by different genetic alterations it is clear that the development 
of any colorectal tumour is a sequential process.  
 The availability of different recombination tools makes it possible to 
recreate the sequential nature of the disease in vivo. As an example, following 
stem cells in pro-oncogenic fields or in tumours in vivo requires two events 
separated in time: firstly, a tumour/oncogenic field causing recombination and 
secondly a recombination event initiating lineage tracing. Expanding the genetic 
tool box to include different recombinases will be crucial to fine-tune such 
modelling.  
 
The most widely used DNA recombinase in in vivo models is Cre. Cre was 
discovered in bacteriophages in 1981 by Stenberg and colleagues (Sternberg 
and Hamilton, 1981) and was shown to recombine DNA between 34 base-pair 
(bp) loxP sites in mammalian cells in 1988 (Sauer and Henderson, 1988). The 
discovery of the Cre/loxP system was the starting point of conditional in vivo 
modelling which has been widely used since the first description of recombination 
driven retina eye-lens cancer in mice (Lakso et al., 1992). Later, Sadowski et al. 
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described a novel DNA-recombinase named Flp that recognises and recombines 
DNA between 34 bp Frt sites (Sadowski, 1995) which had no cross-reactivity with 
Cre. This expanded the recombinases available and allowed sequential 
modelling. 
 
Historically, most disease associated conditional alleles encode loxP sites for Cre 
driven recombination, for instance; Tp53flox2-10 (Marino et al., 2000), Pik3caH1047R 
(Yuan et al., 2013), Ptenflox (Groszer et al., 2001), Apcflox (Cheung et al., 2009) 
and Ctnnb1flox(ex3) (Harada et al., 1999). Some frt alleles for Flp driven 
recombination are also available, for instance; KrasfsfG12D (Young et al., 2011) and 
Tp53frt (Lee et al., 2012).  In the fourth chapter of this thesis a mouse model that 
combines Flp and Cre is utilized for separating two individual recombination 
events in time. There, Cyp1A1FlpO drives the expression of KrasfsfG12D and AhCreErt 
drives lineage tracing in KrasG12D fields. However, using Flp (and not Cre) for the 
initial recombination event greatly decreased this model’s versatility as it 
becomes dependent on the limiting Frt allele catalogue for modelling of different 
phenotypes. Thus, another tool for lineage tracing that can be combined with Cre 
and Flp could enhance in vivo sequential modelling.     
 
Dre is a novel DNA recombinase that recognizes 32 bp rox sites, and it was 
discovered in a screen for Cre-like enzymes in P1-like phages in 2004 (Sauer 
and McDermott, 2004). Later, Anastassiadis et al. showed that the Dre/rox 
system does not cross-react with the Cre/loxP system in mouse embryonic stem 
cells (mESCs) and in mouse embryos (Anastassiadis et al., 2009). Since these 
initial studies, Dre, and Cre (Hermann et al., 2014; Madisen et al., 2015; Sajgo et 
al., 2014) and Dre, Cre and Flp (Plummer et al., 2015) have been combined in 
the same in vivo and in vitro models to identify cell populations defined by 
differential promoter activity. Furthermore, Dre and Flp enzymes have also been 
utilized for designing loxP targeting alleles by allowing removal of Frt-site and rox-
site flanked selection cassettes (Motojima et al., 2016).  
 Importantly, Anastassiadis et al. also showed that Dre could be fused 
to the human progesterone receptor (Pr) to create an inducible DrePr fusion 
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protein. This fusion protein was found to be activatable in fibroblasts by the 
synthetic anti-progestin Ru486 (Anastassiadis et al., 2009). Additionally, DrePr 
has been shown to be active in Zebrafish (Park and Leach, 2013), however, it 
has never been proven active in mammalian tissues in vivo.    
 
Sequential modelling requires spatiotemporal control of DNA-recombinase 
expression and activation. To ensure optimal separation the recombinases used 
in sequence should be expressed under different promoters and should be 
activated by different ligands. Creating a murine DrePr allele would allow for a 
Ru486 inducible Dre different to the Tamoxifen inducible CreErt and the ß-
naphthoflavone inducible Cyp1A1FlpO.  
 The housekeeping locus Rosa26 (R26) confers a constitutive and 
ubiquitous expression of targeted genes in a variety of different tissues 
(Kisseberth et al., 1999) and has been reported as a promoter leading to 
widespread expression of Dre in the mouse embryo (Anastassiadis et al., 2009). 
Thus, in theory DrePr targeted to the R26 allele should be expressed in all cell 
lineages, including intestinal stem cells. Hence, R26DrePr (R_DrePr) could be a 
good candidate for a marker-free inducible lineage tracing tool that can be 
combined with other recombinases without cross-reactivity.  
 
Thus, the aim of this chapter is to develop R_Dre and R_DrePr alleles to conduct 
lineage tracing in both homeostatic intestinal tissue and in a sequential model of 
intestinal tumorigenesis.  
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5.2 Results 
 
5.2.1 Vector construction  
The R_Dre and R_DrePr animals were created by homologous recombination of 
targeting vectors (Appendix 2 for full vector maps, Figure 5.1A for schematic) into 
the R26 locus in mouse embryonic stem cells (mESCs) as described before 
(Vooijs, et al., 2001). In the R_DrePr targeting vector Pr consisted of the Ru486 
responsive mutant hormone binding domain of the human progesterone receptor 
hPR891 (described by Kellendonk et al., 1996). Pr was fused to the N-terminus 
of Dre thereby destroying parts of the endogenous nuclear localisation signal 
(NLS) in Dre and the fusion site was identical to the one reported by 
Anastassiadis et al., 2009. The finished vectors underwent Sanger sequencing 
to ensure all sequences were correct before proceeding with mESC targeting 
(data now shown).  
 
5.2.2 mESC integration site validation  
Screening for correct 5’ integration was carried out by PCR amplifying genomic 
DNA (gDNA) from mESC colonies with F1 and R1 primers (Figure 5.1A, Appendix 
1 for primers). R26 targeting by mESC homologous recombination was effective, 
with 72/96 F1+R1 positive colonies, giving the targeting event a success rate of 
75% (Figure 5.1B). Moreover, the targeting was of similar success rate in R_Dre 
and R_DrePr colonies (Figure 5.1B).  
 
To ensure that the 3’ end of the construct was also integrated correctly the first 
ten F1+R1 positive colonies from either R_Dre or R_DrePr mESC colonies (Figure 
5.1B) were further expanded in vitro and subjected to PCR amplification with 
primers F2 and R2 (Figure 5.1A). Importantly, all ten colonies from R_Dre and 
R_DrePr were also correctly integrated at the 3’ end (Figure 5.1C).  
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This analysis validates Dre and DrePr integration into the intended locus of R26 
in the mouse genome upon homologous recombination.    
 
5.2.3 Copy number assessment  
mESC clones with a single copy insertion of either R_Dre or R_DrePr were 
desired for animal creation.  Clones with more than one copy could arise by: a) a 
tandem insertion at one R26 locus or b) an insert on both R26 alleles or c) an 
additional insert in a random genomic loci. To identify single copy mESC clones 
a quantitative real time PCR (qRT-PCR) copy number assay was carried out on 
gDNA from the ten correctly targeted clones shown in Figure 5.1C. The qRT-PCR 
was performed with a puromycin probe serving as a surrogate marker for 
“inserted vector” (as targeting vectors contained a puromycin selection cassette). 
All samples were normalised against a sample known to contain a single copy of 
puromycin (from a previous R26 targeted mouse known to be heterozygous) 
(Figure 5.2).  
 Importantly, gDNA from the negative control sample with untargeted 
mESCs did not amplify, underlining the specificity of the puromycin probe (Figure 
5.2). As seen on Figure 5.2, all clones except for two in R_Dre group contained 
a single copy of puromycin. To avoid clones with tandem or random insertions 
only single copy R_Dre and R_DrePr clones were chosen to take forward to 
mouse oocyte pro-nuclear injections and mouse model creation. 
 
5.2.4 R_Dre mice have widespread Dre expression  
The R_Dre model serves as a positive control that allows for investigation of the 
expression of Dre. To investigate Dre activity in different tissues, R_Dre animals 
were crossed to animals encoding a rox STOP rox (rsr) tdTomato (tdTom) 
reporter allele (R26rsrtdTom). The R26rsrtdTom was created by germline deletion of 
the loxP flanked STOP cassette (lsl) from the R26rsrlsltdTom mouse obtained from 
Jackson Laboratories (stock no. 021876). The resulting line; R_Dre;R26rsrtdTom 
will be referred to as RD;RTrox and all experimental animals were heterozygote 
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for both alleles. Expression of tdTom visualised by red fluorescence (excited at 
550nm) served as a marker for Dre activity in these mice.  
 To analyse Dre activity, adult 8-10 week old RD;RTrox animals were 
culled and organs from different germ-layers were collected for 
immunohistochemical (IHC) analysis. From endoderm: stomach, liver, pancreas, 
lung and the intestines. From mesoderm: kidney, spleen, bone, striated muscle 
in tongue and smooth muscle in heart. From surface ectoderm: skin. Figure 5.3 
shows IHC analysis of tdTom expression in above-mentioned tissues from a 
control RTrox only mouse and three individual RD;RTrox  animals. All tissues 
examined expressed tdTom in RD;RTrox animals (Figure 5.3). tdTom expression 
was Dre specific, as the RTrox control did not contain any tdTom expression 
(Figure 5.3). These results show that R_Dre targeting leads to ubiquitous 
expression of Dre recombinase in tissues of different germ layers during 
development that persist in adult tissues. Importantly, this seems to be true, also 
for the intestine, which was of special interest for this study.   
 
5.2.5 DrePr is activated in a Ru486 dose dependent manner   
To investigate DrePr activity in adult tissue, R_DrePr animals were crossed to 
R26rsrtdTom mice to create R_DrePr; R26rsrtdTom animals (referred to as RDPr;RTrox). 
All experimental animals were heterozygous for both alleles. As described above, 
tdTom expression served as a marker of DrePr activity in this line.  
 The Pr addition should retain Dre recombinase in the cytoplasm of 
cells until administration Ru486. Upon Ru486 ligand binding to Pr, Dre should 
translocate to the cell nucleus to mediate DNA recombinase activity. To 
investigate whether DrePr was activatable by Ru486 and to determine the 
maximal induction efficiency of DrePr, RDPr;RTrox animals had 1, 2 or 3, 90-day 
slow release pellets containing 10 mg/pellet Ru486 implanted sub-cutaneously 
(Figure 5.4A). These pellets provide a slow but continuous release of Ru486 
made possible by integrating the drug in a bio-degradable matrix. At 75 days post 
implantation animals were sacrificed, and tissues from different germ-layers were 
collected for tdTom expression analysis.  
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Figure 5.4B shows IHC analysis of tdTom in RDPr;RTrox animals either un-induced 
or implanted with Ru486 slow release pellets. Importantly, RDPr;RTrox contained 
no background recombination, as un-induced controls had no tdTom expression 
in any tissue (Figure 5.4B). Furthermore, R_DrePr seemed to be activated in a 
Ru486 dose dependent manner in the stomach, liver, kidney, pancreas and 
spleen, with the number of tdTom positive cells increasing with number of pellets 
implanted (Figure 5.4B). However, the heart, tongue and bone had no tdTom 
expression (Figure 5.4B).  
 
As the intestine was of special interest to this study the small intestine and colon 
of animals implanted with Ru486 slow release pellets were subjected to further 
quantitative analysis. Notably, slow release of Ru486 did in fact lead to 
accumulation of tdTom in small intestinal crypts/villi and colonic crypts (Figure 
5.5A). Importantly, no tdTom positive cells were observed in RDPr;RTrox with no 
pellet(s) inserted (Figure 5.5A). To quantify the number of tdTom+ epithelial cells 
upon pellet administration the first five centimetres of the small intestine was 
subjected to single cell suspension and analysed by flow cytometry to determine 
the percentage of tdTom+ cells in EpCam+ epithelial cells (EpCam+/tdTom+) 
(Figure 5.5B). Flow cytometric analysis showed that proximal small intestines 
from animals with 1 pellet implanted had ~2% EpCam+/tdTom+, animals with 2 
pellets had ~3% EpCam+/tdTom+ and animals with 3 pellets had ~5% 
EpCam+/tdTom+ thus showing an almost linear accumulation of tdTom+ cells 
when treated with Ru486 slow release pellets (Figure 5.5B-C).  
 
These results show that R_DrePr has little to no background activity and suggests 
that it is activated in a dose dependent manner by Ru486 in various tissues, 
including the intestines.  
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5.2.6 DrePr is active in intestinal stem cells and can be used for lineage 
tracing 
As seen in Figure 5.6A, tdTom could be observed in whole crypts and villi after 
Ru486 exposure both in the small intestine and colon. This underlined that DrePr 
could be activated in intestinal stem cells, and that these stem cells could give 
rise to differentiated daughter cells migrating up the crypt (Figure 5.6A). To 
quantify the number of lineage-traced clones present after pellet implantation the 
proximal small intestine and colon were subjected to manual tdTom+ clone 
quantification by fluorescent microscopy (Figure 5.6B-C). Clones were defined as 
tdTom+ crypts (Figure 5.6B). The number of crypt clones both in the small 
intestine and colon arising after 1, 2 or 3 pellet implantations increased in a linear 
fashion (Figure 5.6B-C). However, a decrease in R_DrePr activity from small 
intestine to colon was observed, with approximately half the number of clones 
quantified in colon (~100 clones/cm/pellet) compared to small intestine (~200 
clones/cm/pellet) (Figure 5.6C).   
 
Next, R_DrePr’s ability to operate as a lineage trace tool in the mouse intestine 
was examined. Lineage tracing is commonly carried out by pulse chase 
experiments. To investigate the activity of DrePr after a pulse of inducer, Ru486 
was administered to RDPr;RTrox mice by the intra peritoneal (I.P) route either by 
a single dose of 50 or 80 mg/kg or by 80 mg/kg administered on three consecutive 
days. After 14 days animals were culled, and the small intestine and colon were 
subjected to manual crypt clone quantification by fluorescent microscopy 
analysis. As seen on figure 5.7A, intraperitoneal administration of Ru486 gave 
rise to tdTom+ clones both in the small intestine and colon. Additionally, the 
number of clones observed 14 days post induction increased in a dose 
responsive fashion both in the small intestine and colon (Figure 5.7B). The 
number of clones/cm in the small intestine was ~100 vs ~300 following a single 
or three dose(s) of 80 mg/kg Ru586, respectively, showing an almost linear 
accumulation of signal (Figure 5.7B). From this analysis 50 mg/kg Ru486 was 
used as the pulsing dose in lineage trace experiments as this dose appeared to 
hit <1 stem cell per crypt in small intestine and colon (Figure 5.7C), was well 
tolerated by the mice and provided an appropriate number of clones. 
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To further examine whether DrePr could be a successful tool for lineage tracing, 
results obtained on stem cell dynamics in the widely used and validated 
AhCreErt;tdTom (AhCreErt;RT) model was compared to the RDPr;RTrox model. 
AhCreErt;RTlox animals received a single dose of 40 mg/kg ß-naphthoflavone and 
0.15 mg Tamoxifen and RDPr;RTrox animals received a single dose of 50mg/kg 
Ru486 and animals from both strains were sacrificed 4, 7, 10, 14 and 21 days 
post drug administration (Figure 5.8A). The proximal small intestine and colon 
from both lines were then subjected to manual clone quantification by fluorescent 
microscopy to score the relative sizes of tdTom+ clones in intestinal crypts 
(scored as fractions of 8, Figure 5.8B). 3 mice per timepoint were quantified. In 
RDPr;RTrox animals an average of 100-250 and 85-170 clones/animal/timepoint 
were quantified in the small intestine and colon, respectively. In AhCreErt;RTlox 
animals an average of 200-300 and 175-300 clones/animal/timepoint were 
quantified in the small intestine and colon, respectively. Highest clone numbers 
were found at earliest timepoints.  
 During lineage tracing the average clone size and clone size 
distribution in small intestine and colon were not significantly different in the two 
models (Figure 5.8C + D).  
 
Finally, to quantitively compare stem cell dynamics in the two lines mathematical 
modelling was used to predict stem cell number per crypt (N) and stem cell 
replacement rate per stem cell per day (l) in RDPr;RTrox and AhCreErt;RTlox animals 
(Figure 5.9A-B). The mathematical model utilized encoded the same 
assumptions as the model described in chapter 4. Here, the model predicted 
average clone sizes over 100 days in RDPr;RTrox and AhCreErt;RTlox animals (Fig 
5.9A). The analysis inferred N to be 6 and 7 in the small intestine and colon, 
respectively, in both the RDPr;RTrox and AhCreErt;RTlox models  (Figure 5.10B). 
Furthermore, l was estimated to be 0.147 vs 0.15 in the small intestine and to 
0.19 vs 0.20 in the colon of RDPr;RTrox and AhCreErt;RTlox animals, respectively 
(Figure 5.9B). Importantly the average clone sizes presented here are in line with 
data from lineage tracing in other mouse models as N and l were similar to what 
was inferred in previous reports (Kozar et al., 2013;Vermeulen et al., 2013). 
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Taken together, the data suggests that R_DrePr traced stem cells have a non-
biased neutral behaviour similar to that of AhCreErt traced stem cells. Therefore, 
the R_DrePr allele can successfully be used for lineage tracing in small intestine 
and colon.   
 
5.2.7 R_DrePr can trace single cell derived clones in intestinal tumours 
A lineage tracing tool that is not activated by Tamoxifen and which is different 
from Cre is needed to follow single cell derived clones in Cre recombination 
facilitated tumour models such as the Ctnnb1flox(ex3) model (Harada et al., 1999). 
Here, a new mouse model to trace the fate of single cells in intestinal tumours, is 
presented: the AhCreErt;Ctnnb1lox(ex3);RDPr;RTrox mouse. In this model, AhCreErt was 
utilized to induce tumour initiation and R_DrePr was utilized to trace clones 
derived from single cells within these tumours. 
 
To use the AhCreErt and R_DrePr as sequential tools in the same model it was 
important to determine that the drugs used to activate AhCreErt (ß-naphthoflavone 
and Tamoxifen) did not activate the second recombinase in the sequence: DrePr. 
If ß-naphthoflavone and Tamoxifen would activate DrePr, background tdTom 
clones could greatly skew lineage tracing. In addition, it was important to confirm 
the previous finding that Cre does not recombine RTrox, as this would also create 
background tdTom clones.  
 To this end, RDPr;RTrox and AhCreErt;RTrox animals were administered 
40 mg/kg ß-naphthoflavone and 2 mg Tamoxifen on three consecutive days. 
AhCreErt;RTlox animals + ß-naphthoflavone and Tamoxifen served as a positive 
control for Cre activity. RDPr;RTrox animals + Ru486 served as a positive control 
for DrePr activity. As shown in Figure 5.10A, the ß-naphthoflavone / Tamoxifen 
treated RDPr;RTrox and AhCreErt;RTrox  animals did not contain any tdTom+ cells in 
the small intestine or colon seven days following initial I.P when subjected to 
confocal microscopy. In addition, flow cytometry quantification of recombination 
in the proximal small intestine showed 0% EpCam+/tdTom+ in both RDPr;RTrox 
and AhCreErt;RTrox animals after ß-naphthoflavone and Tamoxifen exposure 
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(Figure 5.10B). Importantly, the positive control AhCreErt;RTlox + ß-naphthoflavone 
/ Tamoxifen and RDPr;RTrox + Ru486 did contain 91% and 1.5% EpCam+/tdTom+ 
cells respectively, underlining Cre and Dre activity in both models (Figure 5.10A-
B). These results demonstrate that AhCreErt and R_DrePr can be used sequentially 
in one mouse line without background activity.  
 
Next, pilot studies to confirm the ability to trace from single cells in early and late 
tumours were carried out. AhCreErt;Ctnnb1lox(ex3);RDPr;RTrox animals were 
administered 40 mg/kg ß-naphthoflavone + 2.5 mg Tamoxifen to initiate tumours 
and after 21 days, lineage tracing was initiated with a pulse of 50 mg/kg Ru486. 
Animals were culled 5, 10 and 15 days after lineage trace induction (Figure 
5.11A). This experimental set-up was enough to stabilize ß-catenin and produce 
hyperplastic crypts in the proximal small intestine 26 days post Ctnnb1 
recombination (Figure 5.11B). At 36 days post Ctnnb1 recombination some of 
these small intestinal crypts had developed into tumours (Figure 5.11B). To 
visualise clones, whole-mounted tissue was subjected to tissue clearing and 
fluorescence microscopy. Ru486 induction marked single cells in the bottom of 
the hyperplastic crypts in early tumour tissue (Figure 5.11C, Day 5). With time, 
fewer but larger clones were observed (Figure 5.11C, Day 10). In late tumours, 
fewer than 5 clones/tumour were observed (Figure 5.11C, Day 15). Although few, 
these clones appeared to originate from a single cell and to be fully clonal (Figure 
5.11C, Day 15).  
 
To determine the number of traceable cells per tumour AhCreErt;Ctnnb1lox(ex3); 
RDPr;RTrox animas where subjected to the same induction scheme as described 
above and aged until maximum tumour burden (38 and 40 days post induction) 
(Figure 5.12A-B). Hereafter, each whole-mounted tumour was subjected to tissue 
clearing and fluorescence microscopy to score the number of clones per tumour. 
As seen in Figure 5.12C tumours of different sizes and with different number of 
clones were observed. Figure 5.12D shows the distribution of clones in all 
tumours. Out of a total of 133 tumours analysed (N=2 animals) 68 tumours (51%) 
did not contain any clones. Furthermore, 29% of tumours contained a single clone 
and the largest number of clones observed was 8 (observed in a single tumour) 
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(Figure 5.12D). The mean clone number per tumours was found to be 0.92 
(Figure 5.12E).  
 
In conclusion these results show that R_DrePr can be used for intra-tumour 
lineage tracing to follow stem cells in tumours from AhCreErt;Ctnnb1lox(ex3); 
RDPr;RTrox animals.         
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5.3 Discussion 
 
Different DNA recombinases are needed to drive sequential activating or deletion 
of disease-causing alleles and reporters to model step-wise intestinal cancer in 
vivo. In this chapter the inducible R_DrePr mouse model is introduced. The results 
show that DrePr is activated in a dose-dependent manner and that it can be used 
for lineage tracing in the small intestine and colon. In addition, R_DrePr can be 
combined with AhCreErt for lineage tracing in stabilised ß-catenin driven tumours.  
 
Once generated the R_Dre and R_DrePr animals were crossed to a R26rsrtdTom 
reporter to produce RD/RTrox and RDPr/RTrox models. When assessing Dre driven 
tdTom expression in different tissues in adult RD/RTrox animals a strong and 
widespread expression pattern was observed. This highlights Dre activity during 
development. Furthermore, analysis of tdTom expression in various tissues of 
RDPr/RTrox animals after Ru486 slow release pellet implantation showed that most 
tissues expressed nuclear DrePr after Ru486 exposure, confirming DrePr activity 
in adult tissue. However, heart, bone, tongue and lung expressed little to no 
tdTom. The lack of tdTom accumulation could have several explanations; 1) DrePr 
is not expressed in these tissues in adult mice 2) Ru486 cannot reach these 
tissues to activate DrePr  or 3) the tdTom locus is less susceptible to recombination 
in these tissues. Vooijs et al., have described differential recombination efficiency 
in different adult mouse tissues when using a R26 targeted CreErt mouse (Vooijs 
et al., 2001). In this report the authors find a reduced recombination efficiency of 
Brcaflox19 and Trp53flox2-10 in adult lung tissue compared to other highly 
recombined tissues such as kidney and spleen. In addition, a study has shown 
that activation of a lung specific Cre produces 50% less R26 YFP+ reporter cells 
in the adult lung compared to the embryonic counterpart (Sinha and Lowell, 
2017). Together this suggest that R26 expression is decreased in some adult 
tissues such as the lung and/or that general delivery of inducing agents is less 
efficient in reaching such tissues. To fully determine that this is occurring in the 
RDPr/RTrox animals it will be of importance to perform qRT-PCR on adult heart, 
bone, tongue and lung tissues to examine DrePr mRNA expression here. 
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However, this immediately means, that R_DrePr most likely cannot be used for 
recombination in these tissues by sub-cutaneous Ru486 administration.  
 
In addition to not being activatable in all tissues, it is clear from the results 
presented here that the induction frequency of R_DrePr is low compared to other 
inducible recombinases frequently used worldwide (such as AhCreErt). The highest 
percentage of tdTom seen in the small intestinal epithelial cells is 5% after Ru486 
exposure. The low induction rate is observed 75 days after implantation of Ru486 
slow release pellets (10mg/pellet). Assuming the pellets have a consistent 
diffusion of Ru486 from the pellet matrix over 90 days, they release approximately 
0.1 mg Ru486/day/pellet. With a relatively low daily dose only a small population 
of cells in different tissues are expected be activated per day. This would result 
in only long-lived clones and newly activated cells expressing tdTom after 75 days 
– possibly explaining the low percentage of tdTom expression observed. To fully 
test the maximum induction rate of R_DrePr it would be interesting to administer 
one pulse of maximum concentration Ru486 to these animals by other routes or 
solutions than tried so far.               
 The low activation rate could also suggest that the Pr fusion to Dre 
creates a very strong cytoplasmic retention of DrePr and a poor nuclear 
translocation after Ru486 ligand binding to Pr. It has been described that nuclear 
import efficiency of proteins fused to the Pr receptor relies on the balance of 
efficiency between encoded NLSs and nuclear export signals (NESs) and the 
localisation properties of Pr (Kakar et al., 2007). In the future, it would be 
interesting to model different DrePr fusion proteins containing NL and NE signals 
of different strengths to optimise the translocation properties of DrePr. 
 
Here, R_DrePr is reported to be a new tool for pulse-chase lineage tracing in the 
intestine. For such experiments it is of high importance to have minimal reporter 
background recombination in the absence of inducer as this would skew the clone 
sizes quantified. Importantly, the results here show that R_DrePr have zero 
background activity. Furthermore, an induction rate of <1 cell per crypt is optimal 
for pulse chase lineage tracing. This is the hit rate observed 24h after Ru486 I.P 
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administration, with very few double-hits per crypt observed. In addition, even 
though the number of clones/mouse/timepoint quantified here was lower than that 
of AhCreErt animals the data collected seems robust with little variation. 
Additionally, the results show that different ways of measuring stem cell 
dynamics, either with DrePr or AhCreErt concludes the same N and l. Importantly, 
the N and l reported here was in line with previous reported values (Kozar, et al., 
2013) thus suggesting that DrePr activity and exposure to Ru486 does not change 
the behaviour of intestinal stem cells. Conclusively, it appears that DrePr lineage 
tracing marks a pool of stem cells that behave in the same manner as stem cells 
marked by AhCreErt.  
 In contrast, models that rely on highly efficient recombination, for 
example VillinCreErt, are often subject to significant background recombination. 
This makes such models good tools for whole tissue recombination but 
inappropriate for sporadic induced recombination. However, sporadic induced 
activation of cancer drivers is ideal to model cancer in vivo, as this recapitulates 
the perceived route to cancer. Thus, it seems that the DrePr model is a good tool 
for low frequency, lack of background, recombination.  
  
Lineage tracing in tumours has previously been carried out by using CreErt 
induced reporter expression in spontaneous tumour models such as Apcmin 
(Kozar, et al., 2013; Yanai et al., 2017). Others have used co-expression of 
Lgr5CreErt and reporters to describe the clonal origin of intestinal tumours 
(Schepers et al., 2012). This is the first description of a recombination driven 
sequential model for lineage tracing in intestinal tumours. The results show that 
each tumour in the AhCreErt; Ctnnb1lox(ex3);RDPr;RTrox model contain an average of 
0.92 traced clones at the end of the experimental animal life span. This underlines 
that single cell derived clones do survive throughout the experimental outline thus 
emphasising the long-term application of this tool. However, 51% of analysed 
tumours did not contain any clones when analysed. No clones detected could 
have several explanations 1) these tumours where not induced with Ru486 2) 
traced clone(s) were lost over the time-course 3) no stem cell activity in the 
tumour. In 2013 Kozar et al. reported that spontaneous Apcmin adenomas are 
maintained by 9 stem cells per tumour gland. The fact that only 1-8 clones are 
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detected per AhCreErt;Ctnnb1lox(ex3); RDPr;RTrox tumour may further support the 
finding that adenomas are in fact maintained by a small number of stem cells. In 
the future, to investigate the intra-tumour clonal dynamics it will be important to 
analyse tumour clones at early timepoints.  
 
Together, these results demonstrate that DrePr can successfully be used to 
lineage trace in sequential mutation tumour models. In the future it would be 
exciting to combine Cre, Flp and DrePr in one model to re-create the step-wise 
process of intestinal cancer. It could be speculated that an efficient model for 
instance could be: Cyp1A1FlpO;KrasfsfG12D;AhCreErt;Ctnnb1lox(ex3);R26DrePr; 
R26rsrtdTom. Here, a pulse of ß-naphthoflavone would drive Flp induced intestinal 
KrasG12D field characterisation. Later, a pulse of ß-naphthoflavone and Tamoxifen 
would induce CreErt driven ß-catenin stabilisation and tumour growth. Lastly, once 
tumours had formed a dose of Ru486 would drive DrePr induced lineage tracing 
to inform tumorigenic clonal dynamics.      
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6  Discussion and perspectives  
Pre-neoplastic oncogenic fields might be a major driver of colorectal cancer 
initiation. Mutant clonal fields accumulate in the colonic epithelium over time and 
when a certain molecular threshold has been reached the primed tissue encodes 
the properties needed to initiate and propagate tumours (Hanahan and Weinberg, 
2011).  
 Mutant KRAS fields are present in human epithelium before overt 
tumour formation and thus could pre-dispose to cancer development in a subset 
of patients (Nicholson et al., 2018). Intestinal stem cell dynamics orchestrate 
tumour initiation and it is known that KrasG12D changes the competitive behaviour 
of stem cells (Vermeulen et al., 2013). Thus, KRAS fields could be over-
represented in human colons compared to other mutations due to the stem cell 
advantage conferred by the oncogenic KRAS mutation. This can be quantified, 
but at the start of this project it was not clear how stem cell dynamics are defined 
in KRAS mutant fields and whether such could be of pro-oncogenic nature. 
Additionally, since the intestinal epithelium is plastic in the sense that committed 
progenitors can revert back to stem cell status, it is not clear which cells are the 
cell of origin for pro-oncogenic mutations that causes fields to arise or whether 
oncogenic mutations could change cell fate choices of progenitors.  
 
If intestinal mutations only occur in stem cells, the total target size for oncogenic 
mutations would be relatively small. Such a small target population might not be 
large enough to explain the relatively high mutational burden found in human 
colonic tissues and cancers. Thus, mature cells and progenitors, that can revert 
back to stem cells, are in all likelihood a large source of oncogenic mutations 
found in intestinal stem cells. 
 Other studies that have investigated the cell of origin in colorectal 
cancer have expressed oncogenes or deleted tumour suppressors in progenitors 
of different lineages to assess whether such could give rise to tumours (Barker et 
al., 2009; Schwitalla et al., 2013, Tetteh et al., 2016). However, to our knowledge, 
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the studies included in this thesis are the first to quantitatively compare stem cell 
contribution from early secretory progenitors with or without oncogenes 
expressed. Thus, these results offer novel measures of the relative cell fate 
choices of progenitors encoding KrasG12D. Such measurements are made 
possible by the Atoh1CreErt;KraslslG12D;R26lsltdTom model as this mouse confers 
large numbers of marked clones, even during homeostatic conditions, thus 
allowing statistical testing of differences.  
 In the third chapter of this thesis, it was discovered that KrasG12D 
expression did not change the stem cell contribution potential of early secretory 
progenitors during tissue homeostasis. Even though no difference in stem cell 
contribution was observed, it was still clear that KrasG12D mutant secretory 
progenitors make a significant contribution to self-renewal during tissue 
homeostasis. However, after Lgr5 depletion, KrasG12D expression increased the 
stem cell contribution potential of Atoh1-expressing cells in the small intestine. 
Therefore, it appears that in a certain context there is an enrichment or higher 
influx rate of KrasG12D mutated progenitors into the stem cell pool, which indicates 
a greater role for progenitors as sources of oncogenic mutations in such cases. 
Furthermore, the results show that KrasG12D stem cells derived from Atoh1+ cells 
have an advantage over their WT neighbours and that KrasG12D mutant crypts 
derived from Atoh1+ cells can spread via fission, both in the small intestine and 
colon.  
 Increased stem cell contribution of KrasG12D progenitors infers an 
advantageous bias for such oncogenes to populate the stem cell pool. With the 
additional KrasG12D stem cell competitive bias these two mechanisms acting in 
sequence gives KrasG12D oncogenic mutations extremely beneficial 
circumstances for clonal fixation and field initiation. Thus, oncogene induced 
plasticity offers an additional layer of mutation-enabled bias. Additional studies 
into this phenomenon will be important for understanding colorectal cancer 
initiation.     
 Furthermore, this thesis is the first study that determines stem cell bias 
and mutant crypt spread of oncogenes derived from progenitors in the same 
mouse model. To further explore Atoh1+ derived KrasG12D crypts, it could be 
envisioned that the Atoh1CreErt;KraslslG12D; R26lsltdTom model could also be used to 
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asses stem cell dynamics within Atoh1 derived KrasG12D fields. To this end, a 
reporter encoding a different colour would be useful, for instance R26lslYFP 
(Madisen et al., 2010). The Atoh1CreErt;KraslslG12D;R26lslYFP model could be 
crossed to the R_DrePr;R_tdTomrox developed in chapter five of this thesis. Within 
this model, Atoh1+ derived YFP+KrasG12D clones could be left to develop into 
fields over time, and DrePr could then be used to lineage trace YFP+/tdTom+ cells 
within KrasG12D fields to determine stem cells dynamics of Atoh1+ derived 
KrasG12D mutant crypts. This would also allow the direct comparison of stem cell 
dynamics in WT crypts neighbouring such fields.  
 
No studies to date have attempted to define stem cell dynamics within pro-
oncogenic fields in vivo. This is possibly because the community have been 
lacking the right model(s) to do so. Thus, the development of the 
Cyp1A1FlpO;KrasfsfG12D;AhCreErt; R26lsltdTom model and the findings presented here 
are inherently novel. Using this model, it is shown that stem cell dynamics are 
accelerated in KrasG12D fields. We find that stem cell fixation is achieved 2-fold 
faster in KrasG12D fields by employing fewer clonogenic stem cells per crypt with 
a relatively increased replacement rate for neutral drift. Accelerated clonal 
dynamics are shown to be of pro-oncogenic nature, as new mutations are fixed 
faster in KrasG12D fields compared to WT fields. This could speed up cancer 
initiation as the crypts in such fields could reach the molecular threshold for 
cancer initiation faster. In addition, the results show that the accelerated KrasG12D 
clonal dynamics are Mek1/2 dependent and that Mek1/2 inhibitor treatment can 
slow them down, thereby offering an exciting possibility for chemoprevention.   
 As discussed in chapter 4, if the increased fixation rate observed in 
KrasG12D fields is translated directly into the human setting, the fixation time within 
KRAS fields would be decreased to approximately 3 years. However, as human 
stem cell dynamics are much slower than in the mouse, it is interesting to 
speculate whether the dynamic range for increased fixation rate could be even 
greater here? If that would be the case, clonal dynamics in KRAS fields could 
potentially be accelerated more than 2-fold in humans.  
 In chapter 4, stem cell dynamics are defined under KrasG12D 
homeostatic tissue conditions. However, as discussed in chapter 1, KrasG12D 
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fields are readily found in patients exposed to recurrent inflammation (Leedam et 
al., 2009; Galandiuk et al., 2012). Thus, to further develop the understanding of 
pro-oncogenic abilities of KrasG12D fields, the Cyp1A1FlpO;KrasfsfG12D;AhCreErt; 
R26lsltdTom model could be exposed to inflammatory agents such as DSS. In such 
a setting, stem cell dynamics in KrasG12D fields could be defined during 
inflammation. In addition, lifestyle, such as obesity, offers one of the biggest risk 
factors for colorectal cancer development. To this end, it has been shown that 
Apcmin mice on western diet have increased tumour initiation capacity, compared 
to mice on normal diet (Baltgalvis et al., 2009). Thus Cyp1A1FlpO;KrasfsfG12D; 
AhCreErt;R26lsltdTom mice fed a western diet could be used to study how obesity 
affects stem cell dynamics in KrasG12D fields. Collectively, such studies could aid 
the understanding of why certain patient groups have an increased tumour 
incidence.   
 This study concludes that KrasG12D fields speed up cancer initiation 
time since new mutations are fixed faster here. Additionally, it is clear that 
KrasG12D fields alone cannot initiate cancer formation and that multiple other 
mutations are needed. It is entirely possible that some oncogenic mutations will 
be positively biased in KrasG12D fields, which would make such combinations 
additive in their pro-oncogenic properties. To measure such an effect, the 
Cyp1A1FlpO;KrasfsfG12D;AhCreErt;R26lsltdTom model could be crossed to other alleles 
such as Tp53lslR172H (Goh et al., 2015). In such an enhanced model, it would be 
possible to define the probability of replacement of KrasG12D+/p53R172H+ stem cells 
over KrasG12D stem cells.  
 In addition, it is also possible that oncogenic fields encoding several 
mutations are present in the human epithelium. To study the stem cell dynamics 
in such fields Cyp1A1FlpO;KrasfsfG12D; AhCreErt;R26lsltdTom  mice could be crossed to 
for instance Tp53frt (Lee et al., 2012). Here, Flp induction would create intestinal 
fields of KrasG12D and deleted Tp53 and lineage tracing could define stem cell 
dynamics within KrasG12D and deleted Tp53 fields. Such studies could shed light 
on additive pro-oncogenic effects in vivo. 
 
Furthermore, results in this thesis mainly focus on studying the effect of the 
oncogenic mutation KrasG12D. However, several different oncogenic KRAS 
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mutations can be found in the human colonic epithelium, such as the KRASG12V 
variant (Nicholson et al., 2018). In addition, there are indications that these 
mutations confer different abilities to the intestinal tissue (Sansom et al., 2006; 
Haigis et al., 2008; Feng et al., 2011). Additionally, oncogenic mutations in other 
genes such as STAG2, PIK3CA and ERB2/3 have also been shown to be present 
in human colonic tissue prior to cancer development (Lee-Six et al., 2018). In the 
future, it will be important to determine whether these and other colorectal cancer 
drivers such as mutations in APC, TP53, FBXW7, PTEN and SMAD4 are present 
in pre-neoplastic fields in human colons. Additionally, defining the stem cell 
dynamics in fields of different mutations in vivo could map the relative cancer-
priming abilities of each mutation. This could help classify high-risk patients that 
should be on increased observation in any future screening procedures for 
colorectal cancer.     
 
Lastly, development of the inducible DrePr and FlpO alleles introduced in the 
fourth and fifth chapter of this thesis greatly enhances novel modelling of 
colorectal cancer in vivo. So-far most colorectal cancer tumour models consist of 
inducing the loss of tumour suppressor genes or gain of oncogenes at the same 
time (Jackstadt and Sansom, 2016). The addition of the new recombination tools 
R_DrePr and Cyp1A1FlpO makes it possible to create models that can temporally 
separate up to three individual recombination events in vivo (Cre, Flp and Dre). 
This makes it achievable to create models where, for instance, it can be tested 
how the sequence of different genetic alterations affects intestinal tumour 
development.        
 
In conclusion, the results in this thesis present a thorough characterisation of 
KrasG12D field initiation and the pro-oncogenic features within such fields. This 
study offers a new way to think about pro-oncogenic abilities of different genetic 
alterations. Here, the additive effect of progenitor stem cell contribution, stem cell 
bias, crypt spread and stem cell dynamics within fields characterise the overall 
pro-oncogenic features of KrasG12D (Figure 6-1A). Based on the findings 
presented in this thesis, a model for KrasG12D field development and their pro-
oncogenic characteristics is presented in Figure 6-1B. Here, KrasG12D fields can 
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arise from mutant secretory progenitors that contribute to a normal extent during 
homeostasis and in an increased manner after Lgr5 depletion. Clonal victory and 
crypt fission can then create KrasG12D fields and once present, these fields are 
able to fix subsequent oncogenic mutations at an accelerated rate. Tantalisingly, 
this increased fixation can be repressed by Mek1/2 inhibition.  
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Appendix 2: Vector maps 
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Appendix 3: Genotyping probes for Transnetyx 
 
The origin and properties of pro-oncogenic fields in the intestinal epithelium 
170 
 
Appendix 4: Antibodies for IHC 
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Appendix 5: Script for random clonal localization  
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Appendix 6: R-Script for Prediction of PR and l in Atoh1 datasets  
library(tidyverse) 
library(CryptDriftR) 
library(cowplot) 
theme_set(theme_cowplot(font_size=20)) 
 
# Function to use neutral drift equations to get ratio 
get_ratio = function(N, lambda, tau, Pr = 0.5, day = 30, remove_size = 0) 
{ 
  prob_vec = th_PulseChase(lambda, N, tau, day, F, Pr = Pr)  
  prob_vec[N+1]/sum(prob_vec[(2+remove_size):(N)]) 
} 
 
find_closest_val <- function(y_th, x_th, x_find){ 
  ind_min = which.min(abs(x_th - x_find)) 
  y_th[ind_min] 
} 
 
ratios_atoh      = c(0.824, 0.688, 0.598)  
ratios_atoh_kras = c(1.93150685, 2.75862069, 1.84810127, 1.43661972 )  
 
size_remove = 1 
N_use       = 7 
tau_use     = 1 
 
 
## First WT 
Chapter 8: Appendices 
173 
mean_ratio_atoh = mean(ratios_atoh) 
se_ratio_atoh   = sd(ratios_atoh)/sqrt(length(ratios_atoh)) 
 
tbl_th = tibble(lambda = seq(0.1, 0.4, length.out =  25),  
                ratio  = lambda %>% map_dbl( ~ get_ratio(N_use, .x, tau_use, 
remove_size = size_remove))) 
pp_WT = tbl_th %>%  
  ggplot(aes(x = lambda, y = ratio)) + geom_point(size = 4) +  
  geom_hline(yintercept = mean_ratio_atoh, col = "red") +  
  ggtitle("Predicted ratio varying lambda, N = 7") 
 
# Get estimates of lambda ========== 
tbl_th = tibble(lambda = seq(0.1, 0.4, length.out =  500),  
                ratio  = lambda %>% map_dbl( ~ get_ratio(N_use, .x, tau_use, 
remove_size = size_remove))) 
 
lambda_est = find_closest_val(tbl_th$lambda, tbl_th$ratio, mean_ratio_atoh) 
lambda_min = find_closest_val(tbl_th$lambda, tbl_th$ratio, mean_ratio_atoh - 
1.96*se_ratio_atoh) 
lambda_max = find_closest_val(tbl_th$lambda, tbl_th$ratio, mean_ratio_atoh + 
1.96*se_ratio_atoh) 
 
 
## Then KRAS ------------------------------------------------------------------------------------- 
mean_ratio_atoh_kras = mean(ratios_atoh_kras) 
se_ratio_atoh_kras   = sd(ratios_atoh_kras)/sqrt(length(ratios_atoh_kras)) 
 
tbl_th_Pr = tibble(Pr = seq(0.5, 0.8, length.out =  25),  
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                   ratio  = Pr %>% map_dbl( ~ get_ratio(7, lambda_est, tau_use, Pr = 
.x, remove_size = size_remove))) 
 
 
pp_KRAS = tbl_th_Pr %>%  
  ggplot(aes(x = Pr, y = ratio)) + geom_point(size = 4) +  
  geom_hline(yintercept = mean_ratio_atoh_kras, col = "red") +  
  ggtitle("Predicted ratio varying Pr, N = 7 (For KRAS)")  
 
# Get estimates of Pr ===================================== 
tbl_th_Pr = tibble(Pr = seq(0.5, 0.8, length.out =  500),  
                   ratio  = Pr %>% map_dbl( ~ get_ratio(7, lambda_est, tau_use, Pr = 
.x, remove_size = size_remove))) 
 
Pr_est = find_closest_val(tbl_th_Pr$Pr, tbl_th_Pr$ratio, mean_ratio_atoh_kras) 
Pr_min = find_closest_val(tbl_th_Pr$Pr, tbl_th_Pr$ratio, mean_ratio_atoh_kras - 
1.96*se_ratio_atoh_kras) 
Pr_max = find_closest_val(tbl_th_Pr$Pr, tbl_th_Pr$ratio, mean_ratio_atoh_kras 
+ 1.96*se_ratio_atoh_kras) 
 
pdf("Plots_Sofie.pdf", 9, 7) 
plot(pp_WT) 
plot(pp_KRAS) 
dev.off() 
 
print(c(Pr_est, Pr_min, Pr_max)) 
print(c(lambda_est, lambda_min, lambda_max)) 
